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Anaemia causes debilitating symptoms in people with cancer, partly through reduced 
tissue oxygenation. Nitrate supplementation, via reduction to nitrite then nitric oxide, 
attenuates the effects of systemic hypoxia on muscle metabolism. Nitric oxide also 
influences cerebral blood flow, neurotransmission and platelet aggregation. 
Aims 
To examine the feasibility of recruiting patients with cancer-related anaemia to a pilot 
study, and to estimate differences in outcome measures and predict resources 
required for a larger study investigating how nitrate supplementation affects 
thrombogenicity, muscle phosphocreatine recovery, exercise tolerance, cognition 
and quality of life.   
Methods 
This prospective, balanced randomised crossover study recruited 33 participants. 
Cycle ergometry, bloods, 31P-magnetic resonance spectroscopy and quality of life & 
cognition questionnaires were completed at two baseline visits and two visits post-
supplementation with either nitrate-rich (BR) or nitrate-depleted (PL) beetroot juice. 
Results 
85% of 33 screened patients were enrolled. 26 completed all visits. Plasma nitrate 
concentration was 8.4±58.8µM (mean±SD) at baseline and 78±33.5µM post-BR 
(p=<0.001*). Nitrite was 142±79nM (baseline) and 923±1006nM post-BR (p=0.000*). 
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Haemoglobin concentration was 111.4±9.8g/l (baseline), 109.1±10.9g/l post-BR but 
114.6±12g/l post-PL (p=0.028*). FACT-An quality of life score was 146±20 at 
baseline and improved to 152±24 post-PL and 150±25 post-BR (p=0.025*). Baseline 
FACT-cog cognitive function was 105±23 and improved to 109±24 post-PL and 
108±23 post-BR (p=0.03*). Gas exchange threshold was53±11W post-PL; baseline 
was 51±12W, BR 50±12W, p=0.0238*. Baseline systolic blood pressure was 
122±15mmHg, higher than post-BR (117±15mmHg) and post-PL (116±15mmHg), 
p=0.0081*). Oxygen uptake, peak power, phosphocreatine recovery, diastolic blood 
pressure and platelet aggregometry were not significantly affected. 
Conclusion 
This pilot study recruited and retained participants well. The enterosalivary 
circulation of nitrate was intact. The study was not powered to prove or disprove its 
hypotheses, but demonstrated that clinical factors (particularly haemoglobin 
concentration which varied because of chemotherapy and cancer 
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CHAPTER 1: INTRODUCTION  
 
The Nobel Prize in Physiology and Medicine 1998 was awarded jointly to Robert 
Furchgott, Louis Ignarro and Ferid Murad for their discoveries regarding nitric oxide 
(˙NO) as a signalling molecule in the cardiovascular system. Working independently, 
Furchgott described an unknown molecule, which he termed ‘endothelial derived 
relaxation factor’ (EDRF); this physiological activator produced by the vascular 
endothelium was found to elicit vasodilation (Furchgott and Zawadzki 1980). In 
unrelated experiments in 1977, while investigating the effect of nitroglycerin, Murad 
discovered that organic nitrates release ˙NO, which relaxes smooth muscle cells 
through activation of guanylate cyclase and increase in guanosine 3’:5’-cyclic 
monophosphate levels (Arnold, Mittal et al. 1977). In 1988, Ignarro’s experiments 
concluded that EDRF was in fact ˙NO (Ignarro, Buga et al. 1987). Since that 
discovery, this simple gas molecule previously thought to be merely an atmospheric 
pollutant, has been found to have a multitude of effects in the regulation of human 
physiology, prompting it to be named ‘molecule of the year’ in 1992 by Science 
journal (Koshland 1992). It is now known that ˙NO plays a fundamental role in 
mitochondrial respiration (Larsen, Schiffer et al. 2011), vasodilation (Ignarro, Buga et 
al. 1987, Bond, Curry et al. 2013, Carlstrom, Liu et al. 2014), glucose uptake 
(Kingwell, Formosa et al. 2002), muscle contractile efficiency and force (Vanhatalo, 
Fulford et al. 2011), exercise efficiency (Bailey, Fulford et al. 2010, Bescos, 
Rodriguez et al. 2011), platelet aggregation (Alheid, Frolich et al. 1987, Radomski, 
Palmer et al. 1987), control of cerebral blood flow (Aamand, Dalsgaard et al. 2013) 
and as a neurotransmitter (Kuriyama and Ohkuma 1995, Garthwaite 2008).  
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Humans derive ˙NO through two means; either through the L-arginine – nitric oxide 
synthase (NOS) pathway (Moncada and Higgs 1993), or through sequential 
reduction of dietary nitrate (NO3
-) through its enterosalivary circulation (Benjamin, 
O'Driscoll et al. 1994, Lundberg, Weitzberg et al. 1994). The latter pathway employs 
facultative anaerobic bacteria on the dorsum of the human tongue, which reduce 
NO3
- to nitrite (NO2
-), which is subsequently further reduced to ˙NO upon exposure to 
gastric acid as outlined below.  
An increasing body of research has attempted to manipulate human physiology 
through dietary supplementation of NO3
- and the resultant upregulation of ˙NO 
bioavailability. The majority of this work has been conducted with healthy individuals 
but such supplementation is now being investigated as a possible therapeutic 
intervention in a multitude of disease states, including peripheral artery disease 
(Allen, Giordano et al. 2012), diabetes (Gilchrist, Winyard et al. 2014), hypertension 
(Bond, Curry et al. 2013), pulmonary hypertension (Baliga, Milsom et al. 2012), and 
protection against cardiac ischaemia-reperfusion injury (Bryan, Calvert et al. 2007). 
The incidence and prevalence of cancer is increasing, with 330,000 new diagnoses 
in the UK in 2011 (C.R.U.K. 2015). Cancer-related fatigue is a multifactorial problem 
which affects 39-90% of people with cancer and can have a profound effect on their 
quality of life (Ludwig, Van Belle et al. 2004). One of the causes of cancer-related 
fatigue is anaemia, which has an incidence of 54% in patients with cancer. Anaemia 
contributes to significant reduction in performance status of patients with malignancy 
(Ludwig, Van Belle et al. 2004); however, physicians only have two effective 
treatments of anaemia, exogenous erythropoietin (EPO) injections or blood 
transfusions. EPO can improve quality of life (Crawford, Cella et al. 2002) but has 
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been associated with an increase in patient mortality in some disease populations 
(Leyland-Jones, Semiglazov et al. 2005), so must be used with caution for patients 
with cancer-related anaemia. Blood transfusions provide some subjective 
improvement in patient quality of life, dyspnoea and fatigue. Unfortunately, the 
duration of this benefit is unexpectedly shorter than the duration of objective increase 
in that patient’s haemoglobin concentration (Mercadante, Ferrera et al. 2009). This 
may in part be explained by alterations in blood during its ‘shelf-life’ of permitted 
storage, which can affect oxygen carrying ability, ˙NO bioavailability and red blood 
cell morphology (D'Alessandro, Kriebardis et al. 2014). Dietary nitrate 
supplementation might counter some of this reduction in ˙NO bioavailability, and 
could potentially reduce some of the adverse symptoms and physiological 
adaptations associated with anaemia in patients with cancer through its effect on 
vascular tone, mitochondrial respiration, calcium handling, muscle contractile force 
and efficiency. 
Chemotherapy-related cognitive impairment, sometimes referred to as ‘chemobrain’ 
by patients and their treating physicians, was first described in the 1970s (Weiss, 
Walker et al. 1974), affecting between 17 and 70% of patients with malignancy 
(Myers 2009). The pathophysiology of this debilitative condition is poorly understood 
but likely to be multifactorial. Firstly,  DNA damage can occur through endocrine 
therapy-induced changes in antioxidant function (Ahles, Root et al. 2012). For 
example, Tamoxifen is genotoxic as it is metabolically activated via alpha-
hydroxylation and sulphate conjugation to give reactive species that bind to DNA at 
the N(2) position of guanine, producing pro-mutagenic genetic lesions. Secondly, 
impairment of hippocampal neurogenesis by anti-cancer therapies can cause 
cognitive impairment (Monje, Vogel et al. 2007). Robust generation of new neurones 
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in this area of the brain occurs throughout life in healthy individuals, and is important 
in the generation of new memories. Cranial irradiation can inhibit this formation by 
perturbation in the neurogenic microenvironment by microglial inflammation, 
although anti-inflammatories can partially restore neurogenesis after radiation 
exposure.  The presence of apolipoprotein E4 allele (APOE) (Ahles, Root et al. 
2012) predisposes to cancer treatment – induced cognitive deterioration. APOE is a 
complex glycoprotein which facilitates the uptake, transport and distribution of lipids 
and plays a role in neuronal repair and plasticity after injury. The APOE4 allele has 
been associated with Alzheimer’s disease, aging and brain trauma. However, 
patients with at least one APOE4 allele who had survived cancer and chemotherapy 
had a significant reduction in their cognitive function compared to those survivors 
who did not carry this allele (Ahles, Root et al. 2012).  Finally, cancer treatment 
factors such as the type, timing and duration of treatment (Myers 2009) can have a 
significant influence on the likelihood that a patient may develop cognitive 
impairment as a result of that treatment. Self-renewing, lineage-committed neural 
progenitor cells and non-dividing mature oligodendrocytes (myelin-forming cells) are 
the most vulnerable cell populations to chemotherapeutic agents. Repetitive 
exposure to chemotherapeutic agents can exceed cellular repair potential and result 
in long-term suppression of cell division and apoptosis in the subventricular zone, 
hippocampus, and major white matter tracts of the central nervous system in animal 
models (Myers 2009), thus producing chemotherapy-induced cognitive impairment.   
Pathological conditions can substantially upregulate the production of ˙NO by 
inducible nitric oxide synthase (iNOS) in activated macrophages and neutrophils 
(Beckman and Crow 1993). iNOS is one of three key enzymes generating nitric 
oxide from L-arginine (Lirk, Hoffmann et al. 2002). INOS-derived ˙NO plays an 
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important role in numerous physiological and pathophysiological conditions, making 
iNOS a mediator of unspecific host defence and central in the clearance of bacterial, 
viral fungal and parasitic infections. The concentration of ˙NO generated can be 
sufficient to produce nitrogen dioxide and thus greatly increase the toxic effects of 
˙NO, linking iNOS to tissue damage and organ dysfunction, for example in the 
hypotensive and vasoplegive state characteristic of septic shock. ˙NO contains an 
unpaired electron, so readily participates in free radical processes of pathological 
relevance. For example, macrophages produce superoxide (O2
·-) which reacts with 
˙NO to produce the powerful oxidant, peroxynitrite (ONOO-) (Beckman and Crow 
1993): 
  O2
·-  +  ˙NO  →  ONOO- 
This potent biological oxidant has been implicated in free radical-induced tissue 
injury, and thus might be an important mediator of central nervous system injury 
following chemotherapy treatment (Tangpong, Cole et al. 2007). Hence, dietary 
nitrate supplementation may have an impact on the cognitive function of cancer 
patients. 
Patients with cancer have an increased thrombotic risk due to a variety of factors 
such as immobility, infection and inflammation (Lee and Levine 2003). ˙NO inhibits 
platelet aggregation and hence, dietary supplementation with nitrate may provide 
some protection against thromboembolic events in this population of patients.   
This introduction will outline current knowledge of nitric oxide synthesis and activity, 
and the effect dietary nitrate supplementation has on these biochemical pathways 
and human physiology both in health and in disease, investigating any potential 
clinical applications.  
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1.1 ˙NO SYNTHESIS 
 
Nitric oxide is a free radical gas molecule which was initially thought to be merely an 
atmospheric pollutant. Its pharmacological properties were discovered in the late 
1970s during studies of the pharmacology of glyceryl trinitrate (Arnold, Mittal et al. 
1977); ˙NO was found to be a potent vasodilator and inhibitor of platelet function and 
leucocyte adhesion. Endothelial-derived relaxing factor, an endogenous vasodilator 
produced by the blood vessel was described in 1979 (Furchgott and Zawadzki 1980, 
Ignarro 2002), but was identified as ˙NO in 1987 (Ignarro, Buga et al. 1987, Palmer, 
Ferrige et al. 1987). There are two main pathways through which ˙NO is synthesised 
in humans; the Nitric Oxide Synthase pathway and the sequential reduction of 
Nitrate. 
1.1.1 THE L-ARGININE-NITRIC OXIDE PATHWAY  
 
Endogenous ˙NO is synthesised from the amino acid L-arginine by the enzyme nitric 
oxide synthase (NOS). Active NOS functions as a tetramer consisting of two identical 
NOS monomers bound to two calmodulins (Alderton, Cooper et al. 2001). Each NOS 
monomer can be functionally and structurally divided into two major domains: a C-
terminal reductase domain and an N-terminal oxygenase domain. The former 
contains binding sites for one molecule each of nicotinamide adenine dinucleotide 
phosphate (NADPH), and the flavins, flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN), in close homology with the cytochrome P-450 reductase. 
The N-terminal oxidase domain binds iron protoporphyrin IX (haem) and the NOS 
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cofactor, tetrahydrobiopterin (BH4), as well as the substrate L-arginine. Between 
these two regions lies the calmodulin (CaM) binding domain. NOS catalyses a 
complex five-stage oxidation reaction involving the transfer of electrons from NADPH 
to FAD and FMN via CaM in the carboxy-terminal reductase domain, to the haem in 
the amino-terminal oxidase domain, where L-arginine is oxidised to L-citrulline and 
˙NO (Andrew and Mayer 1999). This complex reaction is calcium- and oxygen-
dependent, while also relying on the availability of five essential substrates to 
maintain constant ˙NO production (Crabtree, Tatham et al. 2009). Deficiency of 
NADPH, FAD, FMD, haem or BH4 causes a reduction in ˙NO synthesis.  
Three diverse isoforms of NOS exist, which differ in their structure and function; 
endothelial and neuronal NOS (eNOS and nNOS) are expressed constitutively in 
endothelial cells and neurones respectively, and can be collectively referred to as 
constitutive NOS. These are usually calcium ion (Ca2+) dependent, although they can 
be activated in a Ca2+ independent manner. Inducible NOS (iNOS) is expressed at 
high levels only after induction by cytokines or other inflammatory agents, and its 
activity is independent of an increase in calcium (Andrew and Mayer 1999). The 
three NOS isoforms display high homology in their oxidase and reductase domains, 
but each isoform exhibits distinctive features which reflect their specific in vivo 
function in the vascular endothelium, the central nervous system and in white blood 




1.1.2 THE ENTERO-SALIVARY CIRCULATION OF NITRATE 
 
This pathway is the second major source of ˙NO synthesis, and describes the 
sequential reduction of NO3
- to NO2
- then ˙NO. The UK population consumes 
foodstuffs containing 57 mg of NO3
- daily on average. Vegetables are the main 
dietary source of this NO3
-, contributing approximately 70% of the total dietary 
exposure to NO3
- of the general UK population (Ysart, Miller et al. 1999). The 
estimated mean NO3
- intake reported by Ysart Miller et al (1999) was 52 mg per day 
per person in the United Kingdom, although individual dietary preferences and 
variability would significantly affect this intake.  In particular, cruciferous and green 
leafy vegetables, and beetroot contain higher NO3
- concentrations than other foods. 
NO3
- is taken up by plants from soil and the use of nitrogen-based fertilisers may 
further increase NO3
- concentrations in crops. Nitrite (NO2
-) is also found in some 
foods such as meats, where it is used as a food additive to reduce risk of botulism 
and enhance its appearance. Environmental sources of NO2
- include cigarette 
smoke, car exhausts and other environmental pollutants (Lundberg, Weitzberg et al. 
2004). 
NO3
- is rapidly and completely absorbed into the bloodstream through the proximal 
gastro-intestinal tract following ingestion (Florin, Neale et al. 1990) (Figure 1). Sialin, 
an electrogenic NO3
-/H+ transporter found in the plasma membrane of salivary acinar 
cells (Qin, Liu et al. 2012), actively concentrates plasma NO3
- into the salivary glands 
at 10-20 times higher than those levels found in the plasma (Lundberg 2012). Upon 
salivation, this is secreted into the oral cavity where a proportion of it is reduced into 
NO2
- by facultative anaerobic bacteria located posteriorly on the dorsal surface of the 
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tongue (Doel, Benjamin et al. 2005). In this hypoxic setting, bacterial genera such as 
Actinomyces and Veillonella use NO3
- as a terminal electron acceptor and produce 
NO2
- as a by-product, a reaction catalysed by bacterial nitrate reductase (Lundberg, 
Weitzberg et al. 2004). A small proportion of this NO2
- is further reduced to ˙NO in 
the oral cavity through bacteria or periodontal acidity (Gilchrist, Winyard et al. 2010), 
but the majority of NO2
- is swallowed and, when exposed to stomach acid, produces 
a complex array of nitrogen oxides including nitrous acid (HNO2), nitrogen dioxide 
(˙NO2), dinitrogen trioxide (N2O3) and ˙NO (Lundberg, Weitzberg et al. 2004): 
NO2
- + H+ ↔ HNO2 
2HNO2 → N2O3 + H2O 
N2O3 → ˙NO + ˙NO2 
The chemical nature and reactivity of these, and other, reactive nitrogen 
intermediates (RNIs) formed in humans depends on ambient factors of the 
environment in which they are produced, including oxygen tension, acidity, proximity 
to haem-containing proteins, redox state and concentration of thiols. Within the 
stomach and gastrointestinal tract, these RNIs contribute to killing of ingested 
pathogens in the stomach, and the maintenance of gastric mucosal integrity through 
promotion of mucous production and regulation of gastric mucosal blood flow 
(Lundberg, Weitzberg et al. 2004). More distant effects are achieved through 
absorption of NO2





Figure 1: The Enterosalivary Circulation of Dietary Nitrate (Lundberg, 
Weitzberg et al. 2004) 
 
NO3
- ingestion increases plasma NO2
- levels in humans (Bailey, Winyard et al. 2009, 
Vanhatalo, Fulford et al. 2011, Kelly, Fulford et al. 2013). This increase in plasma 
NO2
- is attenuated through the use of antimicrobial mouthwashes (Govoni, Jansson 
et al. 2008) and through spitting of saliva rather than swallowing (Webb, Patel et al. 
2008) after ingestion of inorganic NO3
-, underlying the importance of the 
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1.2 THE EFFECTS OF ˙NO IN HUMAN PHYSIOLOGY  
 
˙NO gas is extremely unstable, being oxidised within seconds to nitrogen dioxide and 
higher oxides of nitrogen. In neutral aqueous solution, ˙NO exposed to oxygen has a 
half-life of less than 10 seconds (Ignarro 1989). Each NOS enzyme increases local 
˙NO production in the vascular endothelium, white blood cells and the central 
nervous system according to local stimuli. Bioavailability of ˙NO produced through 
the L-arginine-nitric oxide synthase pathway or the enterosalivary circulation of 
nitrate may be regulated by formation of NO-containing compounds such as S-
nitrosothiols, N-nitroso proteins and iron-nitrosyl complexes, along with NO2
- (Allen, 
Giordano et al. 2012). These NO-derived species can be transported through the 
circulation in either the plasma or in red blood cells, and ˙NO is liberated in hypoxic 
conditions. This vascular storage pool essentially buffers the concentration of ˙NO 
(Stamler, Jaraki et al. 1992), although controversy exists regarding its nature. Some  
have proposed the theory that the reservoir of ˙NO donors is in the form of S-
nitrosothiols (Foster, McMahon et al. 2003) while others suggested it is in the form of 
NO2
- (Cosby, Partovi et al. 2003). 
While investigating how nitrogen oxide-containing vasodilators such as glyceryl 
trinitrate exert their effect, Ignarro et al (1981) discovered that they react with 
cysteine residues to form S-nitrosocysteine through S-nitrosation (Ignarro, Lippton et 
al. 1981). S-nitrosation is the post-translational modification of a protein or amino 
acid. This term describes the reversible, covalent attachment of nitrogen monoxide 
to the thiol side chain of free cysteine, residues, or low molecular weight thiols such 
as glutathione with a one-electron oxidation of the ˙NO radical.  This forms an S-
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nitroso group (RS-NO) on the protein or amino acid (Hess, Matsumoto et al. 2005, 
Smith and Marletta 2012). RSNOs have long been known to circulate in the plasma 
and to have bioactivities similar to those of ˙NO but with half-lives in the order of 
hours (Stamler, Jaraki et al. 1992). Formation and degradation of RSNOs is a 
dynamic process which is largely influenced by the prevailing redox environment, 
oxygen and metal ion availability, and thiol reactivity (Miersch and Mutus 2005). 
Their formation can only proceed in the presence of an electron sink which enables 
oxidation in human physiology. An electron sink is an electrophilic atom or group of 
atoms that can capture an electron from another part of an electrical system 
(Ducluzeau, van Lis et al. 2009). This sink is either anaerobic metabolism, or 
transition metals in human physiology (Smith and Marletta 2012). RSNO formed 
through the mechanisms described above can then be transferred to small molecule 
or protein molecules through transnitrosation reactions, in which the ˙NO group from 
an RSNO is transferred to an acceptor cysteine thiol on another protein or small 
molecule (Foster, McMahon et al. 2003, Hess, Matsumoto et al. 2005). S-nitrosation 
of a wide range of proteins may therefore enable ˙NO to exert its ubiquitous effect on 
cellular function as outlined in section 1.2.1 below, while also buffering ˙NO 
concentrations in plasma.  
Dinitrosyl iron complexes (DNICs) are bio-organic complexes of ˙NO which have 
also been implicated in RSNO formation. DNICs spontaneously form in aqueous 
solution containing ˙NO, ferrous iron and many anionic species. In biological 
systems, the reaction of ˙NO with iron-sulphur centres of intracellular proteins such 
as mitochondrial aconitase involved in electron transport forms high molecular mass 
DNICs (Henry, Lepoivre et al. 1993). Such protein-bound dinitrosyl-iron-dithiolate 
complexes are characterised by electron paramagnetic response spectra with g = 
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2.04 and g = 2.015 (Vanin, Men'shikov et al. 1992). ˙NO can also react with free 
cellular iron to form low molecular mass DNICs with cysteine or glutathione as the 
major ligands (Giannone, Takeda et al. 2000). Low molecular weight DNICs appear 
to have a significant role in the control of iron-dependent cellular processes. They 
are present in inflammatory cells (Pellat, Henry et al. 1990, Vanin 2009), tissues 
expressing iNOS (Muller, Kleschyov et al. 1996), and upon exposure to ˙NO-
releasing compounds (Watts, Hawkins et al. 2006). In comparison to other ˙NO-
derived adducts such as S-nitrosothiols, DNICs quantitavely represent the largest 
intracellular pool (Hickok, Sahni et al. 2011), although their relative importance is yet 
to be determined. However, they have a long half-life and are found in most tissues 
within most biological systems, and will probably be formed under all cellular settings 
of ˙NO production. The in vitro rate of formation of DNICs in murine macrophages is 
determined by the concentration and duration of ˙NO  exposure, while the absolute 
quantity of DNIC formed is equivalent to or just in excess of the intracellular 
concentration of iron (Hickok, Sahni et al. 2011).  The disappearance of DNICs once 
they are formed has proven impossible to fully characterise. Similarly, the effect of 
anaemia on intracellular low molecular weight iron has not been fully established, 
although it seems likely, albeit not proven, that levels of intracellular low molecular 
weight iron would fall in anaemia. If this were indeed the case, the availability of iron 
to form DNICs would be impaired by anaemia, which would have a series of adverse 
consequences on ˙NO bioavailability and its functions in healthy individuals.  
˙NO metabolism is also likely to be affected by iron overload.  Iron is usually closely 
regulated by a number of homeostatic mechanisms in order to provide an adequate 
intracellular level of this micronutrient whilst preventing its accumulation and toxicity 
(Abbaspour, Hurrell et al. 2014). In healthy individuals, upon infection, macrophages 
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phagocytose excess iron, thereby preventing free radical injury and reducing iron 
availability for the invading microorganism (Weinberg 2000). However, iron can 
accumulate in humans as a result of pathological conditions such as genetic 
haemochromatosis, but also as a result of blood transfusion programs. In such a 
scenario, accumulated iron can generate oxidative stress by acting as a catalyst of 
free radical reactions, increasing the rate of hydroxyl production (˙HO) (Galleano, 
Simontacchi et al. 2004) with resultant tissue damage. A complex relationship exists 
between iron and ˙NO, and is yet to be fully characterised. In response to infection, 
iron-rich macrophages produce vast quantities of ˙NO through the activity of iNOS, 
which in turn is dimerised and activated by heme iron (Stuehr 1999). Hence, the 
phagocytosis of iron by activated macrophages may be intended to allow this rapid 
production of ˙NO in response to invading pathogens, although controversy remains 
regarding the influence and significance of iron on inflammatory ˙NO production. Iron 
dextran, a preparation of intravenous iron used to treat patients with iron deficiency 
anaemia, administered to rats along with lipopolysaccharide from Escherichia coli, 
was found to cause increased iron uptake in the liver Kuppfer cells. This then led to 
an increased plasma ˙NO concentration through increased iNOS activity within the 
Kuppfer cells (Galleano, Simontacchi et al. 2004).  ˙NO also plays a role in 
modulating the response of iron regulatory proteins such as iron regulatory protein 1 
(IRP-1) and IRP-2. These two cytoplasmic iron regulatory proteins modulate the 
translation and stability respectively of ferritin and transferrin receptor messenger 
ribonucleic acid (mRNA) (Cairo, Recalcati et al. 2002), thus controlling the 
homeostasis of iron. ˙NO increases IRP-1 activity while IRP-2 is inactivated by ˙NO. 
The latter effect accounts for the increased ferritin synthesis in cytokine-stimulated 
macrophages producing ˙NO and ONOO-, thus explaining the observed 
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sequestration of ferritin in macrophages under inflammatory conditions (Recalcati, 
Taramelli et al. 1998). It remains unclear if this effect can be used to minimise free 
radical formation in the diseased state. However, further exploration of the 
relationship between iron and ˙NO would be of benefit in improving our 
understanding of inflammatory conditions such as haemophagocytic 
lymphohistiocytosis, the detrimental effect of iron accumulation, and the effect of 
anaemia on iron metabolism and its interaction with ˙NO at a cellular level. Having 
been previously considered biochemically inert, NO2
- appears to play an important 
role in ˙NO metabolism as part of a complex hypoxia-sensitive redox signalling 
biochemical system (Dezfulian, Raat et al. 2007). It exists at concentrations between 
150 - 1000 nM in plasma and >10 μM in aortic ring tissue (Gladwin, Shelhamer et al. 
2000), and has a half-life of tens of minutes (Bryan, Fernandez et al. 2005). This 
potential ˙NO reservoir is in vast excess compared to plasma RSNO concentrations, 
conjectured to be approximately 10 µM (Stamler, Jaraki et al. 1992). As described in 
section 1.1.2, ˙NO can be endogenously synthesised in acidotic conditions through 
reduction of NO2
- by non-enzymatic acidic disproportionation or through the catalytic 
effect of enzymes (Samouilov, Kuppusamy et al. 1998, Dezfulian, Raat et al. 2007). 
NO2
- disproportionation, or spontaneous reduction and oxidation, is described in the 
equation below: 
3NO2
- + 2H+ ↔ 2˙NO + NO3
- + H2O 
Most biochemical reactions which produce ˙NO favour conditions of low oxygen 
tension and low pH, such as hypoxic vascular beds or ischaemic tissues. NOS 
activity is impaired in such conditions (Webb, Patel et al. 2008) but NO2
- reduction 
can occur independent of these enzymes through disproportionation, or other 
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catalysts of reduction of NO2
- to ˙NO such as xanthine oxidase (Zhang, Naughton et 
al. 1998), aldehyde reductase (Li, Cui et al. 2008), deoxyhaemoglobin (Cosby, 
Partovi et al. 2003), myoglobin and mitochondrial cytochrome oxidase (Aamand, 
Dalsgaard et al. 2009, Gilchrist, Winyard et al. 2010).  Deoxyhaemoglobin appears to 
be of particular importance in this context as it reduces NO2
- along the physiological 
oxygen gradient, synthesising more ˙NO, enabling greater blood flow through 
vasodilation, and hence maximising oxygen delivery in hypoxic tissue beds (Cosby, 
Partovi et al. 2003, Dezfulian, Raat et al. 2007). This mechanism was supported by 
the demonstration of an arterio-venous gradient of NO2
- in the presence of 
pharmacological inhibition of NOS (Gladwin, Shelhamer et al. 2000). This group 
reported a reduction in plasma NO2
- in studies of forearm blood composition between 
arterial and venous samples, a gradient which was exaggerated by exercise of the 
limb. This suggests that there is a net consumption of NO2
- in the hypoxic, more 
acidic capillary bed, with subsequent liberation of ˙NO and hence, vasodilation. 
Interestingly they noted no gradient in the concentration of RSNOs.  
The role of deoxyhaemoglobin in NO2
- reduction is somewhat controversial. 
Haemoglobin is a highly efficient transporter of oxygen; a conformational change 
between its high oxygen affinity relaxed or R-state and its low oxygen affinity T-state 
improves this efficiency through an allosteric mechanism. Fully oxygenated 
haemoglobin in the R-state has long been recognised as a destroyer of ˙NO (Ignarro 
1989); in combination they form the ferric (Fe) form of haemoglobin, 
methaemoglobin (MetHb) and  NO3
- through the dioxygenation reaction; 




This reaction occurs extremely quickly with a rate constant of 6-8 x 107 M-1 s-1 
(Doyle, Pickering et al. 1981), meaning the half-life of ˙NO in the oxygenated red 
blood cell (RBC) is 0.5 μs, enough time for it to only diffuse approximately 0.02 μm. 
This effectively means that ˙NO would be trapped within the oxygenated RBC. 
Deoxygenated ferrous (Fe2+) haemoglobin, however, appears to preserve the activity 
of ˙NO through the formation of iron-nitrosyl Hb (Sharma and Ranney 1978). 
 Hb + ˙NO → HbNO 
This reaction can occur at any of the four haem groups in the haemoglobin tetramer 
when it is in its deoxygenated state. However, subsequent release of ˙NO is slow, 
and when it is released, it would be rapidly subject to the dioxygenation reaction and 
therefore RBC release of ˙NO could be prevented.  
While on the above evidence, haemoglobin would appear to be an ˙NO destroyer, its 
role is rather more complex, and several mechanisms have been proposed to enable 
it to contribute to ˙NO signalling. Firstly, compartmentalisation of haemoglobin within 
the RBC reduces its ability to scavenge ˙NO (2). When Hb is encapsulated within a 
RBC, it scavenges ˙NO up to 1000 times slower than when the Hb is not within a 
RBC, possibly through the effect intravascular flow and shear stress has on particles, 
and the subsequent formation of a cell-free zone (Liao, Hein et al. 1999). This RBC-
free zone exists near the blood vessel wall, can be as much as 20-25% of the 
vessel’s diameter, and allows the outflow of ˙NO into the endovascular smooth 
muscle layer, while reducing interaction between endothelium-released ˙NO and the 
circulating RBCs (Butler, Megson et al. 1998, Liao, Hein et al. 1999). Secondly, 




-, acting as a nitrite reductase to produce methaemoglobin (MetHb, FeIIIHb) and 
˙NO (Huang, Keszler et al. 2005).  
 NO2
- + FeIIHb + H+ → ˙NO + FeIIIHb + OH- 
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This nitrite reductase activity of deoxyhaemoglobin produces ˙NO under allosteric 
control. This can be explained by the quaternary structure of Hb; in its deoxygenated 
T state, haemoglobin reacts with a single NO2
- to form MetHb and an iron-nitrosyl-
haem. These products have an R state-stabilising effect which lowers the redox 
potential of between two and six other haemoglobin chains, hence producing 
autocatalysis as R state haems form more R state haems, increasing the rate of 
NO2
- reduction to ˙NO  (Huang, Shiva et al. 2005). This could be allowed to escape 
the RBC through the existence of a membrane-associated nitrite-reductase 
metabolon, a supramolecular complex of sequential metabolic enzymes. This 
metabolon consists of deoxyHb, metHb, anion exchange protein, carbonic 
anhydrase, aquaporin and rhesus channels, hence bringing together nitrite, proton, 
The cell-free zone of 
blood vessels allows 
outflow of ˙NO into the 
endovascular smooth 
muscle layer, while 
reducing interaction 
between endothelium-
released ˙NO and the 
circulating RBCs 
Compartmentalised 
Hb in red blood cells 
has a reduced ˙NO 
scavenging ability 
Deoxyhaemoglobin 
acts as a nitrate 
reductase in red 
blood cells: 
NO2
- + FeIIHb + H+ 
→ 
˙NO + FeIIIHb + OH- 
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deoxyhaemoglobin, and highly hydrophobic channels which could concentrate the 
lipophilic ˙NO at the membrane complex (Cosby, Partovi et al. 2003, Huang, Shiva et 
al. 2005). The lipophilic nature of ˙NO allows it to readily diffuse across the red blood 
cell membrane following production.  
No conclusive evidence exists to back either nitrite or S-nitrosothiols as the major 
vascular storage pool of NO; however, three factors suggest NO2
- plays this role in 
human physiology. Firstly, NO2
- is present in plasma, RBCs and tissues in greater 
concentration than RSNOs (Gladwin, Shelhamer et al. 2000). Secondly, it is more 
stable than RSNOs as it is not easily reduced by intracellular reductants such as 
glutathione (Gladwin, Wang et al. 2002); the reductive intra-erythrocytic environment 
decomposes SNO-Hb and prevents its accumulation as a reservoir of ˙NO. Thirdly, a 
gradient of NO2
- concentration has been observed between the arterial and the 
venous elements of capillary beds indicating NO2
-consumption between the two 
areas, with no difference in RSNO concentration (Gladwin, Wang et al. 2002). 
While controversy exists regarding the storage and transport of potential 
endogenous ˙NO donors, there is no dispute regarding the multitude of potentially 
beneficial effects ˙NO exerts in both local and systemic human homeostatic 
mechanisms and hence, dietary supplementation with inorganic NO3
- may provide a 








It has long been recognised that consumption of a diet plentiful in fruit and 
vegetables is associated with reduction in blood pressure and adverse 
cardiovascular events (Webb, Patel et al. 2008). In particular, the dietary intervention 
which affords greatest protection against cardiovascular disease is to increase 
consumption of green leafy vegetables such as spinach. After initial hypotheses that 
this benefit was derived from an increase in antioxidants, large trials have not 
confirmed their role; however, green leafy vegetables and root vegetables such as 
beetroot have a high nitrate content and their consumption increases ˙NO 
bioavailability, hence exerting cardioprotective and blood pressure lowering effects 
(Webb, Patel et al. 2008, Kelly, Fulford et al. 2013).  
˙NO exerts this blood pressure-lowering effect through vasodilation and a reduction 
in peripheral vascular resistance (Bond, Curry et al. 2013). It acts as a local 
modulator of vascular tone, a role enabled by its lipophilic nature and hence its ability 
to penetrate tissues to exert its effect in the smooth muscle cells beneath the 
vascular endothelium (Ignarro 2002). The vasodilatory effect of ˙NO occurs in 
vascular smooth muscle due to its interaction with the iron haem in guanylate 
cyclase, activating this enzyme and hence catalysing the production of guanosine 
3’5’-monophosphate (cGMP) from guanosine 5’-triphosphate (GTP). cGMP activates 
several protein kinases which cause calcium extrusion from the smooth muscle cell 
and increased uptake by the sarcoplasmic reticulum. This reduction in cytoplasmic 
calcium in turn causes smooth muscle relaxation and subsequent blood vessel 
dilation (Allen, Giordano et al. 2012).  
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˙NO can be endogenously synthesised through reduction of circulating NO2
- by non-
enzymatic acidic disproportionation as mentioned above (Samouilov, Kuppusamy et 
al. 1998, Dezfulian, Raat et al. 2007), thus mediating vasodilation.  
Most biochemical reactions which produce ˙NO favour conditions of low oxygen 
tension and low pH, such as hypoxic vascular beds or ischaemic tissues. NOS 
activity is impaired in such conditions (Webb, Patel et al. 2008) but NO2
- reduction 
can occur independent of these enzymes through disproportionation. Xanthine 
oxidase (Zhang, Naughton et al. 1998), aldehyde reductase (Li, Cui et al. 2008), 
deoxyhaemoglobin (Cosby, Partovi et al. 2003), myoglobin and mitochondrial 
cytochrome oxidase (Gilchrist, Winyard et al. 2010) can all catalyse the reduction of 
NO2
-.  Deoxyhaemoglobin is of particular importance in this context as it reduces 
NO2
- along the physiological oxygen gradient, synthesising more ˙NO, enabling 
greater blood flow and hence maximising oxygen delivery in hypoxic tissue beds 
(Cosby, Partovi et al. 2003, Dezfulian, Raat et al. 2007).  
˙NO synthesis via NO2
- reduction conveys protection against hypoxic 
ischaemia/reperfusion injury in the heart (Bryan, Calvert et al. 2007), brain, liver and 
kidneys (Dezfulian, Raat et al. 2007) of animal models. NO2
- itself can directly 
nitrosate thiols to form S-nitrosothiols (RSNOs) in vitro (Bryan and Grisham 2007) 
which have also been shown to be protective in the setting of ischaemia/reperfusion 
(Dezfulian, Raat et al. 2007). 
Similar to the controversy regarding the nature of the ˙NO-donating vascular storage 
pool, an alternative mechanism has been proposed through which ˙NO matches 
regional blood flow with metabolic demand, involving S-nitrosohaemoglobin (SNO-
Hb). SNO-Hb forms when ˙NO binds the cysteine residue in the 93rd amino acid 
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position of the β subunit of haemoglobin in concert with the oxygenation-induced 
allosteric reaction of haemoglobin, and dissociates to dispense equivalents of S-
nitrosothiol (RSNO) in proportion to the degree of hypoxia of the tissue it is 
perfusing. This enables hypoxic vasodilation and hence, matching of oxygen supply 
and metabolic demand (Bennett-Guerrero, Veldman et al. 2007). However, this 
SNO-Hb hypothesis has been challenged by the results of further research involving 
murine models. Isbell et al (2008) created mouse models that expressed exclusively 
either human wild type haemoglobin, or human haemoglobin in which the β93cys 
residue was replaced by alanine (hence preventing formation of SNO-Hb). This 
substitution did not cause any alteration in red cell mediated hypoxic vasodilation, 
and no deficits in pulmonary or systemic haemodynamics. This suggests that SNO-
Hb is in fact not essential for the physiologic coupling of RBC deoxygenation and 
increased ˙NO-bioactivity in vivo (Isbell, Sun et al. 2008). They conjecture that in 
fact, the mediator of vasodilation in hypoxic capillaries is ATP release from hypoxic 
red blood cells. This ATP binds to purinergic receptors on the endothelium and thus 
stimulates NO˙ production through endothelial nitric oxide synthase, resulting in 
vasodilation. To support this alternative mechanistic theory, the same group found 
that hypoxic capillary vasodilation was restricted by more than 90% in the presence 
of an eNOS inhibitor. However, the extrapolation of this murine model to explain 
human physiology may be misleading and further studies are required to further 
explore this question. 
Platelet activity is governed by a variety of positive and negative stimuli that act to 
precisely regulate the process of homeostasis. Positive stimulators of platelet 
aggregation include subendothelial collagen, thrombin generated from the 
coagulation cascade, ADP and thromboxane A2. The major inhibitory factors 
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dictating platelet function are prostacyclin and ˙NO, which are generated by the 
vascular endothelium (Radomski, Palmer et al. 1987, Apostoli, Solomon et al. 2014). 
˙NO exerts its effect through activation of cGMP which results in reduced free 
cytoplasmic calcium, inhibition of platelet phosphoinositide (PI3) kinase, and hence 
reduction in the number and affinity of the platelet membrane fibrinogen-binding site 
Glycoprotein IIb/IIIa (Loscalzo 2001, Wallis 2005). Dietary nitrate supplementation 
with beetroot juice has also been shown to inhibit ex vivo platelet aggregation to 
ADP and collagen 2.5 hours after ingestion (Webb, Patel et al. 2008). While 
attempting to improve understanding of the physiological mechanism of this effect, 
Velmurugan et al (Velmurugan, Kapil et al. 2013)  discovered that NO3
- 
supplementation only reduced platelet reactivity in males, not females in a small 
study of healthy human volunteers. This was found to be caused by an elevation of 
circulating NO2
- in male participants, and hence an elevation of platelet cGMP which 
was not demonstrated in females. They conjectured that dietary NO3
- 
supplementation could convey some protection against cardiovascular disease 
without the bleeding risk associated with drug treatment such as aspirin or other 
antiplatelet agents. This theory was supported in an experiment using eNOS 
knockout mice to mimic conditions of endothelial dysfunction (Apostoli, Solomon et 
al. 2014). They reported that dietary NO3
- supplementation exerts an antiplatelet 
effect, and hence, that this intervention could reduce platelet hyperactivity in 
endothelial dysfunction. This impact is currently being explored by the NITRATE-
OCT randomised double-blind study investigating the effects of inorganic nitrate 
supplementation on vascular function, platelet reactivity and restenosis of coronary 
arterial stents in patients with stable angina (Rathod, Jones et al. 2016). It is yet to 
report its findings but hypothesises that rates of myocardial infarction, death, 
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cerebrovascular event and coronary arterial stenosis in those patients receiving oral 
nitrate is lower than placebo as a result of the effects of such supplementation on 
endothelial function and platelet activity.  
 
1.2.2 RESTING METABOLIC RATE AND EXERCISE PERFORMANCE 
 
Resting Metabolic Rate (RMR) is the minimum energy required to sustain vital body 
functions in the resting state during fasting conditions. RMR may be reduced by 
acute dietary nitrate supplementation in healthy individuals (Larsen, Schiffer et al. 
2014), although this conclusion does not support the previous findings reported by 
Kelly in 2013 (Kelly, Vanhatalo et al. 2013).  
Classical exercise physiology dictates that, regardless of training status, age, or diet, 
only minor fluctuations occur in an individual’s oxygen consumption at a given 
exercise workload. However, recent research has questioned this belief, 
demonstrating that acute dietary nitrate supplementation can reduce this 
consumption in healthy individuals (Larsen, Weitzberg et al. 2007, Bailey, Winyard et 
al. 2009, Bailey, Fulford et al. 2010, Lansley, Winyard et al. 2011). While dietary 
NO3
- supplementation was not demonstrated to reduce oxygen consumption in 
walking exercise in a small study of 12 older participants aged between 60 and 70 
years old (Kelly, Fulford et al. 2013), a speeding of VO2 kinetics was observed on 
initiation of exercise. 
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The reason for this observed improvement in exercise efficiency following dietary 
NO3
- supplementation is multifactorial, but probably either reflects an effect of NO3
- or 
its metabolites on the mitochondria, or on cellular handling of calcium.  
 
1.2.2.1 EFFECT OF NO3
- SUPPLEMENTATION ON MITOCHONDRIA 
Mitochondria are double membrane-bound organelles found in large numbers in 
most eukaryotic cells. They house the biochemical processes of respiration and 
produce energy in the form of adenosine triphosphate (ATP). Acute NO3
- 
supplementation may improve exercise efficiency either by improving the efficiency 
of mitochondrial ATP production, or through reducing their oxygen consumption not 
directly related to ATP production. In order to explain this effect, it must be 
appreciated how mitochondria generate ATP during oxidative phosphorylation, the 
final stage of respiration. Electrons stripped from oxidisable substrates such as 
glucose, fatty acids etc., pass down a series of electron carriers in the mitochondrial 
respiratory chain to reduce molecular oxygen to water (Figure 3). This process of 
electron transfer generates energy which drives the endergonic (energy-consuming) 
proton pumping activities of respiratory complexes I, III and IV (also known as 
cytochrome c oxidase), which in turn create a protonmotive force across the inner 
mitochondrial membrane. Dissipation of this force through ATP synthase drives 
adenosine diphosphate (ADP) phosphorylation and hence, ATP is produced 




Figure 3: Generation and Consumption of Mitochondrial Protonmotive Force 
Electrons (e-) released by oxidised substrates pass through the respiratory chain. They 
drive proton pumping via hydrogen (H+) from the mitochondrial matrix across the MIM 
(mitochondrial inner membrane) into the IMS (intermitochondrial membrane space) by 
respiratory complexes I, III and IV in an exergonic process. This creates an electrochemical 
gradient which is dissipated either through generation of ATP by ATP synthase, or through 
proton leak which does not generate ATP. Figure adapted from (Divakaruni and Brand 
2011) and (Granger and Kvietys 2015). C is cytochrome c. I – IV are respiratory complexes I 
– IV. 
 
Mitochondrial efficiency is limited by a number of factors, although proton leak 
appears to have the most significant effect on uncoupling of oxidation of substrates 
and ATP synthesis. Protons can return across the inner mitochondrial membrane 
independently of ATP-synthase, relieving the protonmotive force generated by 
oxidation without producing ATP (Divakaruni and Brand 2011). Proton leak occurs in 
















































adenine nucleotide translocase (ANT) in the inner mitochondrial membrane, while 
this basal leak can also be regulated and induced by catalytic uncoupling proteins 
(UCPs) (Divakaruni and Brand 2011). Proton leak has some beneficial physiological 
function in maintenance of homeostasis including the following: Thermogenesis in 
brown fat which, for example, is of critical importance in homeostasis of human 
newborn babies (Ricquier and Bouillaud 2000); Maintenance of  carbon flux (or 
transfer of energy in carbon fuels to electron potential energy despite low ATP 
demand); Modulation of the nutrient response in glucose-sensing pancreatic β cells. 
These cells usually respond to rising blood sugar by increasing oxidative 
metabolism, leading to an increased ATP/ADP ratio in their cytoplasm with a 
subsequent influx of calcium and eventual secretion of insulin (Fridlyand and 
Phillipson 2011).  The majority of this ability to sense glucose concentration is 
derived from glucokinase, found in high concentrations in these cells. This facilitates 
phosphorylation of glucose to glucose-6-phosphate thus triggering the insulin 
response to rising blood glucose concentration. Mitochondrial proton leak dissipates 
protonmotive force, thus restricting ATP production and glucose-stimulated insulin 
secretion (Li, Stojanovski et al. 2012). 
 Mitochondrial proton leak may provide further benefit as it may also protect against 
oxidative tissue damage caused by reactive oxygen species (ROS) by tempering the 
protonmotive force generated and hence mitochondrial superoxide production 
(Divakaruni and Brand 2011).  
Increasing controversy exists regarding the mechanism of the observed 
improvement in exercise efficiency following dietary NO3
- supplementation. This 
beneficial effect on exercise efficiency and resting metabolic rate may be, in part, 
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due to the impact of NO3
- supplementation on mitochondrial oxidative 
phosphorylation efficiency. Termed P/O ratio, this is typically measured as the 
amount of oxygen consumed per unit of ATP produced (Larsen, Schiffer et al. 2011). 
A number of potential mechanisms have been suggested by which NO3
-, NO2
- and 
˙NO may affect the P/O ratio, although with each new pathway suggested, further 
reports are published countering the projected hypotheses. ˙NO partially inhibits 
mitochondrial respiration by rapidly and reversibly inhibiting cytochrome c oxidase 
(COX), the terminal enzyme acceptor of the electron transport chain, as 
demonstrated in mitochondria isolated from rat skeletal muscle (Cleeter, Cooper et 
al. 1994).  This binding of ˙NO to COX is regulated by oxygen, and may also serve to 
control reactive oxygen species (ROS) signalling and to regulate tissue oxygen 
gradients (Thomas, Liu et al. 2001). Dietary NO3
- supplementation can improve 
coupling between respiration and oxidative phosphorylation in human skeletal 
muscle as evidenced by an increase in both the respiratory control ratio and the P/O 
ratio compared to placebo (Larsen, Schiffer et al. 2011). This group demonstrated an 
increase in the maximal rate of mitochondrial ATP production and in oxygen affinity, 
indicating a reduction in proton leak in the electron transfer chain. This was achieved 
through a reported downregulation of adenine nucleotide translocase (ANT) protein 
levels and hence, reduced leak. Contrary to pre-existing research conclusions, 
Whitfield et al (Whitfield, Ludzki et al. 2015) displayed an improvement in the 
exercise VO2 of healthy adults following beetroot juice supplementation, but no 
change in the key parameters of mitochondrial efficiency. Specifically, muscle 
biopsies taken from their participants showed no alteration in mitochondrial leak 
respiration, the content of proteins associated with uncoupling (uncoupling protein 3 
[UCP3], ANT1, ANT2), maximal substrate-supported respiration, or ADP sensitivity. 
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There was no alteration in mitochondrial P/O ratio, respiratory control ratio or 
membrane potential.  Nisoli reported an increase in rat skeletal muscle mitochondrial 
biogenesis following dietary NO3
- supplementation (Nisoli, et al 2003), yet Larsen 
found that, after 3 days of supplementation, no demonstrable effect on mitochondrial 
biogenesis was found (Larsen, Schiffer et al. 2011).  
 
1.2.2.2 EFFECT OF NO3
- SUPPLEMENTATION ON ATP COST AND CALCIUM FLUX 
 
An alternative explanation for the observed improvement in exercise efficiency 
following dietary NO3
- supplementation is the effect of such intervention on cellular 
ATP turnover and handling of calcium. The ATP cost of contraction in skeletal 
myocytes is the sum of ATP consumption via the interaction between actin and 
myosin (actomyosin-ATPase) and by calcium pumping in the sarcoplasmic reticulum 
(Ca2+-ATPase). Membrane depolarisation (Na+-K+-ATPase) makes a further small 
contribution to the total myocyte ATP turnover (Barclay, Woledge et al. 2007). NO3
- 
supplementation, through an increase in the bioavailability of ˙NO, may regulate the 
ATP cost of force production. ˙NO has been demonstrated to slow actin myosin 
cross-bridge cycling kinetics, reduce ryanodine activity, and hence reduce Ca2+ 
release and inhibit Ca2+-ATPase activity (Bailey, Fulford et al. 2010). Ryanodine 
receptors are a class of intracellular calcium channels in the endoplasmic reticulum 
which are responsible for the release of calcium from intracellular stores during 
excitation / contraction coupling in skeletal and cardiac muscle (Lanner, Georgiou et 
al. 2010). Any inhibition of their activity through ˙NO would therefore induce 
significant change in the calcium flux and ATP utilisation of muscles. Hence, this 
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mechanism would enable NO3
- supplementation to reduce VO2 for the same work 
rate in an individual by reducing total ATP turnover, without affecting mitochondrial 
P/O ratio. This hypothesis was proven in a murine model by Hernández et al 
(Hernández, Schiffer et al. 2012), who provided nitrate in the drinking water of 
experimental mice for 7 days. They reported a resultant increase of contractile force 
at low stimulation frequencies, as fast twitch muscles were activated at a lower 
frequency, achieving equivalent force output but requiring reduced ATP cost. As a 
result of this increased efficiency of contraction, fewer motor units were recruited in 
order to achieve the same force output, indicating that dietary nitrate 
supplementation could reduce the ATP cost of muscle contraction.  
 
1.2.3 OXYGEN DELIVERY IN CONDITIONS OF HYPOXIA 
 
Low barometric pressure at high altitude causes lower arterial oxygen content (both 
total saturation, and percentage of haemoglobin saturation) in Tibetan highlanders. 
Erzurum (Erzurum, Ghosh et al. 2007) found that this population’s oxygen use at rest 
and during exercise was similar to that of a sea-level dwelling population. The 
reduced arterial oxygen component is offset through an increase in bioactive forms 
of ˙NO such as plasma and red blood cell nitrate and nitroso proteins, and plasma 
nitrite. Tibetan highlanders also have a lower concentration of iron-nitrosyl 
complexes in red blood cells. This alteration in regulation of metabolic pathways 
causes vasodilation, increased blood flow and hence improved oxygen delivery. 
Furthermore, mammalian erythropoiesis is stimulated by the release of erythropoietin 
in response to hypoxia in order to meet tissue oxygen demands. However, at 
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altitude, prolonged exposure to hypoxic atmospheric conditions or severe chronic 
respiratory pathologies such as cystic fibrosis or chronic obstructive pulmonary 
disease can lead to such marked elevation in haematocrit that a detrimental increase 
in blood viscosity may occur. An increased haematocrit may not, therefore, 
substantially increase oxygen delivery when atmospheric oxygen and tissue oxygen 
saturation are low. Ashmore et al (Ashmore, Fernandez et al. 2015) describe a 
pathway whereby erythropoiesis is suppressed by dietary nitrate supplementation in 
male Wistar rats in both hypoxia and normoxia. Improved tissue oxygenation and 
downregulation of tissue hypoxia markers in the liver of these animal models leads to 
reduced hypoxia-driven hepatic erythropoietin release. This effect was reversed at 
higher nitrate doses where the renal expression of erythropoietin increased, probably 
as a result of relative anaemia. Hence, dietary nitrate supplementation appears to 
decrease blood viscosity while matching oxygen supply to demand, whereas renal 
oxygen sensing may act as a brake, averting a potential detrimental fall in 
haematocrit. 
 
In an experimental extrapolation of these observed findings, Vanhatalo et al 
(Vanhatalo, Fulford et al. 2011) reported that dietary supplementation with inorganic  
NO3
- ameliorated the detrimental effects of systemic hypoxia on exercise tolerance 
(Tlim) in healthy individuals. This group found that subjects given nitrate-rich beetroot 
juice (9.3 mmol nitrate) had no deterioration in Tlim in hypoxia compared to normoxia, 
while those participants given nitrate depleted placebo beetroot juice had the 
expected deterioration.  The exercise tests were performed within the bore of a 31P 
magnetic resonance spectrometer (31P-MRS), utilising this non-invasive method of 
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recording high-energy phosphorylated metabolites and pH changes before, during 
and after exercise.  Simply speaking, the use of this magnetic resonance 
spectrometer allows real-time assessment of muscle ATP and pH during exercise 
without the requirement for muscle biopsies, allowing investigation into the effect of 
exercise and various interventions on skeletal muscle physiology. During exercise in 
hypoxia, ATP is resynthesized from anaerobic metabolism through phosphocreatine 
(PCr) breakdown and glycolysis (Bogdanis, Nevill et al. 1996) enabling ongoing 
muscle contraction. Intracellular pH correlates with glycolytic flux, or the rate at which 
molecules pass through the pathway of glycolysis, the fundamental pathway through 
which humans produce energy.   The PCr to inorganic phosphate (Pi) ratio correlates 
with energy available as ATP for muscle activity. Phosphocreatine, the 
phosphorylated form of creatine, is primarily found in the skeletal muscles of 
vertebrates. There, it serves a critical role as a rapidly acting energy buffer for 
muscle cell actions such as contractions via its ability to regenerate adenosine 
triphosphate (ATP) from adenosine diphosphate (ADP). During muscle contraction, 
PCr is depleted to maintain constant ATP levels, while Pi accumulates. The ratio of 
PCr to Pi is therefore a measure of depletion of PCr and of production of ATP, while 
it also indicates reduction in cellular pH. Post-exercise PCr resynthesis is inversely 
proportional to the rate of oxygen consumption and hence, is an index of oxidative 
ATP production and mitochondrial function (Roussel, Bendahan et al. 2000). 
Vanhatalo et al (Vanhatalo, Fulford et al. 2011) reported that participants given 
placebo had more intramuscular metabolic changes during exercise in hypoxic 
conditions compared to those supplemented with beetroot juice in hypoxia, or those 
in normoxia. Specifically, muscle PCr concentration, Pi concentration and pH 
changed faster in the placebo arm in hypoxia than either the normoxia arm or the 
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beetroot juice arm in hypoxia. This indicates a reduction of muscle dependency on 
anaerobic metabolism when satisfying energy demand at a given work rate after 
nitrate supplementation, and an improvement in the matching of oxygen delivery and 
oxygen demand. 
 
1.2.4 COGNITION  
 
In the central nervous system, nNOS catalyses the production of ˙NO, although the 
proposed mechanism through which it exerts this effect has recently been called into 
question. Previously it has been proposed that ˙NO is produced via the nitrite 
anhydrase activity of carbonic anhydrase (Aamand, Dalsgaard et al. 2009). 
However, further evaluation of this proposed mechanism using enzyme kinetics, 
vascular myography and carbonic anhydrase knockout mice demonstrated that 
purified bovine carbonic anhydrase failed to catalyse NO2
- reduction to ˙NO in vitro 
or in vivo (Wang, Sparacino-Watkins et al. 2019). Hence, future studies are required 
to explore other potential NO2
- reductases which may have physiological significance 
in the human central nervous system.  
 
Within the central nervous system, ˙NO plays a number of roles contributing to 
neurotransmission and to neurovascular coupling. The receptor proteins specialised 
to detect ˙NO are coupled to cGMP formation and provide exceptional amplification 
of even brief, low amplitude ˙NO signals (Garthwaite 2008).  
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As in the vascular endothelium, ˙NO stimulates guanylyl cyclase to form cGMP, 
which activates cGMP-dependent protein kinase (PKG), and phosphorylation of the 
transcription factor cyclic adenine monophosphate response element-binding protein 
(CREB). This has a number of effects on the mammalian brain. Firstly, it contributes 
to long-term memory formation (Lu, Kandel et al. 1999). This group studied the effect 
of electrical stimulation on post-mortem mouse hippocampus cells in the presence of 
˙NO. They delivered 3 and 4 trains of electrical stimulation directly into the stratum 
radiatum of the hippocampus at 100 Hz for one second in the presence and absence 
of an nNOS inhibitor. They found that late long-term potentiation, a long-term form of 
synaptic plasticity, was blocked by the addition of an inhibitor of nitric oxide synthase 
in three trains of tetanic stimulation and reduced in four trains of stimulation.  
Synaptic plasticity is the biological process by which specific patterns of synaptic 
activity between neurones in the brain result in changes in synaptic strength and is 
thought to contribute to learning and memory. With further biochemical and 
immunofluorescent assays on the mouse hippocampi, they demonstrated that ˙NO, 
cGMP and PKG have a crucial role in producing long-term memory in response to 
stimuli.  
Further evidence to support the crucial role ˙NO has in long-term memory formation 
was published by Kemenes et al (Kemenes, Kemenes et al. 2002). They reported an 
experiment in which the snail Lymnaea stagnalis was subjected to one trial appetitive 
conditioning in amyl acetate followed by sucrose solution. This induced them to 
demonstrate specific feeding behaviours upon further exposure to amyl acetate as a 
result of long-term memory formed following their conditioning. However, some 
snails were also exposed to three different agents which caused ˙NO depletion, NOS 
inhibition and inhibition of the soluble guanylyl cyclase (sGC) were used to interfere 
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with the ˙NO-cGMP pathway thought to be important in long-term memory formation. 
They discovered that those snails who were exposed to the above agents interfering 
with ˙NO-cGMP displayed no evidence of long-term memory formation. They also 
demonstrated that consolidation of such long-term memory is also dependent on an 
intact ˙NO-cGMP pathway. Hence, ˙NO is demonstrated to play a vital role in animal 
behaviour, synaptic plasticity and long-term memory formation. 
Through both calcium-dependent and calcium-independent pathways, ·NO 
stimulates release of the neurotransmitters acetyl choline, dopamine, 
norepinephrine, along with the neuroactive amino acids glutamate, gamma-
aminobutyric acid and taurine (Kuriyama and Ohkuma 1995).  
The term ‘neurovascular coupling’ describes the coupling of local neuronal activity to 
regulation of blood flow in the brain, ensuring homeostasis of the cellular 
environment (Attwell, Buchan et al. 2010). This is controlled via forward feedback, 
whereby neuronal activity causes an increase in local cerebral blood flow and hence 
increased energy supply to those active neurones. Disruption of the mechanisms 
linking the neurovascular unit causes brain dysfunction and disease (Piknova, 
Kocharyan et al. 2011). The amino acid glutamate plays a central role in both the 
normal and abnormal functioning of the central nervous system (CNS). It is the main 
excitatory neurotransmitter in the CNS, estimated to be released at up to half of the 
synapses within the brain. It exerts its excitatory effect through three receptors, one 
of which is N-methyl-D-aspartate (NMDA). This receptor has been extensively 
implicated in CNS diseases, both through hyperstimulation such as in hypoxia – 
ischaemia of the CNS, and chronic hypostimulation as recorded in AL amyloidosis 
and Alzheimer’s disease. In health, glutamate is released in the presynaptic 
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membrane and activates neuronal NMDA receptors (Figure 4), causing calcium 
influx and activation of neuronal NOS releasing ˙NO. This directly mediates vessel 
dilation in the cerebellum but not in the cortex, where ˙NO modulates astrocyte 
signalling to cause vessel dilation. It exerts this effect through inhibition of astrocyte 
enzymes that synthesise the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-
HETE). This mechanism of vasodilation is independent of that mediated by cGMP. 
This allows preferential production of the vasodilatory prostaglandin and 
epoxyeicosatrienoic acid (EET) derivatives of arachidonic acid in the astrocytes, 
causing an unopposed effect on the arteriole diameter (Attwell, Buchan et al. 2010).  
Hence, unlike most neurotransmitters, ˙NO acts not only as a line of communication 
between neuronal cells, but between them and non-neuronal cells (Garthwaite 
2008). Thus, through the action of ˙NO, the neurovascular unit, made up of neurons, 
glial cells and blood vessels, tightly couple local neuronal activity at the cellular level 




Figure 4: Neurovascular Coupling. Glutamate is released in the presynaptic membrane. In the 
cerebellum, it causes an influx of calcium ions through the NMDA receptor which in turn 
activates nNOS, releasing ˙NO. This is released by the neuron and directly mediates relaxation 
of the smooth muscle walls of the microvessels and therefore vasodilation within the 
cerebellum. In the cortex, ˙NO exerts a similar effect by inhibiting astrocyte signalling 
pathways (depicted by red hashed arrows) and reducing production of 20-HETE, opposing 
vasoconstriction. The net result of each of these actions is that the neuroexcitatory amino 
acid, glutamate, stimulates neuronal activity and this induces vasodilation and therefore 
improved delivery of glucose and oxygen to those nerves that are most active. Figure adapted 
from (Attwell, Buchan et al. 2010). PGE2 is prostaglandin E2, while PLA2 is phospholipase A2.  
Global impairment of blood flow within the brain has long been linked with disease. 
Meyer et al (Meyer, Rogers et al. 1988) measured cerebral blood flow in elderly 
patients with either multi-infarct dementia or Alzheimer’s Disease, and compared it 
with age-matched controls whilst longitudinally monitoring both groups’ cognitive 
function. They reported a steady deterioration in cognition and vascular flow over 
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time in patients with Alzheimer’s, compared to a more stepwise and fluctuating 
course of deterioration in those with multi-infarct dementia. Each group had a 
significantly reduced cerebral blood flow compared to the control participants.  In 
order to counter this observed effect, a number of groups have attempted to improve 
cerebral blood flow and neurovascular coupling by harnessing the effect of dietary 
NO3
- supplementation. Presley et al (Presley, Morgan et al. 2011) compared the 
effect of high and low nitrate diets on cerebral perfusion in 16 older adults using 
arterial spin labelling magnetic resonance imaging. They found that, while there was 
no observed difference in global cerebral perfusion, nitrate supplementation was 
linked with improvement in regional cerebral perfusion of frontal lobe white matter, 
particularly the dorsolateral prefrontal cortex and the anterior cingulate cortex. These 
areas are of crucial importance, providing much of the brain’s higher executive 
functioning, yet are at risk of chronic ischaemia (Nordahl, Ranganath et al. 2006). 
Hence dietary nitrate supplementation may provide some protection against this very 
common and often debilitating effect of the aging process. Furthermore, dietary 
supplementation with inorganic nitrate alters the haemodynamic response to visual 
stimulation through improvement in neurovascular coupling (Aamand, Dalsgaard et 
al. 2013). This was demonstrated using 20 healthy volunteers, who were given either 
sodium nitrate or sodium chloride (placebo) supplementation in a crossover study. 
Participants were then exposed to visual stimuli during high resolution functional 
magnetic resonance imaging of their cerebral blood flow, which assessed their blood 
oxygen level dependent (BOLD) response in cerebral blood flow. While this 
demonstrated no change in the baseline cerebral blood flow, participants’ BOLD 
response was faster and smaller after nitrate supplementation, and oral nitrate 
induced a reduction in the variation in the local cerebral cortex. This was consistent 
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with enhanced neurovascular coupling during elevated nitrate concentration, with a 
fast but small increase in blood flow isolated to areas of the brain pertinent to the 
visual stimuli.  
Hence, these studies indicate that dietary inorganic nitrate supplementation may be 
of therapeutic benefit in central nervous system functioning in health and in the 
pathological state. 
 
1.2.5 THE POTENTIALLY HARMFUL EFFECTS OF ˙NO  
 
While there are a large number of beneficial effects attributable to ˙NO as outlined 
above, its role in cancer may not be entirely advantageous. Its role in tumour biology 
is complex given its combination of facilitatory and inhibitory effects in cellular 
processes. This role is dependent on intracellular conditions such as the cell’s 
genetic make-up, the local concentration of ˙NO, and the presence of other 
regulators such as ˙NO scavengers (Lala and Chakraborty 2001).  Most human 
carcinogenesis is caused by somatic mutations which either activate oncogenes or 
inactivate tumour suppressor genes. The development of these mutations is dictated 
by the chemicals within the cellular microenvironment and to a lesser extent, by 
genetic predisposition of the individual. ˙NO is a free radical and therefore has 
mutagenic properties as a result of its potential to both cause DNA damage and to 
hinder DNA repair. These effects are either directly attributable to the impact of ˙NO 
itself, or through its interaction with superoxide forming peroxynitrite (ONOO-) and 
dinitrogen trioxide (N2O3) (Bonavida, Khineche et al. 2006). It can also increase 
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angiogenesis (blood vessel formation) within tumours, promoting metastatic spread 
and tumour growth, while ˙NO can also reduce chemotherapy-induced inflammation 
of tumour cells, thus contributing to limited efficacy of these agents in the treatment 
of some tumours (Bonavida, Khineche et al. 2006).  
Intrinsic nitric oxide synthase (iNOS) has a compelling relationship with cancer 
progression and metastasis of tumours. Expression of iNOS is correlated with poor 
outcomes in terms of overall survival in a number of tumours including breast cancer 
(Loibl, Buck et al. 2005) and malignant melanoma (Ekmekcioglu, Ellerhorst et al. 
2000). Similarly, patients with stage III ovarian cancer had better responses to first 
line of chemotherapy if iNOS was not present (Raspollini, Amunni et al. 2004). The 
explanation for these observed effects is poorly understood, and in fact many 
experiments investigating the effects of increased iNOS concentrations in cancer cell 
lines in vitro have reported a reduced metastatic potential (Hickok and Thomas 
2010).  
There is evidence of a dichotomy of effects of ˙NO on cancer metabolism and 
outcomes. While the papers outlined above describe detrimental effects of ˙NO, 
further studies describe the role of ˙NO in chemosensitisation and 
immunosensitisation of cancer to induction of apoptosis, or programmed cell death. 
An increase in NOS activity within tumour cells can trigger p53 accumulation, a 
potent tumour suppressor which induces cell cycle arrest and apoptosis (Ambs, 
Hussain et al. 1997). Chemotherapy-induced tumour cell death is detrimentally 
affected by hypoxia; the killing of human breast cancer cells and mouse melanoma 
cells by chemotherapy was impaired by ˙NO inhibition (Matthews, Adams et al. 
2001), indicating that the role of ˙NO in matching blood flow with hypoxia is crucial in 
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ensuring efficacy of these agents. The sensitivity of cells to immune-mediated 
chemotherapy is affected by ˙NO, via its effect on transcription, causing upregulation 
of pro-apoptotic proteins and down-regulation of anti-apoptotic proteins. For 
example, the expression of Fas receptor, a receptor to the apoptotic protein fas 
ligand (FasL) in aortic ring smooth muscle was increased by exposure to ˙NO, thus 
mediating increased sensitivity of those cells to apoptosis (Bonavida, Khineche et al. 
2006). Inteferon gamma upregulates NOS activity and has sensitised human ovarian 
cell lines to FasL mediated apoptosis.  
Hence ˙NO has a number of complex and contrasting roles within cancer. It can 
promote tumorigenesis and can affect risk of progression and metastasis of tumours. 
However, it can also be targeted to sensitise patients to both chemotherapies which 
affect cell cycle, and to immunotherapy.  
 
1.2.6 ˙NO BIOLOGY SUMMARY 
 
˙NO is an extremely important regulator of human physiology, exerting a broad range 
of effects on a number of target organs and organ systems. It plays an essential role 
in the maintenance of endothelial function and vascular tone, hence controlling 
vasodilation, blood pressure and oxygen delivery to hypoxic tissue beds, whilst 
affording some protection against hypoxic ischaemia/reperfusion injury. It affects 
mitochondrial respiration, myocyte calcium handling and ATP turnover, hence 
contributing to the efficiency of resting metabolic rate, and muscle function in 
conditions of normoxia and hypoxia. ˙NO is implicated in the neurovascular pairing of 
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cerebral blood flow and neuronal activity, long term memory formation and learning. 
It also controls platelet aggregation. It has an array of potential effects in cancer, 
some of which are proven to be beneficial but some of which are detrimental to 
patient outcomes.  
 
1.3 CANCER, FATIGUE AND ANAEMIA 
 
The incidence and prevalence of cancer is increasing throughout the world. More 
than 331000 people in the UK were diagnosed with a form of cancer in 2011, which 
equates to 910 people every day (C.R.U.K. 2015). Cancer-related symptoms vary 
according to the tumour, its site and its treatment, but its burden is significant and 
can have a major impact on quality of life, and may affect clinical treatment. Cancer-
related fatigue (CRF) affects 39–90% of patients with malignancy; this is a subjective 
feeling of tiredness, weakness or a lack of energy, which is not relieved by rest 
(Stone and Minton 2008). The aetiology of this phenomenon is multifactorial and 
poorly understood, but contributory factors include psychological stress, malnutrition, 
infection, chronic pain, downregulation of the hypothalamo-pituitary-adrenal axis, 
inactivity, dysregulation of central serotonin metabolism and anaemia. There has 
been a distinct lack of well-designed randomised controlled trials of drug 
interventions to improve cancer-related fatigue. Only three agents have any 
significant published research. The psychostimulant methylphenidate shows no 
statistically significant effect, while the haematopoietic growth factors erythropoietin 
and darbepoietin both showed an improvement in cancer-related fatigue (Crawford, 
Cella et al. 2002, Wagner and Cella 2004, Stone and Minton 2008). Haematopoietic 
59 
 
growth factors must be used with caution in this patient population however, as 
outlined below (Leyland-Jones, Semiglazov et al. 2005). 
Anaemia is usually defined in terms of a reduction in the concentration of 
haemoglobin or the number of red cells in the peripheral blood. The symptoms and 
severity of anaemia depend on the degree of anaemia, rapidity of its onset, and the 
age and co-morbidities of the patient. Reduction in oxygen delivery to the vital 
organs causes symptoms of cold skin, dizziness, lethargy, palpitations, and can 
develop into pulmonary oedema, heart failure, depression and severe impairment of 
cognitive function (Ludwig and Strasser 2001). There are a number of publications 
reporting poor quality evidence for the co-existence of anaemia and cognitive 
deterioration (Stivelman 2000, Peters, Burch et al. 2008, Terekeci, Kucukardali et al. 
2010). However, there is a lack of reference in the literature to the phenomenon 
often observed by clinicians; most patients with severe chronic anaemia do not 
exhibit symptoms of cognitive impairment. The lack of published evidence may be a 
result of publication bias and the lack of enthusiasm to publish negative findings. 
Anaemia is a commonly occurring consequence of cancer and its treatment, 
affecting 39% of cancer patients at diagnosis and 67% of them at some point during 
their illness and treatment (Ludwig, Van Belle et al. 2004). In this study of 15,000 
European cancer patients, Ludwig et al described an incidence of anaemia of 54%, 
and reported a significant association between anaemia and deterioration in 
objective measures of performance status. Caro (Caro, Salas et al. 2001) found a 
correlation between anaemia and poorer survival rates in patients with lung 
carcinoma, cervico-uterine carcinoma, head and neck carcinoma, prostate 
carcinoma, lymphoma and myeloma. This link between anaemia and increased 
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mortality is very likely to be multifactorial and therefore, cannot be solely attributed to 
the anaemia itself: for example, more advanced, metastatic carcinomas or 
lymphomas may cause anaemia through infiltration of the bone marrow and through 
chemotherapy, and are associated with deterioration in survival compared to 
localised disease. A recent Danish study reported that one- and 5-year survival of 
patients with prostate carcinoma was 87% and 56% in those without bony 
metastases at diagnosis, but 47% and 3% in those who did have skeletal 
metastases (Nørgaard, Jensen et al. 2010).  
Despite the questionable causality of evidence linking anaemia and deteriorating 
prognosis in patients with cancer, more conclusive evidence exists demonstrating 
that a lower haemoglobin level correlates with a poorer quality of life in this patient 
group (Crawford, Cella et al. 2002). While the primary objective of most cancer 
research is the prolongation of survival for this cohort of patients, quality of life is also 
extremely important. Supportive and palliative therapies that do not directly impact 
survival can have important positive effects on day-to-day physical, mental and 
social functioning, and self-perceived overall quality of life. Regardless of this, 61% 
of patients included in the European Cancer Anaemia Survey (Ludwig, Van Belle et 
al. 2004) received no treatment for their anaemia. It seems likely that the level of 
anaemia of those patients was deemed insufficiently depressed to warrant treatment; 
mean haemoglobin at the point of treatment initiation was 97 g/l, while 29.3% of 
patients had mild anaemia with Haemoglobin levels of between 100 g/l and 119 g/l. 
The decision to treat patients with a lower haemoglobin (Hb) concentration reflects 




Table 1: World Health Organisation Performance Status Score 
WHO Performance Status Score Functional Ability 
0 Normal activity 
1 Symptoms but fully ambulant 
2 Requiring bed rest for less than 50% of 
the day 
3 Requiring bed rest for more than 50% of 
the day 
4 Unable to get out of bed 
 
The WHO Performance Status is a standardised measure of functional ability giving 
a score of 0 to 4 (Zubrod, Schneiderman et al. 1960). WHO scores of 2-4 were 
recorded for 50.7% of patients with Hb <80g/l, 40% of those with Hb 80-99g/l, and 
24.8% of those with mild anaemia (Hb 100-119g/l) (Ludwig, Van Belle et al. 2004). 
This indicates that 70% of patients with mild anaemia do not receive treatment for 
anaemia but a quarter of this group of patients experience significant deterioration in 




1.4 TREATMENT OF CANCER-RELATED ANAEMIA 
 
Physicians treating patients with cancer-related anaemia can prescribe one of two 
main supportive therapies to improve their haemoglobin level; transfusion of packed 
red cells, or exogenous erythropoietin (EPO) injections. 
 EPO injections given to anaemic patients with cancer have been shown to improve 
quality of life measures in several studies. Demetri et al (Demetri, Kris et al. 1998) 
treated 2370 non-myeloid cancer patients with EPO which brought about 
improvement in Hb and quality of life irrespective of baseline Hb, tumour type and 
disease response but not performance status.  Crawford et al (Crawford, Cella et al. 
2002) reported that EPO treatment of this cohort of patients can improve subjective 
quality of life scores up to an Hb concentration of 140 g/l. Each of these studies is 
potentially flawed by their design, as neither included a control group treated with 
placebo, while they were also open label trials. These factors allow both reporter 
bias and placebo effect. EPO treatment can also be associated with significant side 
effects including an increased risk of mortality (Leyland-Jones, Semiglazov et al. 
2005): in an attempt to improve quality of life and survival, 939 patients with 
metastatic breast cancer with a Hb concentration between 120 and 140 g/l were 
given EPO weekly from the start of their chemotherapy. The Independent Data 
Monitoring Committee recommended early cessation of the trial because of higher 
mortality in the group being treated with EPO (12 month overall survival of 70% vs 
76%). While the reason for a difference in mortality could not be determined, there 
was an association with increased rate of thromboembolic disease in the intervention 
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group. Hence EPO is not deemed a suitable treatment for those patients with mild 
anaemia.  
Blood transfusion in anaemic patients almost always increases their haemoglobin 
concentration in the absence of active bleeding or haemolysis; however, patients 
with cancer have been found to derive limited symptomatic benefit from this 
therapeutic approach to their anaemia. Mercadante (Mercadante, Ferrera et al. 
2009) transfused cancer patients with an Hb concentration of 80 +/- 5 g/l. This 
improved their dyspnoea (breathlessness) and fatigue at day 1 post-transfusion but 
the benefit was reduced by day 15 post-transfusion despite maintained Hb 
concentration.  
Hence, neither exogenous erythropoietin injections nor blood transfusions provide an 
entirely effective or safe means of treating cancer-related anaemia and associated 
symptoms of fatigue. While the patient’s malignancy, treatment and comorbidities 
may explain some of the limitation of the symptomatic benefit of transfusion on their 
symptoms, the biochemical and morphological changes within stored blood might be 
a contributory factor. 
 
1.5 THE EFFECTS OF STORAGE ON BLOOD   
 
Joint UK Blood transfusion and Tissue Transplantation Services Professional 
Advisory Committee guidelines state that, after donation, leukocyte-depleted packed 
red cell units can be stored for up to 35 days before transfusion (N.B.S. 2013). Blood 
is preserved by collection into sealed bags containing 63ml of citrate phosphate 
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dextrose (CPD) anticoagulant and its core temperature is maintained at 4 +/- 2°C. 
However, significant alterations occur within the sealed units during storage. These 
include slowing of cation transport, depletion of ATP and 2,3 diphosphoglyceric acid 
(2,3-DPG) reservoirs with resultant change in oxygen transport, accumulation of 
lactate, oxidative damage of proteins and lipids, and morphological changes, all of 
which contribute to progressive accumulation of oxidative stress and in turn, 
oxidative lesions to proteins and lipids (D'Alessandro, Kriebardis et al. 2014). While 
the unexpected limitation in the clinical benefit of transfusion is likely to be 
multifactorial, changes in oxygen transport and red blood cell morphology appear to 
be of particular relevance, in part through their effect on ˙NO bioavailability. 
 
1.5.1 THE OXYGEN TRANSPORT DEFICIT OF STORED BLOOD 
 
Adenosine triphosphate (ATP) and 2,3-DPG are consumed by, and rapidly depleted 
in stored blood (Gelderman, Yazer et al. 2010). This impairs the stability of 
deoxyhaemoglobin, which consequently has a higher affinity for oxygen (O2), 
causing a steady increase in haemoglobin oxygen saturation up to 99% on day 42 of 
storage (Bennett-Guerrero, Veldman et al. 2007). This increase in affinity of 
haemoglobin is countered by glycolysis which, during storage, causes acidification of 
the intracellular environment. Through the Bohr effect, acidification causes the O2 
affinity of haemoglobin to fall again, although through negative feedback, 
acidification causes inhibition of glycolysis and hence limits the effect of this 
pathway. However, the net effect is an increase in oxygen affinity of haemoglobin in 
older stored red blood cells (D'Alessandro, Kriebardis et al. 2014). Storage also 
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causes deregulation of S-nitrosation of Hb, potentially reducing the bioavailability of 
˙NO.  In turn, this may limit the RBC’s ability to induce hypoxic vasodilation and 
hence, reduce its ability to match O2 supply to metabolic demand (Reynolds, Bennett 
et al. 2013).  
This potential effect is somewhat controversial; two schools of thought exist 
regarding the nature of the ˙NO reservoir, both of which have equally credible 
backing: ˙NO gas is extremely unstable, oxidised within seconds to nitrogen dioxide 
and higher oxides of nitrogen. In solution, ˙NO  exposed to oxygen has a half-life of 
less than 10 seconds (Ignarro 1989) so, in order to exert an effect when required, a 
reservoir must exist which releases ˙NO in order to exert its effect, essentially 
buffering its concentration (Stamler, Jaraki et al. 1992).  As described above, this 
vascular storage pool is advocated to either be in the form of S-nitrosation (Foster, 
McMahon et al. 2003)  or as NO2
- (Cosby, Partovi et al. 2003).  
Organic nitrites are potent vasodilators in vitro (Ignarro, Lippton et al. 1981). While 
both organic and inorganic nitrates and nitrites mediate their principle effects in vivo 
via nitric oxide, there a number of important differences between them. Inorganic 
nitrate and nitrite have simple ionic structures, are produced endogenously and are 
also present in the diet, whereas their organic counterparts are far more complex, 
and, with the exception of ethyl nitrite, are all medicinally synthesised products 
(Omar, Artime et al. 2012). As a result, they have differing bioavailability and 
metabolic profiles, while their pharmacodynamic profiles are more markedly different 
still. Organic nitrates have potent acute effects causing vasodilation, whereas 
inorganic nitrates’ effects are more subtle and depend on certain conditions. NO2
- 
exists  in vivo at concentrations of 150 - 1000 nM in plasma and >10 μM in aortic ring 
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tissue (Gladwin, Shelhamer et al. 2000), although both plasma and vascular 
endothelial NO2
-  concentrations are probably in vast excess compared to plasma S-
nitrosothiol concentrations, conjectured to be approximately 10 µM (Stamler, Jaraki 
et al. 1992).  
S-nitrosothiols, have long been known to circulate in the plasma and to have 
bioactivities similar to those of ˙NO  but with half-lives in the order of hours (Stamler, 
Jaraki et al. 1992). While investigating how nitrogen oxide-containing vasodilators 
exert their effect, Ignarro discovered that they react with cysteine to form S-
nitrosocysteine. They found that this is a potent activator of guanylate cyclase, 
stimulating cGMP accumulation and hence smooth muscle relaxation. 
The most characterised and established mechanism by which ˙NO acts as a second 
messenger in signal transduction is its reaction with the haem centre of soluble 
guanylate cyclase and a consequential increase in cGMP, with a subsequent effect 
on vasoactivity (Foster, Hess et al. 2009) (see section 1.2.2.1 above). Further 
mechanisms must exist explaining some of the post-translational effects of ˙NO, as 
haems generally do not elicit cellular signalling involving post-translational 
modification of proteins. The process of S-nitrosation may enable ˙NO to exert its 
ubiquitous effect on cellular function through mechanisms analogous to 
phosphorylation as outlined above (Hess, Matsumoto et al. 2005).  
 
1.5.2 CHANGES IN MORPHOLOGY OF STORED RED BLOOD CELLS 
 
Following donation, stored RBCs become progressively smaller and more dense as 
a result of ATP depletion and lipid loss, forming Hb-containing microparticles 
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(Haradin, Weed et al. 1969) particularly after the second week of storage. Oxidative 
stress to lipids in the red blood cell membrane causes transformation of the RBC 
morphology into spheroechinocytes. The term ‘echinocyte’ describes an RBC with 
regular finger-like projections of cytoplasm around its circumference. The tips of 
these echinocytic spines can release haemoglobin-containing microvesicles of lipid 
bilayer through exovesiculation (Hess 2014). While most extracellular Hb in packed 
red blood cell units is contained within these microparticles, cell-free Hb also 
increases as a function of storage duration (Liu, Zhao et al. 2013). When Hb is 
encapsulated within a RBC, it scavenges ˙NO up to 1000 times slower than when 
the Hb is not within a RBC, possibly through the effect intravascular flow and shear 
stress has on particles, and the subsequent formation of a cell-free zone (Liao, Hein 
et al. 1999). This RBC-free zone exists near the blood vessel wall, can be as much 
as 20-25% of the vessel’s diameter, and allows the outflow of ˙NO into the 
endovascular smooth muscle layer, while reducing interaction between endothelium-
released ˙NO and the circulating RBCs (Butler, Megson et al. 1998, Liao, Hein et al. 
1999). As older stored blood contains more microparticles and free haemoglobin 
than normal blood in vivo, it would therefore have a far greater ˙NO scavenging 
capacity. Free Hb exists as a homogenous solution within the blood vessels and is 
free to enter the cell-free zone where it readily scavenges ˙NO given its very high 
affinity. Hence, stored blood has a far greater propensity for ˙NO scavenging. The 
extracellular Hb increases the transfused blood’s immunogenicity, thrombogenicity, 
its pro-inflammatory and pro-coagulant nature, and its ˙NO scavenging activity (Liao, 
Hein et al. 1999, Bennett-Guerrero, Veldman et al. 2007, Stamler, Singel et al. 2008, 
D'Alessandro, Kriebardis et al. 2014). The reduction in ˙NO bioavailability after blood 
transfusions may therefore have a further detrimental effect on the transfusion 
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recipient’s ability to vasodilate in conditions of hypoxia. This may influence the 
burden of symptoms in people with chronic anaemia requiring transfusion support.  
In an animal model of bacterial pneumonia with septic shock, massive transfusion of 
42 day old blood was found to profoundly increase mortality, lung injury and degree 
of haemodynamic shock compared to 7 day old blood (Solomon, Wang et al. 2013). 
Stored RBCs were found to haemolyse in vivo resulting in persistent increased 
intravascular cell-free haemoglobin over days, and more ˙NO scavenging. As a 
result, the older blood was found to be more vasoactive; during transfusion, systemic 
blood pressures and pulmonary artery pressures were higher. The pulmonary 
hypertension remained elevated for 10 hours after transfusion and was severe 
enough to adversely affect left ventricular filling and cause right ventricular dilatation. 
Increased free oxyhaemoglobin, a vasoconstrictive substance in the plasma, was 
found to worsen ischaemic vascular damage in the lung at the site of the pneumonia. 
Hence, older blood had a detrimental effect on outcomes in a canine model of septic 
shock and massive transfusion through reduction in ˙NO bioavailability. 
In contrast to the paper described above (Solomon, Wang et al. 2013), transfusion 
with older blood had no detrimental effect on outcome in a different animal model, 
this time mimicking haemorrhagic shock (Solomon, Cortés-Puch et al. 2015). They 
noted that the physiological response to this insult was altered, with an association 
between transfusion of 42 day old blood and a reduction in norepinephrine 
requirements and cardiac outputs. This also demonstrated a trend towards improved 
survival in this cohort of animals compared to those given 7 day old blood 
transfusion. Hence this study suggests that the vasoconstrictive effect of reduced 
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˙NO bioavailability associated with older blood was perhaps beneficial in this 
population of patients at high risk of hypoxic ischaemia/reperfusion injury. 
Sickle cell disorders including sickle cell disease represent some of the commonest 
inherited genetic disorders worldwide, affecting 2.28 of conceptions per 1000, 
causing 3.4% of mortality in children under the age of 5 (Modell and Darlison 2008). 
This condition is caused by a single nucleotide polymorphism (glutamine to valine 
substitution) at the 6th residue of the beta globin gene found on the short arm of 
chromosome 11 (Stuart and Nagel). HbS, the variant beta haemoglobin product of 
this mutation, polymerises readily when deoxygenated, distorting the red cell 
morphology into sickle or crescent forms, causing haemolysis and vaso-occlusion. 
This increased haemolysis explains the association between sickle cell disease and 
an increase in haemoglobin-containing red blood cell microparticles (Liu, Zhao et al. 
2013).  This extracellular haemoglobin readily scavenges ˙NO, contributing to the 
hypertensive and thrombotic tendency seen in sickle cell disease and other disorders 
of intravascular haemolysis, along with the potentially life-threatening sequelae of 
acute haemolytic transfusion reactions (Wallis 2005). It also promotes painful 
episodes of vaso-occlusion, which are the leading cause of hospitalisation and 
emergency department visits in sickle cell disease, and are associated with 
increased mortality (Morris, Kuypers et al. 2013).  In an attempt to overcome the 
reduced bioavailability of ˙NO, this group gave children with sickle cell disease 
dietary arginine supplementation, hence providing increased substrate for the L-
arginine NOS pathway of ˙NO production amongst other effects, counteracting the 
vasoconstrictive effect of intravascular haemolysis, increased free haemoglobin and 
increased ˙NO scavenging. This intervention brought about an improvement in pain 
and a 54% reduction in opioid use in hospitalised children with painful episodes of 
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vaso-occlusion indicating improved oxygenation of affected tissues (Morris, Kuypers 
et al. 2013). Supplementation of dietary NO3
- could have a beneficial effect in 
patients with sickle cell disease via similar mechanisms; this intervention has been 
demonstrated to decrease middle cerebral artery blood flow velocity and hence 
cerebrovascular resistance (Bond, Curry et al. 2013). This simple intervention could 
potentially reduce the risk of stroke in patients with sickle cell disease, although this 
effect is yet to be studied in this population.  
No previous studies have investigated the effect of dietary NO3
- supplementation on 




1.6 THE NEUROCOGNITIVE EFFECTS OF CHEMOTHERAPY 
 
Chemotherapy-related cognitive impairment sometimes referred to by patients as 
‘Chemobrain’, was first described in the 1970s (Weiss, Walker et al. 1974), affecting 
between 17 and 75% of cancer patients with a plethora of malignancies undergoing 
a range of treatment modalities (Myers 2009). Patients with Non-Hodgkin’s 
Lymphoma treated with RCHOP or R Bendamustine chemotherapy were found to 
have an objective cognitive impairment compared to control during the 3 months 
following chemotherapy (Zimmer, Mierau et al. 2014). Women with breast cancer 
reported a deterioration in memory and distraction, while an objective worsening of 
attention, concentration, memory and processing speed was reported when 
compared to controls (Ganz 2012). While many short-term studies have revealed 
this effect, a more durable cognitive impairment has also been revealed in patients 
with breast cancer (Wefel, Lenzi et al. 2004). In this study, prospective 
neuropsychiatric testing was undertaken in people newly diagnosed with this 
condition, and at short-term (3 weeks) and long-term (6 months) intervals after 
chemotherapy. They noted that 33% had cognitive impairment before treatment 
started, and 61% displayed a deterioration in their baseline function, particularly in 
attention, learning and processing speed. At the long-term follow-up, 50% of patients 
had not recovered to their baseline cognitive function.  
The pathophysiology of chemobrain is likely to be multifactorial but is poorly 
understood. Potential contributors include social factors such as age, educational 
levels, IQ and social support, and psychological factors such as anxiety and 
depression. Physical factors including fatigue, disease site, stage, co-morbidities, 
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hormone levels, cytokines, damage to neural progenitors and presence of the 
apolipoprotein E4 allele can all influence cognitive function. Finally, cancer treatment 
factors affecting cognition include treatment type, timing, duration and any 
concomitant management (Myers 2009). 
Central nervous system (CNS) function is affected by both chemotherapy and 
radiotherapy, via variable mechanisms depending on the agent involved. The drugs 
or their metabolites can cause direct injury to the grey or white matter, microvascular 
injury or immune-mediated CNS inflammatory responses (Wefel, Lenzi et al. 2004). 
Interleukin-6, a pro-inflammatory cytokine able to penetrate the blood-brain barrier, 
was found in higher levels in post-chemotherapy blood samples from patients with 
breast cancer complaining of fatigue than those who were not (Zimmer, Mierau et al. 
2014). Doxorubicin chemotherapy was reported to induce an increase in tissue 
necrosis factor α (TNFα) in a murine study. This was associated with a decline in 
CNS mitochondrial respiration and mitochondrial protein nitration in wild type mice, 
but not in iNOS knock-out mice. This single study suggests ˙NO might mediate 
Doxorubicin-induced CNS injury (Tangpong, Cole et al. 2007), although this has not 
been studied in the human population. Conversely, a further murine study 
demonstrated a reduction in doxorubicin-induced ventricular dysfunction, cell death, 
oxidative stress and mitochondrial respiratory chain damage in mice given seven 
days of sodium nitrate supplementation (Zhu, Kukreja et al. 2011). This group 
described a significant decrease in tissue peroxidation as a result of preservation of 
mitochondrial complex I activity and oxidative phosphorylation. Hence, dietary nitrate 
supplementation may provide a cardioprotective effect in humans undergoing 
chemotherapy with anthracyclines, although further work is required to fully establish 
the nature of this relationship. 
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˙NO may also have a protective role in the aetiology of chemotherapy-related 
cognitive impairment. Magnetic resonance diffusion tensor imaging of patients with 
breast cancer post-chemotherapy showed decreased white matter integrity in tracts 
involved in cognition in the fronto-parietal and occipital lobes. This correlated with 
deterioration in objective measures of cognitive function, and suggests some 
uncoupling of blood flow and neuronal activity (Deprez, Amant et al. 2011) 
Hence, although this has not been studied in this population previously, dietary 
supplementation with inorganic NO3
- might have some benefit in countering the 
detrimental effects cancers and their treatments have on cognitive function, through 
modification of cerebral blood flow, subsequent improvement in cerebrovascular 
neuronal coupling, and hence matching of oxygen supply with neuronal activity 
(Bond, Curry et al. 2013).  
 
1.7 LITERATURE REVIEW SUMMARY 
 
˙NO is a simple yet extremely active gas molecule which plays a fundamental role in 
human homeostatic mechanisms. Produced through the L-arginine – NOS pathway 
or through sequential reduction of dietary NO3
- via the enterosalivary circulation, it 
has a profound influence on mitochondrial respiration, vasodilation, muscle 
contractile efficiency and force, exercise efficiency, platelet aggregation, cerebral 
blood flow and neurotransmission. Three decades of research have demonstrated 
potential clinical efficacy of increasing the bioavailability of ˙NO in both health and 
disease through manipulation of its production through either of the pathways above. 
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This includes treatment of pathological conditions as diverse as sickle cell disease 
(Morris, Kuypers et al. 2013), chronic obstructive pulmonary disease (Berry, Justus 
et al. 2015), peripheral vascular disease (Allen, Giordano et al. 2012), type 2 
diabetes mellitus (Gilchrist, Winyard et al. 2014) and cognitive impairment (Piknova, 
Kocharyan et al. 2011) amongst others. It has not yet been studied in the anaemic 
population but, given its wide-ranging effects, particularly those on the circulation, 
the matching of oxygen demand and supply, and efficiency of muscle metabolism 
and respiration, dietary NO3
- may provide a viable complement to existing 
treatments. Of further interest is the storage deficit associated with donated blood; 
the biochemical and morphological changes which occur between donation and 
transfusion may explain why patients requiring blood transfusions still experience 
symptoms related to anaemia despite improvement in haemoglobin. Dietary 
supplementation of NO3
- could potentially ameliorate or overcome these symptoms 
and improve the quality of life, exercise function and cognitive function of patients 
with anaemia and cancer.  
˙NO inhibits platelet aggregation (Alheid, Frolich et al. 1987, Apostoli, Solomon et al. 
2014). As having a cancer diagnosis is associated with increased risk of thrombosis 
(Lee and Levine 2003), dietary supplementation with NO3
- might overcome this effect 







1.8 AIMS AND OBJECTIVES 
 
The aim of this research was to perform a pilot study examining the feasibility of 
recruiting patients with cancer related anaemia to a randomized controlled trial 
studying nitrate supplementation.  Patients with malignancies usually develop 
anaemia as a consequence of infiltration of their bone marrow by their disease, or as 
a consequence of therapy. This dynamic patient population can undergo intensive 
treatment or develop unpredicted complications of their cancer or its therapies, and 
are often subjected to psychological stresses related to their diagnosis and 
prognosis. This pilot study aimed to provide estimates of differences in potential 
outcome measures and guide the likely requirement for resources to run a full scale 
study.  Following this pilot study, a larger study will be planned, investigating whether 
nitrate supplementation is beneficial for patients with anaemia with respect to 
symptoms of anaemia, cognitive function, muscle strength and efficiency, and 
platelet aggregation. 
The key objectives were to assess: 
  Percentage of patients who are eligible for inclusion in the study 
 Of patients who are eligible, percentage who consent to study entry 
 Of patients consenting to study entry, percentage who complete the study 
 Percentage of enrolled participants who complete all aspects of the study 




 Refinement of nitrate and nitrite measurements and other data collection 
methods 
 Estimation of standard deviations of the main outcome measures: 
o Quality of life 
o Exercise tolerance and related measures 






Relative to a nitrate-depleted placebo beetroot juice, dietary supplementation of 
anaemic patients with nitrate-rich beetroot juice will have no effect on: 
 Thrombogenicity 
 Muscle phosphocreatine recovery rate 
 Exercise tolerance 
 Cognitive function 








Prior to initiation of patient recruitment and data collection, this trial was registered as 
a clinical trial at the Integrated Research Application System (IRAS, reference 
number 123901). Ethical approval was also obtained from the south west regional 
ethics committee (REC, reference 14/SW/0081, Appendix 6). The Royal Devon and 
Exeter Foundation NHS Trust gave its approval for this study to proceed (Research 
and Development reference number 1404914, Appendix 1), while the University of 
Exeter also approved its initiation for the purposes of a Doctor of Medicine Degree 
(candidate number 032816). 
 Adult patients with anaemia attending the Haematology and Oncology Departments 
of the Royal Devon and Exeter Hospital were offered recruitment into the trial. 
Patients in these departments are anaemic for a variety of different reasons, 
including chemotherapy side effects, aplastic anaemia, acute and chronic 
leukaemias, lymphoma, myeloma, chronic blood loss and bone marrow infiltration 
with solid tumour. 
Advice was sought from the Royal Devon and Exeter Foundation NHS Trust 
Consultant Statistician regarding participant recruitment and power calculation. As 
this was a pilot study, no power calculation was performed as no previous data was 
available on which to base it. However, the aim was to recruit 30-40 patients. Data 
generated by this study would therefore allow power calculations to be performed to 
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inform future similar studies of the number of participants required to give results 
statistical significance. 
 
Inclusion Criteria  
 Age >18 years 
 Haemoglobin level of <120 g/l 
 Blood transfusion requirement of less than 3 units per fortnight 
 Ability to give informed consent 
 Written consent 
 Understanding of the procedures to be undertaken as part of the study 
 Willingness to participate in exercise testing and follow intervention 
guidelines and other instructions provided by the experimenters. 




 Allergy to beetroot. 
 Significant cardiac, respiratory, renal or liver comorbidities 
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 Aspirin, clopidogrel, dipyridamole, NSAID or other anticoagulant use (e.g. 
warfarin, low molecular weight heparin or other oral anticoagulants) will be 
excluded from the platelet aggregometry arm of the study. 
 Platelet count of <50 will be excluded from platelet aggregometry 
 Musculoskeletal disorders that would make exercise testing impractical 
(inability to walk one mile) 
 Inability to lie flat for the conduction of exercise testing 
 Anyone unable to have an MRI scan was offered alternative exercise 
testing (as assessed by MR ‘Participant Safety Checklist’) 
Of note, while the use of antibacterial mouthwashes is commonplace amongst the 
population of patients within the oncology and haematology departments who were 
approached for recruitment to the current study, this was not restricted amongst 
participants. Many used Difflam® 0.15% (methylparahydroxybenzoate and ethanol) 
or Corsodyl® (chlorhexidine digluconate) in order to reduce both chemotherapy-
induced oropharyngeal inflammation and bacterial growth. Given the chemotherapy 
and immunosuppression of this population of patients, their inherent vulnerability to 
infection meant that antibacterial mouthwash use was not used as an exclusion 
criterion despite its effect on the oral microbiome and the potential for an effect on 
the individual’s ability to reduce salivary nitrate to nitrite in the oral cavity. 
Informed consent 
All trial participants were given a Patient Information Sheet (Appendix 2) giving 
detailed information about the trial objectives, structure, interventions, investigations, 
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risks and benefits in layman’s terms.  After a period of time sufficient to digest this 
information, they met with a member of the research team on a one-to-one basis.  
The trial was explained to them verbally, explaining each of the above points and 
checking the subject’s understanding throughout.  The researcher made clear that 
enrolment in the trial had no effect on the normal treatment of their underlying health 
condition, and that their usual healthcare team would not be informed of the results 
of their tests.  Participants were also reassured that they were free to end their 
involvement in the trial at any point and that this would not influence their usual care. 
They were given the opportunity to ask any questions throughout the discussions, 
which were answered fully and in layman’s terms.  Once satisfied with all aspects of 
the trial, if they were still keen to be enrolled, written consent was obtained by the 
researcher. 
 
2.2 GENERAL RESEARCH DESIGN 
 
This was a prospective, balanced randomised cross-over pilot study. Once recruited 
into the trial, participants underwent baseline assessment of quality of life, muscle 
performance and exercise capability along with blood tests. They were randomised 
to receive either concentrated beetroot juice rich in nitrates (BR) (Beet It Sport Pro-
Elite Shot, James White Drinks Ltd, Ashbocking, Suffolk, UK), or nitrate-deplete 
placebo beetroot juice (PL) (Nitrate-Depleted Beet It Sport Pro-Elite Shot, James 
White Drinks Ltd, Ashbocking, Suffolk). The latter juice is produced purely for 
research purposes by passing beetroot juice through a column containing the anion 
exchange resin Purolite a520e which exchanges nitrate for chloride (Gilchrist, 
Winyard et al. 2014). Normally used in the treatment of water for human 
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consumption, Purolite a320e produces a safe dietary product which is identical in its 
appearance, taste, texture and smell to BR. 
After their initial baseline appointment, participants drank 5 x 70ml bottles of their 
allocated juice at 48, 36, 24, 12 and 2.5 hours prior to their second point of 
assessment. All of the above assessments were repeated following this period of 
supplementation at experimental visit 2. Once completed, participants were asked to 
return 3-6 weeks after their second appointment for a repeat of all of the above 
assessments to update their baseline results. They were then given 5 x 70 ml bottles 
of either nitrate-rich or nitrate-deplete beetroot juice (whatever they did not receive at 
randomisation) which they again drank in the days leading up to their final 
assessment at 48, 36, 24, 12 and 2.5 hours prior to their appointment (Figure 5). To 
avoid any ‘order effect’, in which a patient received BR first, but the effects were 
carried over to the period when they received PL, there was a minimum three week 
‘washout’ period before testing was repeated. Data from healthy subjects suggested 
that the effects of nitrate are lost within 24 hours (Wylie, Kelly et al. 2013) so it was 
postulated that three weeks would be ample to prevent carry-over of the active 
compound. 
One disadvantage of this ‘cross-over’ design was the inadvertent introduction of bias, 
whereby patients who remained in the study long enough to complete the second 
half of the study may not have been comparable to the group as a whole.  Patients 
receiving chemotherapy have regular fluctuations in their blood counts and general 
well-being. One of the advantages of the cross-over design is that each participant 
acts as their own control; this can be helpful in unstable participant populations. For 
example, patients are likely to suffer from the effects of their cancer early on in 
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treatment, but over time, will typically be more affected by the side effects of 
treatment. The cross-over design aimed to help correct for these fluctuations over 
time, ensuring that data collection would inform the researchers about the effects of 
nitrate supplementation, rather than measuring the changes in physiology caused by 
active malignancy or chemotherapy.  However, participants who remained in the 
study for all four visits may have performed better in all of their tests than those who 
were forced to withdraw as a result of ill health, hence giving a potential source of 
confounding. The other reason a cross-over design was utilised in this study was 
that it is much more acceptable to patients to know that they will at some point 
receive the ‘active’ ingredient. 
Prior to initiation of recruitment to the study, both beetroot juice and nitrate-depleted 
beetroot juice were code labelled by a scientist in the University of Exeter 
Department of Sport and Health Sciences not otherwise involved in this research. 
The person labelling the supplements ensured that their order was counter-
balanced; meaning equal numbers of participants received each intervention at the 
first point of supplementation. Therefore, no-one involved in the study knew the order 
of supplementation until after data collection was complete. Hence participants, 
clinicians, research nurses and scientists were all blinded to the order of 
supplementation for each participant until the coding was revealed upon data 
analysis once data collection was complete. 
Through this study design, each participant was their own internal control, reducing 
confounding and selection bias. In order to reduce recruitment bias, consecutive 
patients attending haematology/oncology outpatient clinic who were eligible to enter 
the trial were approached to consider participation in the study. Blinding ensured 
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there was no recall, reporting or observer bias. Trained research staff used the 
functional assessment of cancer therapy – anaemia scale (FACT-An) validated 
questionnaire (Appendix 3) (Cella 1997, Cella, Eton et al. 2002) to measure 
participant quality of life and the ‘functional assessment of cancer therapy - cognition 
(FACT-cog) questionnaire (appendix 4) (Jacobs, Jacobsen et al. 2007, Bell, Dhillon 
et al. 2018) to assess their cognitive function. These validated questionnaires were 
devised in order to obtain reproducible, validated methods of obtaining objective 
qualitative feedback of the symptomatic burden participants experienced as a result 
of anaemia, and the effect that cancer and its therapy has on a participant’s cognitive 
function. Each questionnaire uses a standard set of questions, allowing participants 
to select one of five possible responses to each one. The responses are scored 
according to the guidelines accompanying the questionnaires and were allocated a 
total score of between 0 and 188 (FACT-An) or 0 and 132 (FACT-Cog). The higher 
the score obtained, the better the quality of life and lower the symptomatic burden 
experienced by that patient. The participants completed these questionnaires 
unaided reducing observer bias. Questionnaires were used with the kind permission 










































Figure 5: Experimental Design 
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2.3 HEALTH AND SAFETY 
 
Researchers underwent appropriate health and safety training prior to obtaining 
access to the biochemistry laboratories, and ensured these guidelines were adhered 
to.  A Control of Substances Hazardous to Health (COSHH) health and safety 
assessment was performed before any investigations or sample analyses were 
undertaken. All researchers wore disposable latex gloves and laboratory coats when 
handling blood products, while any sharps and biohazards used were disposed of in 
a sharps bin.  
All exercise physiology testing procedures were compliant with the University of 
Exeter health and safety policies.  This included strict maintenance of hygiene and 
cleanliness through regular cleaning of work surfaces, ergometers and other 
equipment in the exercise physiology laboratory.  Each participant was afforded an 
appropriate period of ‘warm-down’ after the cycle ergometry test.  
The hygiene and cleanliness of the magnetic resonance spectroscopy room was 
also maintained through regular cleaning.  Access to this area was strictly controlled 
given the extremely powerful magnetic field; only staff specifically trained in the 
operation of the MRI scanner were allowed to perform this part of the experimental 
procedure, and completed an MRI safety checklist before initiation of data collection.  
All tests were performed under the direct supervision of a Post-Doctoral Research 
Fellow in MRI. Participants also completed an MRI safety checklist prior to each 
scan to ensure they were suitable candidates to complete that arm of the 




All investigations were performed under close supervision by a member of the 
research team who was also a qualified medical doctor. Participant symptoms, 
oxygen saturations, heart rate and age-predicted heart rate reserve were constantly 
monitored during exercise. The participants were given instructions about when to 
terminate the ergometry according to their symptoms and heart rate, ensuring they 
did not exercise excessively. Basic resuscitation equipment was available in the 
laboratory. 
 
2.4 ADVERSE EVENTS 
 
This study of dietary supplementation had some potential risks. The above exclusion 
criteria prevented patients with significant pre-existing co-morbidities from entering 
the trial, reducing the risk from gentle exercise testing. However, there was a 
significant risk associated with asking unhealthy and potentially unstable patients to 
exercise as this could have precipitated cardiovascular or respiratory compromise.  
Magnetic resonance spectroscopy was chosen as a means of assessing muscle 
strength and metabolic activity because it is non-invasive and safe, as it does not 
expose participants to ionising radiation.  
Beetroot juice itself was taken in small quantities repeatedly, but does not taste 
particularly pleasant.  Study participants were reassured that, should they feel 
unable to drink the supplements, they could withdraw from the study with no effect 
on their ongoing medical care. 
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An adverse event was defined as the appearance or worsening of any undesirable 
sign, symptom, or medical condition occurring after starting the study even if the 
event was not considered to relate to the study intervention. Medical conditions and 
diseases present before starting the study were only considered adverse events if 
they worsened after starting the study. Abnormal laboratory values or test results 
constituted adverse events only if they induced clinical signs or symptoms that were 
considered clinically significant or required therapy.  
The occurrence of adverse events was sought by non-directive questioning of the 
participant at each visit during the study.  Adverse events also could have been 
detected when they were volunteered by the participant during and between visits, or 
through physical examination, laboratory test or other assessments.  Any adverse 
events were to be recorded within the participant’s clinical research file with the 
following information:  
• The severity grade (mild, moderate, severe) 
• Its relationship to the study (suspected/not suspected) 
• Its duration (start and end dates or if continuing at final exam) 
• Whether it constituted a serious adverse event (SAE) 
 
Any adverse events would have been treated with one or more of the following: No 
action taken (i.e. further observation only); Study permanently discontinued due to 
this adverse event; Concomitant medication given; Non-drug therapy given; Patient 
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hospitalised / patient’s hospitalisation prolonged.  The action taken to treat the 
adverse event was recorded in the participant’s clinical research file. 
Adverse events which affected participants would have been followed until resolution 
or until they were judged to be permanent, and an assessment would have occurred 
at each visit (or more frequently, if necessary) of any changes in severity, the 
suspected relationship to the study intervention (beetroot juice), the interventions 
required to treat it, and the outcome. 
To ensure patient safety, every serious adverse event (SAE), regardless of 
suspected causality, occurring after the patient had provided informed consent and 
until 90 days after the patient had stopped study participation was reported to the 
chief Investigator.  A log of all adverse events was recorded in the patient’s CRF, 
which was shared with the Research and Development department. 
 
2.5 DATA COLLECTION AND QUALITY CONTROL 
 
Case report forms (CRFs) were used to collect the data.  At the end of each 
participant’s involvement in the study, the research nurse was responsible for 
ensuring the accuracy, completeness, legibility and timelines of the data reported in 
the CRFs. The CRFs were completed in black or blue ink. Only the chief investigator 
and those personnel authorised by him were allowed to enter or change data in the 
CRFs. All laboratory data and observations were transcribed into the CRFs.  31P-
MRS scans were reported in summary in the CRFs. The original reports, traces and 
films were retained by the principal investigators for future reference. 
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Corrections were made only by striking out any errors, with a single stroke, and not 
by using correction fluid. The correct entry was entered by the side. The incorrect 
figure remained visible and the correction was initialled and dated by the person 
authorised by the chief investigator to make the correction. 
After all the queries were resolved at the end of the study, the chief investigator 
confirmed this by signing off the CRFs. The original CRFs were subsequently 
archived by the research nurse.  
2.6 DATA MANAGEMENT 
 
Participants were given a Unique Identifying Number (UIN) upon recruitment to the 
study. All blood samples, questionnaire responses and ergometry performance data 
were anonymised using this UIN. These results were not accessible to the clinician 
caring for the patient. Research nurses gathered anonymised information using the 
Functional Assessment of Cancer Therapy - Anaemia (FACT-An) and Functional 
Assessment of Cancer Therapy - Cognition (FACT-Cog) questionnaires and a trial 
data collection sheet at each clinic appointment. Exercise testing, blood tests and 
31P-MRS results were documented using the same participant UIN.   
The only personal data stored was in the written CRFs, and comprised solely of the 
participant's initials, date of birth, and hospital number.  CRFs were stored according 
to hospital trust policy, in the locked room retained specifically for the purpose of all 
haematology trials. 
In order to ensure participant confidentiality, the NHS Code of Confidentiality was 
followed, along with the GMC's 'Confidentiality' guideline (2009). Patient identifiers 
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were kept to a minimum through use of the UIN on results from blood tests, exercise 
testing and MRS along with FACT-An and FACT-Cog questionnaires. 
 
2.7 MEASUREMENT PROCEDURES 
 
This thesis reports the results of 104 exercise tests. These were conducted in an air-
conditioned exercise physiology laboratory and an air-conditioned 31P-magnetic 
resonance spectroscopy room, each at sea level, with an ambient temperature of 19-
21°C. Also included are the results of 104 Functional Assessment of Chronic Illness 
Therapy (FACIT) questionnaires, investigating participants’ cognitive function and 
quality of life. These questionnaires were completed in the presence of a trained 
researcher in a formal interview setting with minimal distraction and interruption. All 
procedures were in accordance with the standards set out by the Declaration of 
Helsinki and Good Clinical Practice. They were approved by the National Regional 
Ethics Service Committee South West (ref: 14/SW/0081), the University of Exeter 
and the Royal Devon and Exeter Hospital Research and Development department 
prior to initiation of data collection.  
 
2.7.1 DESCRIPTIVE DATA 
 
Prior to study entry, the participant’s height, weight, gender and underlying diagnosis 
were recorded on the CRF, along with their age.  Each time they attended for 
exercise physiology testing and questionnaires, their haemoglobin was also 
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recorded, along with the number of days since their last transfusion of packed red 
cells and the number of days since their last course of chemotherapy.  They then 
went on to undergo the specific testing as detailed below. 
 
2.7.2 BLOOD COLLECTION AND PROCESSING 
 
Upon arrival at each appointment, participants underwent venepuncture using a 21G 
butterfly needle. Blood was drawn into room temperature vacutainers appropriate to 
the experimental arms that individual was enrolled in. All participants gave 8 ml of 
blood into a clotted vacutainer (Sarstedt S-Monovette, Nümbrecht, Germany) which 
was later used for quantitation of ferritin, serum iron, transferrin and transferrin 
saturation. They also gave 8ml of blood into Lithium-Heparin vacutainers (later used 
for nitrate and nitrite quantitation) and 8ml into EDTA vacutainers (later used for 
quantitation of cGMP and haemoglobin.. All lithium heparin samples and all but one 
EDTA sample were immediately centrifuged at 4000 rpm for 10 minutes which 
equates to a g-force of 1729 g (Heraeus Labofuge 200 centrifuge, Thermo Fisher 
Scientific Inc, Waltham, MA, USA). Following centrifugation, the supernatant plasma 
was immediately removed and placed in 1.5 ml reaction tubes before transferring on 
ice to -80 °C storage freezers pending analysis (Kapil, Rathod et al. 2018).  
During the same venepuncture process, those participants who satisfied the 
inclusion and exclusion criteria for platelet aggregometry gave 18ml of blood in 
Citrate vacutainers (Sarstedt, Germany) which were stored vertically for 30 minutes 
at room temperature, prior to centrifugation and ongoing processing as detailed in 
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the section on platelet aggregometry. Further laboratory analysis of each blood 
sample is outlined below (section 2.7.7).  
 
2.7.3 FACT-AN AND FACT-COG QUESTIONNAIRES  
 
Upon completion of venepuncture, trained researchers explained how to complete 
the Functional Assessment of Cancer Therapy - Anaemia (FACT-An) and Functional 
Assessment of Cancer Therapy – Cognitive Function (FACT-Cog) questionnaires 
(Yellen, Cella et al. 1997, Wagner, Sweet et al. 2009) before participants were asked 
to complete the forms themselves. Researchers were available throughout should 
the participant have any queries. Investigators assisted those patients who were 
unable to self-complete by reading the questions for them, and asking the participant 
to choose which response from a card of options they were given for the duration of 
the questionnaire. Responses were scored according to the scoring template and a 
score of between 0 and 188 was allocated to each completed FACT-An 
questionnaire and between 0 and 132 for each completed FACT-Cog questionnaire. 
Higher scores indicated better quality of life and cognitive function respectively. 
 
2.7.4 BASELINE OBSERVATIONS 
 
After the quality of life questionnaires were completed, following 10 minutes of 
seated rest in a quiet, darkened room, baseline blood pressure of the brachial artery 
(systolic and diastolic) and heart rate was recorded using a DINAMAP® ProCare 
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Monitor (General Electric Healthcare, Little Chalfont, United Kingdom) and the mean 
of three readings was recorded. This widely used monitor contains a sensitive 
transducer which measures cuff pressure, and attributes tiny oscillations in pressure 
to the appearance and disappearance of the arterial pulse once it overcomes the 
occlusive pressure exerted by the cuff as the cuff deflates. These points correspond 
to the systolic and diastolic blood pressure while pulse pressure is calculated as the 
difference between the two. Blood pressure and pulse was checked four times over 
four consecutive minutes; the first values were discarded while the mean of the 
readings from the second, third and fourth minutes was recorded as the patient’s 
pre-exercise values in order to maximise accuracy.  
 
2.7.5 CYCLE ERGOMETRY 
 
After completion of venepuncture, questionnaires and baseline observations, all 
participants underwent a symptom-limited incremental cycle ergometer test at each 
experimental visit to the exercise physiology laboratory. These were performed on 
an electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, The 
Netherlands) which was regularly recalibrated by a laboratory technician in order to 
ensure maintenance of data quality throughout the study.  Pulmonary oxygen uptake 
and carbon dioxide exhalation was measured throughout the test on a breath-by-
breath basis in order to determine the participant’s gas exchange threshold (GET, 
see relevant section). Each test started with a 2 minute seated rest, followed by 3 
minutes of unloaded pedalling, before commencing a linear work rate increase to 
intolerance. Participants were asked to maintain a cadence which they found 
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comfortable during the unloaded pedalling. As each participant maintained the same 
cadence throughout their tests, the ergometer was able to impose a fixed work rate 
increase through electronic braking via flywheel resistance. Hence participants 
pedalled with a known power output (‘ramp rate’) during this section of the test. The 
power output of 10 watts per minute was selected by the researcher aiming to 
achieve the limit of exercise tolerance in around 8-12 minutes. Participants were 
instructed to exercise until they were breathing heavily, the exercise became 
challenging or when the pedal rate began to feel uncomfortably fast. Alternatively, if 
their heart rate reached 80% of age-predicted maximum, the exercise test was 
terminated. This maximum was determined by subtracting the patient’s age from 
220; for example, a 60 year old patient will have a maximum heart rate of 160, 
meaning they were allowed to exercise until they reached a heart rate of 128 beats 
per minute (160 x 0.8). Time to exhaustion was documented. 
Pulmonary gas exchange 
Dynamic breath-by-breath pulmonary gas exchange and ventilation was analysed 
throughout all cycle ergometry tests using an open circuit system.  Prior to every 
tests, a 3-litre calibration syringe was used to calibrate flow volume, while a 
pressurised gas cylinder containing known concentrations of oxygen and carbon 
dioxide (close to 15% and 5% respectively with 80% nitrogen) was used to calibrate 
the analysis of participants’ respiratory gases. An appropriate low dead space, tight-
fitting face mask was selected according to the size and shape of each participant’s 
face. This mask was connected to a metabolic cart analyser (Jaeger Oxycon Pro, 
Hoechberg, Germany) containing a transducer.  
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The widely used metabolic analyser quantified the carbon dioxide component of 
exhaled air using differential infrared absorption, and the oxygen component via 
paramagnetic absorption. The first technique relies on the fact that molecules such 
as CO2 containing dissimilar atoms will absorb infrared radiation and convert this 
energy into molecular vibration. The frequency of this vibration depends on 
molecular mass and atomic bonding within each molecule within the gas being 
analysed. Different molecules therefore absorb infrared at specific wavelengths and 
can be quantified (Langton and Hutton 2009). Oxygen quantification is enabled by 
the somewhat unusual characteristic of molecular oxygen; it is magnetic as a 
consequence of the two unpaired electrons in its outer electron ring, and is attracted 
into an electromagnetic field. Using a switched electromagnetic field generated at 
approximately 110Hz and a pressure transducer, a pressure difference is created 
between the reference sample (clean air) and the patient’s sample. A sensitive 
transducer then detects pressure variations and converts them to a DC voltage 
which is directly proportional to the concentration of oxygen (Langton and Hutton 
2009). 
The metabolic cart simultaneously quantified ventilation through a bidirectional digital 
volume sensor (‘TripleV’).  Breath-by-breath raw data on minute ventilation (VE), 
oxygen uptake (VO2) and carbon dioxide output (VCO2) was displayed digitally 
during cycle ergometry on a real-time basis after automated correction of 
concentration and volume signals of each breath. This was then exported for later 
analysis on completion of the study. This analysis included assessment of the 
VO2peak, maximum power output, time to exercise limit, and calculation of gas 
exchange or anaerobic threshold. Gas exchange threshold (GET) is defined as the 
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work rate at which anaerobic metabolism supplements aerobic mechanisms during 
progressive exercise.   
 
Oxygen Saturations 
Participants’ oxygen saturations were continuously analysed peripherally with a 
finger probe using a Masimo SET Rainbow Pulse Co-Oximetry monitoring platform 
(Masimo Europe Ltd, Matrix House, Basing View, Basingstoke, Hampshire, RG21 
4DZ). Conventional pulse oximetry cannot distinguish between arterial and venous 
blood in the exercising patient as it assumes that the only blood moving in the 
patient’s finger is arterial, whereas in exercise, venous blood moves more rapidly 
than at rest. As a result, these analysers under-read the arterial oxygen content as 
they cannot distinguish between the two blood pools, whereas the Masimo SET 
technology overcomes this difficulty. This widely used technology utilises adaptive 
filters in parallel processing mode along with conventional red over infrared 
algorithms to identify the venous  blood signal and extract the arterial signal, giving 
an accurate measure of arterial oxygen saturation (Barker 2002). It also assessed 
methaemoglobin as part of its standard capability. 
Heart rate 
During cycle ergometry, participants’ heart rate was recorded every 5 seconds using 
short range radiotelemetry (Polar S610, Polar Electro Oy, Kempele, Finland). This 
raw data was displayed to the researcher digitally, and was used to ensure no 
participant exceeded 80% of their age-predicted maximum heart rate during 
exercise. It was exported for further analysis on completion of the test.  
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2.7.6 31PHOSPHOROUS - MAGNETIC RESONANCE SPECTROSCOPY (31P-MRS) 
 
At each experimental visit, those participants who were not precluded from entering 
the magnetic resonance imaging (MRI) scanner underwent an exercise protocol 
involving single-legged knee extensions while the quadriceps muscles of their right 
leg were analysed. 
During the 31P magnetic resonance spectroscopy scan, participants underwent a 
gentle exercise protocol using a single-leg knee extension ergometer. Prior to their 
first such scan they underwent familiarisation in order to ensure they were 
comfortable with the exercise that was required of them, and to find an appropriate 
load for the ergometer. This was determined as the mass which caused their 
quadriceps muscles to begin to ache at the end of 24 seconds of exercise, and at 
which the participant judged the exercise severity as 7/10 if 1/10 is very light 
exercise and 10/10 is extremely difficult. 
Participants lay prone in the bore of the MRS scanner and Velcro straps were used 
to immobilise their lumbar back, buttocks and thighs. Their right foot was attached 
securely to a padded foot brace again using a Velcro strap. The brace was in turn 
attached to the custom-built, non-ferromagnetic ergometer by a rope and pulley 
system housed in a nylon frame.  The rope was attached to a load basket into which 




Figure 6. Knee extension ergometry during 31P-magnetic resonance spectroscopy. 
This figure shows a volunteer ready to perform knee-extension exercise in the MR 
scanner. A weight is attached to the foot via a rope and a padded foot strap. The 
exercise is performed by extending the knee, so that the foot will move up and down 
as indicated by the yellow arrow. The grey pad strapped to the quadriceps of the 
right leg is the 31P transmit / receive surface coil (see below).  
 
Participants were asked to undergo 24 seconds of right leg knee extensions over a 
distance of 22cm, followed by a 3.5 minute rest. During these 24 second bursts, 
participants extended their leg 40 times per minute, timing each exercise downstroke 
with an auditory stimulus from the MRI scanner.  This stimulus was emitted by noisy 
expansion and contraction of the magnetic coils within the scanner as pulses of 
electricity passed through them causing predictable changes in the magnetic field 
they created.  All power levels were later estimated according to the masses used, 
as rate of PCr recovery was the measure of interest in this study and exercise was 
merely used as a means to reduce intracellular PCr. To ensure a constant work rate 
and muscle position relative to the magnetic coil, participants were visually queued 
and given verbal feedback by the researcher. 
31P magnetic resonance spectroscopy (31P-MRS) offers a unique means of 
performing non-invasive, longitudinal analysis of energy metabolism in skeletal 
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muscle during exercise.  The human body comprises predominantly of water. 
Magnetic fields generated by the powerful electromagnets in the MRI scanner cause 
excitation and hence, alignment of all protons within the body. Additional, smaller 
specific magnetic fields are applied during the scan to allow orientation of the data 
generated, and also to create an individual label for each proton relative to its 
velocity.  Simultaneously, specific radio frequencies (RFs) are applied to the tissue of 
interest in the subject, such as the quadriceps muscle in the current study. These 
alter the alignment of the protons within that tissue, before the RF signal ceases, 
causing the protons to move back into alignment. This movement of protons 
generates a nucleic signal which is amplified and used to create detailed images or 
calculate volumes within the body.  In this study, it was used to assess the kinetics of 
phosphorous metabolites within the right quadriceps muscle group.  
Participants in this trial performed the exercise protocol whilst lying prone in a 1.5T 
superconducting magnetic resonance scanner (Gyroscan Clinical Intera, Philips 
Medical Systems, Best, The Netherlands). A 6cm 31P transmit / receive surface coil 
was placed within the subject bed, centred over the quadriceps muscle. This was 
matched and tuned before an automatic shimming protocol was performed. The term 
shimming refers to the process of removing small inhomogeneities which are present 
in the magnetic field. This process is both passive, whereby sheet metal is placed at 
specific locations on the external surface of the MRI machine, and active. In active 
shimming, an electric current is passed through specifically designed coils and is 
adjusted and optimised to fine tune the homogeneity of the magnetic field. 
Once shimming was complete, an unsaturated 31P spectrum was acquired to allow 
for T1 correction of those spectra obtained during exercise. Throughout the entire 
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exercise protocol, phosphorous spectra were acquired every 1.5 seconds at a 
spectral width of 1500Hz, generating 1000 data points.  The multi-pulse experiment 
was repeated four times and for each repetition the phases of the radiofrequency 
pulses were varied through a carefully designed sequence (phase cycling). Through 
combination of the free induction decays from each repetition, this reinforced desired 
phosphorous signals through addition and allowed unwanted signals to cancel each 
other out, providing an accurate 31P magnetic resonance spectrum of the 
participant’s quadriceps muscle group every 6 seconds (Jones, Wilkerson et al. 
2008).   
Analysis of each 31P spectrum was performed by the jMRUI (version 3) software 
package (Java-based Magnetic Resonance User Interface) which used the AMARES 
(Advanced Method for Accurate, Robust and Efficient Spectral) fitting algorithm.  
Spectra were fitted assuming the presence of the following peaks; Pi (inorganic 
phosphorous), PCr (phosphocreatine), phosphodiester, α-ATP (two peaks, amplitude 
ratio 1:1), β-ATP (three peaks, amplitude ratio 1:2:1), and γ-ATP (two peaks, 
amplitude ratio 1:1).  A baseline spectrum was obtained for each subject prior to 
exercise initiation with long repetition time (20 s). This allowed quantification of the 
unsaturated peak amplitudes and, hence, allowed the relative amplitudes during 
exercise to be corrected for partial saturation.  Intracellular pH was calculated using 
the chemical shift in the position of the Pi peak relative to the PCr peak. 
The rate of PCr recovery was of particular interest in this study. PCr is a high-energy 
phosphate reserve found in vertebrates and some invertebrates. It is used to 
maintain ATP levels in the activation of cells in excitable tissues such as muscles 
and the brain, overcoming the very limited supply of ATP within cells in those 
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tissues. Without PCr, excitable cells would only maintain a muscle contraction for a 
few seconds before their intracellular ATP reservoir is exhausted (Wallimann, Wyss 
et al. 1992). ATP is continuously replenished from large intracellular pools, catalysed 
by the enzyme creatine kinase through the following reaction: 
   MgADP- + PCr2+ + H+ ↔  MgATP2- + Cr 
Recovery of the intramuscular PCr reservoir following exercise is inversely 
proportional to the rate of oxygen consumption (Mahler 1985, Haseler, Hogan et al. 
1999); therefore the rate constant of the exponential PCr recovery curve could be 
used as an index of oxidative ATP production (Roussel, Bendahan et al. 2000). This 
provides an in vivo assessment of skeletal muscle mitochondrial function. 
 
2.7.7 BLOOD ANALYSIS 
 
Platelet Aggregometry 
Those participants who were not excluded from this arm of the study were advised to 
avoid aspirin-containing medications and non-steroidal anti-inflammatory drugs 
(NSAIDs) for 14 days prior to their appointment, and caffeine and alcohol for twenty-
four hours. 6 x 3ml citrated vacutainers (Sarstedt S-Monovette, Nümbrecht, 
Germany) of venous blood were taken from both the participant and from one of the 
researchers acting as a control.  The person acting as control also avoided aspirin, 
NSAIDs, caffeine and alcohol. Venepuncture was as atraumatic as possible, using a 
21g needle and minimal use of the tourniquet to avoid artefactual platelet activation. 
Blood samples were left to stand for a minimum of 30 minutes before centrifugation 
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using a Heraeus Labofuge 200 centrifuge (Thermo Fisher Scientific Inc, Waltham, 
MA, USA) at 1600rpm for 5 minutes. Samples were visually inspected for clarity 
before the supernatant platelet rich plasma (PRP) was carefully pipetted using a 
plastic Pasteur pipette into a separate plastic tube for the patient and control 
specimens, which were capped. The previously centrifuged specimen tubes were 
then returned to the centrifuge for a further 10 minutes at 4000rpm before the 
supernatant was pipetted off into plastic tubes marked platelet poor plasma (PPP) for 
both the participant and the control.  
Portions (0.5 ml) of each of the participant’s and control’s PPP and PRP were 
pipetted into aliquot tubes and a platelet count was obtained using a Coulter DXH 
analyser (Beckman Coulter Ltd, Miami, FL, USA). Aggregation should be performed 
on PRP with platelet counts of at least 100x109/L, White Cell Count (WCC) of 
<0.5x109/L and Red Cell Count (RBC) of <0.5x109/L. If the RBC or WCC were higher 
than 0.5, the sample was re-centrifuged. PPP was analysed to ensure platelet count 
was <10x109/L, WCC of <0.5x109/L and RBC of <0.5x109/L. Light transmission 
platelet aggregometry was then performed on both the control and the study 
samples simultaneously using a PAP-8 platelet aggregation profiler (BioData 
Corporation, Horsham, PA, USA), with the reagents ADP (10 μM), arachidonic acid 
(5 mg/ml), collagen (1.9 mg/ml) and epinephrine (1x10-3 M). Prior to the addition of 
reagents, light aggregometry was performed on the PRP to ensure no spontaneous 






Nitrate and Nitrite Quantification 
At each participant appointment, 8 ml of venous blood was taken for nitrate (NO3
-) 
and nitrite (NO2
-) quantification in Lithium Heparin vacutainers (Sarstedt S-
Monovette, Nümbrecht, Germany) before immediate centrifugation at 4000rpm for 10 
minutes (Heraeus Labofuge 200 centrifuge, Thermo Fisher Scientific Inc, Waltham, 
MA, USA). Using a plastic pipette, the supernatant plasma was then immediately 
removed to prevent reduction of ˙NO by haemoglobin to methaemoglobin. The 
plasma was placed in 1.5ml reaction tubes before transferring on ice to -80°C 
storage freezers pending analysis.  
The samples were later tested using a nitric oxide analyser based on gas phase 
chemiluminescence (Sievers NOA 280i analyser, General Electric Healthcare, Little 
Chalfont, UK). This technique involves chemical reduction of NO3
- and NO2
- to ˙NO 
which is then quantified, hence giving an indirect measure of NO3
- or NO2
- contained 
within the sample. ˙NO quantification is performed through its gas phase reaction 
with ozone in the chemiluminescence chamber, producing an excited state of 
nitrogen dioxide (NO2) which emits light in the infrared region of the electromagnetic 
spectrum. The quantity of photons produced in this reaction is directly proportionate 
to the concentration of ˙NO within the chemiluminescence chamber. The intensity of 
this light is amplified and then quantified by a thermoelectrically cooled, red-sensitive 
photomultiplier tube housed in the nitric oxide analyser, producing an analogue 
millivolt output signal. Nitrate and nitrite concentration of patient samples is derived 
from the integral of the ˙NO-generated millivolt signal over time via comparison with 




A standard curve was prepared daily using sodium nitrate at known concentrations 
ranging between 100nM and 10μM. Resultant luminescence was plotted via signal 




In order to quantify NO3
-, all participant samples were deproteinised using zinc 
sulphate precipitation prior to analysis. 100 μl of patient plasma was added to 500 μl 
of 0.18 M sodium hydroxide (NaOH), vortexed and incubated at room temperature 
for 10 minutes. 300 μl of 5% zinc sulphate (ZnSO4) was added before the resultant 
solution was vortexed again and incubated at room temperature for a further 10 
minutes. This was centrifuged at 14000 rpm for 10 minutes before storage in a 
refrigerator pending analysis. 50 μL of sample plasma was injected into a sealed 
system at 95°C and reduced to ˙NO using a 5 ml solution of vanadium (III) chloride 
(VCl) in 1 M hydrochloric acid (0.8% w/v). All ˙NO produced then bubbled up a feed 
line through a filter into the chemiluminescence chamber where it was quantified 
through the analysis outlined above (Bateman, Ellis et al. 2002).  Each participant 
plasma sample was analysed in duplicate in order to improve reliability. 
When quantifying NO2
-, samples did not require deproteinisation as less bubbling 
and foaming occurred during quantitation of NO2
- than NO3
-. 50 μL of sample plasma 
was injected into a sealed system at 30°C and reduced using 5ml glacial acetic acid 
and 1 ml sodium iodide (NaI) solution. ˙NO produced by these reductions was again 
bubbled up a feed line into the chemiluminescence chamber where it reacted with 
ozone, produced an excited state of nitrogen dioxide and photons which were then 
quantified as outlined above; thus NO2
- concentration was deduced (Bateman, Ellis 




Guanosine 3’, 5’-cyclic Monophosphate (cGMP) Quantification 
cGMP is formed by the action of the enzyme guanylate cyclase on glycerine 
triphosphate. Presence of ˙NO stimulates the action of guanylate cyclase, hence 
stimulating cGMP levels. Blood was taken in a vacutainer containing the 
anticoagulant ethylenediaminetetraacetic acid (EDTA) before centrifugation at 4000 
rpm for 10 minutes. The supernatant plasma was pipetted into reaction tubes which 
were then placed on ice before storage in a -80°C freezer pending analysis at a later 
date. cGMP quantification used a colourimetric competitive immunoassay kit from 
Enzo Life Sciences (Enzo Life Sciences Inc, Farmingdale, New York, USA). 
Participant samples were treated with 0.1 M hydrochloric acid to stop endogenous 
phosphodiesterase activity and stabilise any released cGMP. They were then 
acetylated through the addition of acetic anhydride and triethylamine. The kit uses a 
polyclonal antibody to cGMP which competitively binds either the cGMP in the 
standards or samples, or an alkaline phosphatase molecule which has cGMP 
covalently attached to it. After a simultaneous incubation the excess reagents are 
washed off and a substrate is added. After another shorter incubation period, the 
enzyme reaction is stopped and the yellow colour generated is read on a microplate 
reader at 405 nm wavelength. The intensity of the bound yellow colour is inversely 
proportional to the concentration of cGMP in either standards or participant samples. 
The measured optical density is used to calculate the concentration of cGMP. 
Haemoglobin Quantification 
Haemoglobin was quantified using a Coulter DXH analyser (Beckman Coulter Ltd, 
Miami, FL, USA) courtesy of the Royal Devon and Exeter Hospital Department of 
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Haematology. This lyses whole blood before quantification of haemoglobin 
photometrically at 525 nm. 
Ferritin, Serum Iron, Transferrin and Transferrin Saturation Quantification 
Ferritin, serum iron, transferrin and transferrin saturation were determined using 
Roche E170 automated immunoassay platforms (Roche Diagnostics Ltd, West 
Sussex, UK) courtesy of the Royal Devon and Exeter Hospital Department of 
Biochemistry. 
 
2.8 STATISTICAL ANALYSIS 
 
The statistical analysis plan was incorporated within the study protocol. It dictated 
the exclusion and exclusion criteria and general study population, the target number 
of participants to include in the trial, and the randomisation and blinding methodology 
as outlined above. No interim analysis was intended given the small size of the study 
population. All data obtained from participants who completed all study visits were 
analysed fully, meaning those participants who withdrew from further involvement in 
the trial after the second experimental visit were not included in the analysis. This 
was intended to ensure that the cross-over design was effective at providing its own 
control. There was very little missing data except for the platelet aggregometry data; 
very few participants had no missing data in this aspect of the trial, but only those 
with aggregometry results from all four experimental visits were included in the 
analysis given the expected marked inter-subject variation.  
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All data were assessed for normality and are presented in the results section as 
means +/- standard deviation (SD) +/- 95% confidence intervals (CI). Observed 
differences in the parameter of interest were tested using students’ two tailed paired 
t-tests when comparing two groups of data and one way analysis of variant (ANOVA) 
when comparing three groups. Pair-wise post-hoc analysis of statistically significant 
ANOVA results was performed using the Fisher’s Least Significant Difference (LSD) 
test as appropriate. Non-parametric data was analysed for significance using the 
Wilcoxon matched-pairs signed rank test. Further analysis was performed calculating 
the pre- versus post-supplementation delta for each group of data, then an unrelated 
sample test was used to compare these values. 
Statistical significance was accepted at p = < 0.05, while a trend towards significant 
results was accepted as p = < 0.1 as recommended by the statistician during initial 
consultations. Results which were statistically significant following post hoc analysis 
are denoted with an asterisk (*) in figures and their legends.  Statistical analysis was 
performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, 
Washington, USA), GraphPad Prism 5.04 (GraphPad software incorporated, San 





CHAPTER 3: RESULTS 
 
Participant recruitment was easily achievable at a rate which matched the availability 
of MRI appointments; when approached, many of the patient population were 
motivated and keen to enrol. While the reasons for this enthusiasm were not 
recorded formally, a number of participants volunteered that they felt significant 
goodwill towards the recruiting departments in the local hospital, as many pointed 
out that they had received excellent care there. Altruism was a recurring theme 
within participants’ comments, as many wanted to ‘give something back.’ Others 
hoped that their enrolment in the study would afford them some empowerment in 
their control of symptoms and treatment of their disease. However, a number of 
participants were living with terminal diagnoses and, while neither the Patient 
Information Sheet (Appendix 2) nor researchers suggested it may have any effect on 
their underlying cancer, one could speculate that they felt this trial may have enabled 
them access to a ‘treatment’ that offered them hope of improved symptoms and 
survival. This reflects formally gathered reasons from qualitative research 
investigating the incentives reported by those patients volunteering to participate in 
health research. The main reasons identified were that the trial allowed patients 
access to medications that offered hope of relief, to better care and to technologies 
for monitoring illness and health (Townsend and Cox 2013).  
Thirty-three participants were recruited into the study out of 36 who were 
approached (92.5%) (Figure 7). Of those who were recruited, twenty-six people 
attended all 4 experimental visits (79%). Three participants withdrew from the study 
prior to their first visit due to ill health; two had progression of malignancy while one 
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had severe pneumonia and rib fracture. One participant withdrew after changing his 
mind about involvement as he had a poor prognosis and did not want to commit time 
to travelling the significant distance to Exeter from his home. A further participant 
was withdrawn by the investigator after another trial which the patient had been 
actively involved in declined to give their consent for her involvement in this trial. Two 
participants withdrew after attending for their first two experimental visits for personal 




Figure 7: Consort diagram. This demonstrates that 33 of 36 people approached to 
enter the trial decided to do so (92.5%). 5 people withdrew or were withdrawn from 
the trial before their first experimental visit, either as a result of ill health due to 
progressive malignancy or pneumonia, and one because a trial she was already 
enrolled in declined her permission to enter the current study. 2 participants withdrew 
after 2 of their experimental visits due to personal reasons or ill health, while 26 
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completed all experimental visits. One person was unable to tolerate cycle ergometry 
while one further participant was also unable to complete magnetic resonance 
spectroscopy. 
Of the 26 participants who proceeded with all four experimental visits, one was 
precluded from involvement in the 31P-MRS arm of the study having previously had a 
spinal decompression / stabilisation procedure during which titanium rods were 
inserted into her spine. This participant was excluded as her titanium implants were 
large and the theoretical risks associated with MRI scanning were slightly increased 
compared to those without these rods. These risks include heating of the metal 
through induction of electrical currents in the rods, which may have been capable of 
causing localised tissue heating (Davis, Crooks et al. 1981). In reality, as titanium 
implants are paramagnetic and therefore not affected by magnetic fields, this risk 
was negligible but the need to ensure no patient was harmed by their trial entry was 
reason enough for her to be excluded (Kim, Choi et al. 2019). A further patient 
withdrew from involvement in the MRI arm as his marked thoracic kyphosis made 
lying in the prone position in the bore of the MRI scanner intolerable. The same 
patient also experienced dizziness and light-headedness after just over 2 minutes of 
cycling without any resistance during cycle ergometry so, although he recovered 
within seconds of stopping exercise, he was also withdrawn from that arm for safety 
reasons. 
Hence, 24 participants completed all aspects of the study, one person completed all 






3.1 POPULATION DEMOGRAPHICS 
 
Results of the 26 patients who completed all 4 experimental visits in this pilot study 
are included in this analysis (Table 2). Their age ranged from 40 to 93 years old with 
a mean of 66 and standard deviation of 12 years. There was a slight preponderance 
for male sex (15 of 26 participants, 57.7%). The study group were anaemic for a 
variety of reasons, representing a spectrum of haematological and oncological 
disorders. 50% of participants were undergoing active chemotherapy of varying 





Table 2: Population Demographics. This table demonstrates the breadth of demographic 
characterising those participants who enrolled in this study. There was a broad range in 
the age of the 26 people, from the young middle-aged to the very elderly. There was a 
slight preponderance for male sex, while their health was very heterogeneous. They had a 
wide variety of medical problems causing their anaemia ranging from anaemia of 
Age (years) Mean 61 
Range 40 – 93 
Standard Deviation 12 
Gender: n (%) Male 15 (57.7%) 
Female 11 (42.3% 
Diagnosis: n (%) 
 
 
Low-Grade Non-Hodgkin’s Lymphoma 5 (19.2%) 
Myeloma 4 (15.4%) 
Myelodysplasia 5 (19.2%) 
Gastric Carcinoma 2 (7.7%) 
Chronic Lymphocytic Leukaemia 1 (3.8%) 
Myelofibrosis 2 (7.7%) 
Myeloproliferative Neoplasm 3 (11.5%) 
Aplastic Anaemia 1 (3.8%) 
Colorectal Carcinoma  1 (3.8%) 









Rutuximab & Bendamustine 1 (3.8%) 
Irinotecan & Capecitabine 1 (3.8%) 
Lenalidomide 2 (7.7%) 
Pomalidomide  1 (3.8%) 
Rituximab, Cyclophosphamide, Vincristine & Prednisolone 2 (7.7%) 
Hydroxycarbamide 3 (11.5%) 
Rituximab & Chlorambucil 1 (3.8%) 
Etoposide, Oxaliplatin & Capecitabine 1 (3.8%) 
Etoposide, Carboplatin & Capecitabine 1 (3.8%) 
Azacitidine 1 (3.8%) 
Nil 13 (50%) 
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uncertain benign aetiology which was behaving in a benign manner, to anaemia as a result 
of terminal malignancy. They were also on a variety of different treatments; while half of 
the study participants were on no chemotherapy, the remainder were on treatments 
ranging from relatively intensive chemotherapy such as the etoposide, oxaliplatin and 
capecitabine combination, to the very gentle such as hydroxycarbamide. 
 
 
3.2 BLOOD ANALYSIS: HAEMOGLOBIN 
 
Three participants were given a blood transfusion of 2 units of packed red cells 
within 2 months of any of their experimental visits. One received this blood 60 days 
prior to their first visit and hence 71 days before their second visit which was post-BR 
supplementation visit. This participant’s Hb was stable thereafter, measuring 99 g/l, 
93 g/l, 98 g/l and 95 g/l at each of their experimental visits. One participant was 
transfused 5 days prior to visit three, an unsupplemented visit, which was 12 days 
prior to the post-PL supplementation visit. Despite this change, this participant’s Hb 
was similar at each of the experimental visits (92 g/l, 99 g/l at the visits before 
transfusion, then 99 g/l and 102 g/l after transfusion). This participant was transfused 
as his Hb had fallen significantly between the second and third visits, but the Hb on 
each of the visit days was similar. A further participant received a blood transfusion 5 
days prior to visit 2 (i.e. 5 days before their post-BR supplementation visit). As a 
result, this participant’s Hb rose from 77 g/l to 96 g/l between baseline 1 and the 
post-BR supplementation visit. However, despite receiving no further transfusions, 
this participant’s Hb actually continued to rise prior to their next experimental visit as 
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a result of response to chemotherapy, and their next Hb at the second baseline visit 
was 123 g/l.  
While the mean lifespan of human RBCs in vivo is 110-118 days (Mock, Matthews et 
al. 2011), transfused red blood cells survival is similar, with a maximum reported 
lifespan of 135 days after transfusion. A proportion of these cells are removed from 
the circulation within 24 hours of transfusion; this varies according to the duration of 
storage of the cells, and can be between 9% and 23% (Luten, Roerdinkholder-
Stoelwinder et al. 2008). Hence, some of these transfused cells were still present in 
the first participant’s circulation at the time of testing despite the amount of time 
which had elapsed between transfusion and that visit. The other two participants’ 
transfusions are potentially more significant given the proximity to their experimental 
visits, but are balanced in terms of experimental arms; one potentially affected the 
participant’s performance on their post-PL supplementation visit and the other 
potentially affected that participant’s post-BR supplementation visit. However, those 
participants receiving transfusions did not display a significant improvement in their 
haemoglobin level following receipt of blood.  
Blood samples from participants were photometrically analysed at the Royal Devon 
and Exeter Hospital haematology laboratory using Coulter DXH analysers (Beckman 
Coulter Ltd, Miami, FL, USA). The interbatch coefficient of variation was up to 1.8%. 
The haemoglobin concentrations of all participants at all study visits demonstrated a 
normal distribution, while the mean concentration was 111.7 g/l, indicating relatively 
mild anaemia; the normal range of Hb concentration is 120 – 160 g/l in females and 
130 – 180 g/l in males. The Hb of the participant population was expected to be 
dynamic as it was subject to external factors such as progression or relapse of 
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malignancies, initiation or cessation of chemotherapy or radiotherapy, bleeding, 
transfusion etc. Hence, the crossover study design was chosen in an attempt to 
counter any fluctuation in the level of anaemia during the participants’ involvement in 
this trial. However, there was a trend towards a difference in the haemoglobin 
between the experimental arms. Of those participants who received BR at their first 
supplemented visit, the mean haemoglobin increased from 105.0 g/l (standard 
deviation 10.6 g/l, 95% confidence interval [CI] 6.0) at their post-BR visit, to 110.7 g/l 





















































Figure 8: Mean haemoglobin concentration (g/l) in the cohort of participants 
who received BR at first post-supplementation experimental visit. This bar 
graph demonstrates the mean and standard deviations of the haemoglobin 
concentrations of those 13 participants in the current study who received five 70 ml 
bottles of nitrate-rich beetroot juice (BR) in the 48 hours before their second 
experimental visit, and five 70 ml bottles of nitrate-deplete beetroot juice (placebo 
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[PL]) in the 48 hours prior to their fourth experimental visit.  This figure demonstrates 
that the participants’ haemoglobin concentration increased during the 3 to 6 weeks 
washout period between the BR supplemented  visit and their return to the next 
baseline visit. Hence the mean haemoglobin concentration was significantly higher at 
the experimental visit investigating the effects of supplementation with PL (Hb 110.7 
g/l) than following BR supplementation (Hb 105.0 g/l) (paired one tail t-test p = 0.04). 
Students’ t test comparison of the two baseline (non-supplemented) visits, 
demonstrated no statistically significant difference (p = 0.15). However, an ANOVA 
analysis demonstrated that there was a trend towards statistical significance 
amongst all group differences (p = 0.0559). See Appendix 5: Raw Data Graphs for 
the raw data for each participant’s haemoglobin change with time. 
       
The Haemoglobin results of 2 of the participants who received BR prior to their first 
supplemented visit had a significant effect on the change in the group mean through 
the experimental timepoints. The first such participant’s Hb increased from 104 g/l at 
the post-BR visit to 137 g/l at the post-PL visit, while the second such participant’s 
Hb improved from 96 g/l to 126 g/l over the same time period (See raw data graph in 
appendix 5). Each of these participants demonstrated a response to chemotherapy, 
with improvement in anaemia as a result of reduced bone marrow infiltration with 
lymphoma following its treatment. One participant received no transfusions of blood, 
while the second received two units of blood after their initial baseline visit as 
outlined above, but their haemoglobin continued to rise despite needing no further 
blood.  
The remaining 13 participants received PL at first supplementation and BR at the 
second. Their mean Hb in the first post-supplementation visit was 118.5 g/l (SD 9.3 





















































Figure 9: Mean haemoglobin concentration (g/l) of the cohort of 13 participants who 
received PL at first supplementation visit. This bar graph demonstrates the mean 
and standard deviations of the haemoglobin concentrations of those 13 participants 
in the current study who received  nitrate-deplete beetroot juice (placebo [PL]) in 48 
hours before their second experimental visit, and nitrate-rich beetroot juice (BR) in 
the 48 hours prior to their fourth experimental visit.  This figure demonstrates that the 
participants’ haemoglobin concentration fell during the 3 to 6 weeks washout period 
between the PL supplemented  visit and their return to the next baseline visit. Hence 
the mean haemoglobin concentration was significantly lower at the experimental visit 
investigating the effects of supplementation with BR (Hb 113.3 g/l) than following PL 
supplementation (Hb 118.5 g/l) (paired two tail t-test p = 0.01). There was no 
difference between the two baseline (non-supplemented) visits (p = 0.47), although, 
a one way ANOVA of all data sets demonstrated statistical significance (p = 0.0449). 
Further analysis using the Fisher’s Least Significant Difference (LSD) post hoc test 
demonstrated no signficant difference however. 
 
Of this group of participants who received PL then BR prior to their post-
supplementation visits, there were less marked changes in the Haemoglobin. 
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However, one participant’s Hb fell from 126 g/l to 108 g/l and a second fell from 120 
g/l to 108 g/l, while no participants in this group had an improvement in their Hb of 
greater than 10 g/l during their involvement in the trial (See appendix 5 for raw data). 
Hence, whether they received BR at their first or their second supplementation, the 
mean Hb for participants at their post-PL supplementation visit was 114.7 g/l 
(standard deviation 10.9 g/l, CI 4.6) while the mean Hb of all participants at the time 
of their post-BR supplementation visit was 109.1 g/l (standard deviation 10.9 g/l, CI 
4.2, p-value 0.0028) (Figure 10). The mean Hb at each of the supplementation visits 
was 111.4 g/l (SD 11.6, CI 3.1), meaning no two experimental conditions were 
performed when the group mean Hb was at the same level.  
Two participants had a swing in their Hb between their post-BR and post-PL visits in 
excess of 30 g/l while another 3 had a swing in excess of 12 g/l. Whatever the order 
of actual supplementation, all of these larger fluctuations in Hb were between a lower 
value at the post-BR visit and a higher value post-PL. The crossover study design 
was selected in an attempt to overcome such bias, but chance appears to have 
skewed the level of anaemia between the two post-supplementation visits. This pilot 
study has therefore highlighted that fluctuation in clinical variables such as 
haemoglobin concentration would affect power calculations when designing a full 
study. All haemoglobin fluctuations demonstrated were due to progression of 
underlying cancers, the effect of chemotherapy itself on the process of 
haematopoiesis within the bone marrow, or due to response of malignancy to 
chemotherapy.  
Blood transfusions did not significantly impact on haemoglobin through the study. If 
Hb data for those participants who received transfusions were excluded from this 
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analysis, the mean Hb of participants at baseline visits was 113.1 g/l (SD 8.98), 
115.5 g/l post-PL supplementation (SD 11.5) and 110.8 g/l post BR (SD 10.4). 
Compared to the mean of the entire cohort of all participants, these mean values 
were 1.7g/l greater at baseline, 0.8g/l higher post-PL and 0.9 g/l higher post-BR.  
Hence data for those participants who received transfusions was included in the 

























Figure 10: Haemoglobin concentration (g/l) of all participants at non-
supplemented (Baseline 1 + 2), post-PL and post-BR study visits. This bar chart 
compares the mean haemoglobin concentration of participants at their baseline (non-
supplemented) visits with both the haemoglobin concentrations at their experimental 
visits after a 48 hour period of supplementation with nitrate-rich beetroot juice (BR) 
and after a 48 hour period of supplementation with nitrate-depleted beetroot juice 
(PL). The error bars display the standard deviations. This graph demonstrates that, 
irrespective of the order in which the 26 participants received the different beetroot 
juice supplements, their mean haemoglobin concentration was higher at the ‘PL’ visit 
(114.6 g/l, SD 12 g/l, CI 109.8 – 119.5 g/l) than the ‘BR’ visit (109.7 g/l, SD 10.9 g/l, 
CI 104.7 – 113.5 g/l). This data reaches statistical significance (two tailed t-test p = 
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0.008). The mean haemoglobin concentration at all baseline experimental visits (i.e. 
participants’ first and third experimental visits before which they received no beetroot 
juice supplementation) was 111.4 g/l (SD 9.8 g/l, CI 107.4 – 115.3 g/l), lower than PL 
(p = 0.047) and higher than BR (p = 0.03). An ANOVA analysis of all data 
demonstrates statisitical significance (p = 0.028) while LSD post hoc tests 
demonstrate a signficant difference between all experimental conditions (LSD tests 
comparing each condition range from 0.007 to 0.47). 
As this was a pilot study, only relatively small numbers of participants were enrolled. 
It was not powered to overcome chance changes in variables such as Hb despite the 
fact such variables can have a profound effect on the results the study obtained. A 
larger study involving more participants could potentially have enrolled people whose 
Hb was higher during the post-BR visit than the PL. This could have negated the 
skew exerted by the small number of participants whose Hb changed markedly 





3.3 BLOOD ANALYSIS: NITRATE AND NITRITE 
 
One of the key objectives of this study was to ascertain whether the nitrate-nitrite-
˙NO enterosalivary pathway is intact in people with anaemia related to 





-) concentration of stored participant plasma samples was quantified 
using gas-phase chemiluminescence (see section ‘2.7.7 Blood Analysis’). Prior to 
this, nitrate in plasma was sequentially chemically reduced to nitrite (NO2
-) then nitric 
oxide (˙NO) which was then quantified, hence giving an indirect measure of the NO3
- 
concentration of the sample. ˙NO quantitation was performed through its reaction 
with ozone in the chemiluminescence chamber, yielding an excited state of nitrogen 
dioxide. This emits light in the infra-red region of the electromagnetic spectrum, 
which is amplified and then quantified by a red-sensitive photomultiplier tube. This 
produced an analogue millivolt output signal. The NO3
- concentration within the 
plasma sample was derived from an integral of the ˙NO-generated millivolt signal 
over time in comparison with those previously obtained for standard concentrations 
of NO3
-. 
Standard curves were created daily using known concentrations of sodium nitrate 
ranging from 250 nM to 10 µM over at least five points. The resultant luminescence 
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was plotted via signal area in mV and a standard curve was produced (Figure 11: 
Standard curve derived from area under the curve in millivolts compared to 
known concentrations of nitrate. A range of concentrations of sodium nitrate were 
reduced sequentially to nitrite then nitric oxide which, when exposed to ozone in the 
chemiluminescence reaction chamber produced nitrogen dioxide which emitted 
photons of light in the infra red spectrum. This was amplified and quantified 
producing an area under the curve measured in millivolts. The R2 value of 0.998 






























Slope = 208.2 +/- 3.3 mV/M
 
Figure 11: Standard curve derived from area under the curve in millivolts 
compared to known concentrations of nitrate. A range of concentrations of 
sodium nitrate were reduced sequentially to nitrite then nitric oxide which, when 
exposed to ozone in the chemiluminescence reaction chamber produced nitrogen 
dioxide which emitted photons of light in the infra red spectrum. This was amplified 
and quantified producing an area under the curve measured in millivolts. The R2 
value of 0.998 indicates very good fit. 
Once satisfied with the quality of the daily standard curve, analysis of plasma 
samples from all four experimental visits of each of the 26 participants was 
performed using the same technique of gas-phase chemiluminescence which was 
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used to make the standard curves. A screenshot of one such batch is displayed 
below (Figure 12) 
 
Figure 12: Nitrate quantification through chemiluminescence. This figure is a 
screenshot of the analysis of plasma samples from 4 participants (unique 
identification numbers 19, 20, 21 and 22), showing the electrical output from 
chemiluminescence. Each curve corresponds to a separate sample analysis. 
Quantification of the area under each curve was used to calculate the nitrate 
concentration of that patient’s plasma sample.  Every sample was analysed in 
duplicate in order to improve accuracy of the results. While 50 µl of participant 
samples was analysed in most cases, only 25 µl of Participant 19’s samples from 
their fourth experimental visit (name ‘19/4’) was analysed as this visit followed 
supplementation with BR and therefore their millivolt output was anticipated to rise 
above the scale used in this batch. This decision was made as in response to 
problems with samples from earlier batches; those samples from BR-supplemented 
participants repeatedly generated outputs in millivolts which rose above this scale. 
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Their areas under the curve and therefore nitrate concentrations could not be 
quantified as some of the data was not captured, so the samples had to be 
reanalysed using 25 µl aliquots of participant plasma rather than 50 µl. No serial 
dilutions were performed on these high-nitrate concentration samples. If the millivolt 
output of samples from participants at their BR supplementation visit was lower than 
anticipated, analysis was repeated without reducing the volume analysed. 
Analysis of all 26 participants’ plasma samples from each experimental visit was 
performed in duplicate to improve accuracy. There was significant variability in 
participants’ plasma nitrate concentration results as described below. This affected 
the standard deviations and therefore coefficient of variation (CV) for the assay, with 
the latter varying from 15.6% in all participants at the post-BR supplementation visit, 
to 12.5% at the post-PL supplementation visit.  
While there was significant variability amongst the trial population, 25 of the 26 
participants in this study (96%) demonstrated an increase in plasma nitrate 
concentration following supplementation with BR compared to the mean of their 
baseline visits and after PL supplementation (Figure 13). This demonstrates that 
those participants recruited into this pilot study were compliant with their 
supplementation, and despite their various medical complaints and treatments 
(chemotherapy and otherwise), they absorbed it in good quantity. The only 
participant who did not develop an increase in nitrate concentration took over 10 
different herbal remedies and lived on a diet which only consisted of juiced fruit and 
vegetables. While the precise content of the herbal remedies is unclear, her diet was 
extremely rich in nitrate prior to and during her involvement with this trial. The mean 
of this participant’s two unsupplemented baseline visits and her post-PL visit was 
18.1 µM, higher than all other participants, although this was only 0.1 µM greater 
than the second highest patient. This information is an important guide for the design 
127 
 
of future trials following this initial pilot study, as such participants would probably 































Figure 13: Plasma nitrate concentration at non-supplemented, post-PL and 
post-BR experimental conditions. Black points and lines indicate each of the 26 
individual participants’ plasma nitrate concentration at all of their experimental 
conditions, while the red data points and red line displays the mean of the entire 
cohort of participants within this study. The red error bars demonstrate the standard 
deviation of the means. The mean was used as these data are parametric. The 
experimental condition ‘Baseline 1 + 2’ indicates all nitrate concentrations of  
participants at their non-supplemented visits, while ‘PL’ and ‘BR’ indicates the study 
visit following a period of supplementaion. Participants ingested a 70 ml bottle of 
nitrate-depleted beetroot juice (PL) at 2.5, 12, 24, 36 and 48 hours before study visit 
‘PL’, while they ingested a 70 ml bottle of nitrate-rich beetroot juice (BR) at the same 
time points prior to visit ‘BR’. Each data point represents the mean of duplicate 
nitrate concentrations quantified by gas-phase chemiluminescence analysis of each 
participant plasma sample from every experimental visit (see Methods section 2.8.7).  
This graph demonstrates that, while there was some variation in the individual 
response to BR supplementation, the mean plasma nitrate concentration was 
significantly higher at experimental condition BR (78.0 µM, SD 33.5, CV 15.6%) than 
at either baseline (8.4 µM, SD 58.8, CV 10.3%) or PL (8.6 µM, SD 72.3, CV 12.5%) 
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(one way ANOVA p = < 0.0001, LSD test confirms statistical significant difference [*] 
in baseline 1 + 2 vs BR and in baseline 1 + 2 vs BR). 
 
The mean plasma nitrate for participants at baseline was 8.4 µM (standard deviation 
4.9 µM) while the mean concentration at the post-PL visit was 8.6 µM (SD 6.1 µM), 
giving a mean of all of these experimental timepoints of 8.5 µM. In comparison, the 
mean plasma nitrate for participants in this study at the post-BR supplementation 
visit was 78.0 µM. Hence, despite some variability in the degree of this response 
between individuals, this cohort of anaemic participants absorbed a significant 
quantity of the ingested nitrate within their BR supplementation, with an increase in 





-) concentration of stored participant plasma samples was quantified 
using gas-phase chemiluminescence (see ‘2.7.7 Blood Analysis’). Prior to this, 50 μL 
of sample plasma was injected into a sealed system at 30°C and reduced using 5ml 
glacial acetic acid and 1 ml sodium iodide (NaI) solution. Nitric oxide (˙NO) produced 
by these reductions was bubbled up a feed line into the chemiluminescence 
chamber for quantification which was then quantified as outlined above, hence giving 
an indirect measure of the NO2
- concentration of the sample. The NO2
- concentration 
within the plasma sample was derived from an integral of the ˙NO-generated millivolt 





Standard curves were created daily using known concentrations of sodium nitrate 
ranging from 250 nM to 10 µM over at least five points. The resultant luminescence 
was plotted via signal area in mV and a standard curve was produced. Analysis of all 
26 participants’ plasma samples from each experimental visit was performed in 
duplicate to improve accuracy. Similar to the results obtained from plasma NO3
- 
concentration quantification, there was significant variability in participants’ plasma 
nitrite concentration results as described below. This affected the standard 
deviations and therefore coefficient of variation (CV) for the assay. The CV ranged 
from 5.8% and 13.8% in the baseline and post-PL supplementation visits 
respectively, to 9.5% at all of the post-BR supplementation visits. 
A significant increase in plasma nitrite (NO2
-) after supplementation with BR was 
observed in the majority of the participants in this trial (Figure 14). The median NO2
- 
concentration of this cohort at their baseline (non-supplemented) visits was 135 nM 
(SD 79 nM, IQR 88 - 165 nM) while the median plasma NO2
- following PL 
supplementation was 112 nM (SD 69 nM, IQR 92 - 147 nM). This median 
concentration rose markedly to 485 nM (SD 1006 nM, IQR 365 – 1104 nM) following 
supplementation with BR. This was statistically significant according to a 2 way 











































p = 0.0003 *
 
Figure 14: Plasma nitrite concentrations of participants at each experimental 
visit. Unlike most results in the current study, these data were non-parametric in 
distribution according to visual inspection and Shapiro-Wilk test exhibiting a positive 
skew in each experimental condition. Hence a box and whisker plot was used to 
display the median, interquartile range and extreme nitrite concentrations of 26 
participants’ plasma samples from each of their 4 visits. The experimental condition 
‘Baseline 1 + 2’ indicates all nitrate concentrations of  participants at their non-
supplemented visits, while ‘PL’ and ‘BR’ indicates the study visit following a period of 
supplementation. This graph demonstrates that the median plasma nitrite 
concentration was significantly higher at experimental condition BR (485 nM, SD 
1006 nM, interquartile range 365 – 1104 nM) than at either baseline (135 nM, SD 79 
nM, IQR 88 – 165 nM) or PL (112 nM, SD 69 nM, IQR 92 – 147 nM) (2 way ANOVA 
p = < 0.0001, statistically significant according to Fisher’s LSD post hoc analysis 
[LSD = 0.000]). The data was positively skewed and therefore made non-parametric 
by two participants’ nitrite concentration at condition BR which rose far more than the 
remainder of the participants. See Appendix 5: Raw Data Graphs for the individual 





While the group median NO2
- concentration rose significantly following BR 
supplementation compared to their non-supplemented and PL-supplemented visits, 
there was a large variation in the degree of this response with a standard deviation 
of the BR experimental state of 1006 nM. NO2
- concentration rose by a median of 
1235% between the post-PL visit and the post-BR condition.  However, 2 
participants’ plasma NO2
- concentration increased to over 3750 nM, in excess of 
2000%, while at the other end of the spectrum, one participant’s plasma NO2
- 
concentration only rose by 155% to 142 nM. Interestingly, the latter person with a 
minimal response in plasma NO2
- was the same participant in whom there was 
observed only a minor increase in plasma NO3
- concentration following 
supplementation. Hence it would seem likely that, as there was only a modest rise in 
plasma NO3
-, there was only a small increase in available substrate for the 
facultative anaerobic bacteria located on the base of her tongue, and therefore less 
plasma NO2
- was produced. As outlined above, this participant routinely ingested 
large quantities of nitrate daily as a result of a ‘juicing’ diet, so this may have 
ameliorated her response to oral nitrate and therefore her plasma nitrite 
concentration. She also had previously undergone significant surgery to her upper 
gastro-intestinal tract in order to treat oesophageal carcinoma, so anatomic and 
gastric pH changes may have altered the enterosalivary circulation of her dietary 
nitrate. One must also consider the possibility that she was non-compliant with the 
supplementation regimen, although the participant appeared highly motivated in 
each of her experimental visits.  
In summary, almost all participants involved in this pilot study derived a good 
response to BR supplementation both in terms of an increase in their plasma NO3
- 
and NO2
- concentration. This indicates that they were compliant with 
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supplementation and absorbed it despite their medical complaints, previous 
surgeries in some cases, co-morbidities and treatments. 
 
3.4 QUALITY OF LIFE 
 
The quality of life of participants enrolled in the trial was recorded through sequential 
monitoring of their responses to the FACT-An questionnaire at each of their four trial 
visits (Yellen, Cella et al. 1997, Wagner, Sweet et al. 2009). This subjective score of 
the severity of symptoms associated with anaemia has been validated to assess the 
quality of life of people experiencing anaemia. Participants in this trial were asked to 
self-complete this questionnaire which included 57 questions about a range of 
factors which contribute to their quality of life. They were asked about their emotional 
wellbeing, functional wellbeing, physical wellbeing and social / family wellbeing over 
the previous seven days. Each answer was allocated a score out of 4, giving a total 
which was scored out of 188. The higher this total score was, the fewer and milder 
the symptoms the participant was experiencing at the time they completed the 
questionnaire.  
Following the initial explanation about how to complete this questionnaire, 
participants involved in the trial required very little help or instruction and found it 
straightforward to fill in. The only problem encountered was that occasional patients 
missed out a question by mistake, although these were spotted by the research team 
at that appointment and the patient was prompted to complete all they were happy to 
answer. As a result, all questionnaires were fully completed. Responses were scored 
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according to the scoring template and a score of between 0 and 188 was allocated to 
each completed FACT-An questionnaire.  
The coefficient of variation observed amongst the total scores of all completed 
questionnaires was 15.3 %, demonstrating some breadth of the range of scores 
obtained.  
This study demonstrated that supplementation with both PL and BR brought about 
an improvement in the median values recorded compared to the median of all 
baseline visits of this cohort (Figure 15). At their baseline visits, the participants’ 
median FACT-An score was 147 (standard deviation 20) out of a possible 188; this 
rose by 8 to 155 (SD 24) after supplementation with PL (t test p = 0.009, CI -10.1 to -
1.6). This median score also increased from baseline by 4 points after 
supplementation with BR to 151 (SD 25, t test p = 0.025, CI -8.2 to -0.61). These 
results indicate that supplementation with either BR or PL brought about a small 
subjective improvement in the quality of life of the trial participants. 
The above results were derived from a comparison of the FACT-An scores on each 
of the post-supplementation visits with the mean of the participant’s baseline FACT-
An scores. However, further analysis was performed analysing the change in FACT-
An score between each baseline visit and the following post-supplementation visit in 
an attempt to limit the confounding effect of any change in each participant’s 
wellbeing through the study. This demonstrated no significant difference in the 
FACT-An score between baseline and post-PL supplementation (Δ4 points, SD 13, 
CI 4.9, p = 0.44). It also showed no significant difference between the baseline pre-
BR and the post-BR supplementation visit’s FACT-An score (Δ7 points, SD 8, CI 3.1, 



































Figure 15: FACT-An quality of life scores of participants at each experimental 
visit. All 26 participants were asked to self-complete a Functional Assessment of 
Cancer Therapy - Anaemia (FACT-An) questionnaire to objectively quantify their 
quality of life over the seven days leading up to each of their 4 experimental visits, 
with a higher score indicating a better quality of life.  The experimental condition 
‘Baseline 1 + 2’ indicates all FACT-An scores of participants at their non-
supplemented visits, while ‘PL’ and ‘BR’ indicates the study visits following a period 
of supplementation with either nitrate-depleted beetroot juice (PL) or nitrate-rich 
beetroot juice (BR). This box whisker plot shows the median, interquartile range and 
the extreme total FACT-An scores recorded at each experimental visit. This graph 
demonstrates statistically significant difference in the FACT-An scores of each 
experimental visit, with improvement following both PL and BR supplementation 
when compared to baseline 1 + 2 (one way ANOVA p = 0.0261). A Fisher’s LSD 
demonstrates post-hoc statistical significance between Baseline 1 + 2 and PL 
(0.009), and between Baseline 1 + 2 and BR (0.025). The graph demonstrates a 
broad range of responses particularly at the ‘PL’ experimental visit. 
The degree of improvement of FACT-An scoring after supplementation was relatively 
small. Significant work has been performed recently in order to assist interpretation 
of these scores; the Functional Assessment of Chronic Illness Therapy 
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(FACIT) group has issued guidance regarding the minimal important differences 
(MIDs) for scores and scales of several similar qualitative assessments of health-
related quality of life, including FACT-An. They define MID as the "smallest 
difference in score in the domain of interest that patients perceive as important, 
either beneficial or harmful, and that would lead the clinician to consider a change in 
the patient's management" (Cella, Eton et al. 2002). According to their ‘tentative’ 
guidance, the MID for FACT-An is 7 points, meaning the observed difference in 
patients’ symptoms is statistically significant but may not be clinically significant 
across this population of participants. However, some individual participants derived 
a larger improvement in the FACT-An score results (Figure 16). Participants 5 and 
15 both recorded an improvement in the FACT-An score of 16 points between 
baseline and post-BR supplementation, although participant 15 also derived a FACT-
An benefit of 16 points from the PL supplementation compared to the baseline. 


































Figure 16: FACT-An quality of life scores of each individual participant at each 
experimental condition. All 26 participants were asked to complete a Functional 
Assessment of Cancer Therapy - Anaemia (FACT-An) questionnaire to objectively 
quantify their quality of life over the seven days leading up to each of their 4 
experimental visits, with a higher score indicating a better quality of life.  The 
experimental condition ‘Baseline 1 + 2’ indicates all FACT-An scores of participants 
at their non-supplemented visits, while ‘PL’ and ‘BR’ indicates the study visits 
following a period of supplementaion.. The total FACT-An Quality of Life score 
recorded for each individual participant at their baseline and post-supplementation 
visits, demonstrated a marked range in scores and individual variability through the 
study (SD of all scores at all experimental visits was 22.8). 
This subjective, qualitative aspect of the study of this cohort of anaemic participants 
demonstrated significant variability in all FACT-An quality of life scores with a 
coefficient of variation (CV) of 15.3%. The highest scoring individual rated their 
quality of life as 184 out of 188 while the lowest score recorded by any participant 
was only 85. The mean score of all participants at all study visits was 149 out of 188, 
while the standard deviation of all scores was 23. There was no correlation between 
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extent of change of FACT-An score post-supplementation and level of baseline 
rating.  
 
3.5 COGNITIVE FUNCTION 
 
The cognitive function of all participants within this study was objectively assessed at 
each trial visit through sequential monitoring of their responses to the FACT-Cog 
questionnaire. This 37-item questionnaire is divided into six cognitive domains: 
memory, concentration, mental acuity, verbal fluency, functional interference, and 
multitasking ability. This questionnaire also includes two other subscales, 
“noticeability” (comments from others) and “effect of perceived cognitive impairment 
on quality of life.” Participants record their answers on a 5-point scale ranging from 0, 
“never,” to 4, “several times a day,” the frequency of each occurrence over the 
7 days leading up to the test. In the sections on perceived cognitive abilities and the 
effect of cognitive impairment on quality of life, responses were rated on a 5-point 
severity scale ranging from 0, “not at all,” to 4, “very much.” The FACT-Cog total 
score was derived from the summation of all of the individual subscale scores, 
ranging from 0 to 132, with higher scores indicating better cognitive functioning. 
Within the 26 study participants, there was a marked variability in FACT-Cog 
responses, ranging from 37 to 132 out of 132 (SD 24), with a mean score of 107 and 
a CV of 22.2%. There was a minor improvement in the recorded score between 
baseline and both post-supplementation visits, irrespective of the type of 
supplementation consumed. The mean of all participants’ FACT-Cog total score was 
105 (SD 23) at baseline and rose by 4 to 109 (SD 24) after supplementation with PL 
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(p = 0.021, CI -7.1 to -0.6) and by 3 to 108 after BR (p = 0.013, CI -6.0 to -0.8) 
(Figure 17). Each of these values represents only ~3% of the total FACT-Cog score 
respectively which makes the clinical significance of this improvement uncertain. 
Indeed, Cheung et al (Cheung, Foo et al. 2014) reported that the minimum clinically 
important difference in FACT-Cog scored amongst a population of Chinese patients 
with breast cancer ranged from 6.9 – 10.6 depending on the statistical method used 
for interpretation.  
The above results were derived from a comparison of the FACT-Cog scores on each 
of the post-supplementation visits with the mean of the participant’s baseline FACT-
Cog scores. However, further analysis was performed analysing the change in 
FACT-Cog score between each baseline visit and the following post-
supplementation visit in an attempt to limit the confounding effect of any change in 
each participant’s cognitive function through the study. This demonstrated no 
significant difference in the FACT-Cog score between baseline and post-PL 
supplementation (Δ5 points, SD 9.5, CI 3.7, p = 0.41). It also showed no significant 
difference between the baseline pre-BR and the post-BR supplementation visits’ 





























Figure 17: FACT-Cog cognitive function scores at each experimental 
condition. All 26 participants were asked to complete a Functional Assessment of 
Cancer Therapy - Cognition (FACT-Cog) questionnaire to objectively quantify their 
cognitive function over the seven days leading up to each of their 4 experimental 
visits. The experimental condition ‘Baseline 1 + 2’ indicates all FACT-Cog scores of 
participants at their non-supplemented visits, while ‘PL’ and ‘BR’ indicates the study 
visits following a period of supplementaion with either nitrate-depleted beetroot juice 
(PL)  or nitrate-rich beetroot juice (BR). This box and whisker plot shows the median, 
interquartile ranges and extreme values of the FACT-Cog scores recorded by the 
trial participants. This demonstrates the presence of some extreme outliers whose 
self-reported cognitive function was markedly impaired by their health problem, 
although this was consistent for those participants across each of the experimental 
visits. It showed no clinically significant difference in any of the experimental 
conditions, although statistical significance was reached (1 way ANOVA p value = 
0.03). Fisher’s LSD test confirmed statistically significant differences between the 
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3.6 CYCLE ERGOMETRY  
 
Individuals enrolled in this study had a striking variability in physical characteristics, 
ranging from relatively frail nonagenarians to quite athletic individuals in their early 
40s. While anyone with significant cardiac or respiratory co-morbidities were 
excluded from the study, all participants were carefully observed during their cycle 
ergometry testing by a trained physician. All participants were strongly advised to 
cease exercise if they had any adverse symptoms such as dizziness or chest 
discomfort, if they reached 80% of their age-predicted maximum heart rate, if their 
oxygen saturations fell below 92% and if they experienced the following: If they felt 
they were breathing heavily; If they felt the exercise was challenging or; If they felt 
that maintaining a steady pedalling rate was uncomfortably fast. 
Most participants managed this well. However, the eldest person began to 
experience slight dizziness with no associated symptoms or deterioration in heart 
rate or pulse oximetry during the 3 minutes warm-up phase during which he pedalled 
without resistance. He was immediately advised to cease and his symptoms 
resolved within a few seconds, but this episode precluded him from further 
participation in the cycle ergometry aspect of this study. Hence, 25 of the 26 study 
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participants (96%) who attended all 4 investigational visits completed the cycle 
ergometry testing on each visit. 
Twenty-four of the 25 participants (96%) who were able to complete the cycle 
ergometry stopped the test themselves because they were experiencing one of the 
above symptoms. Only one participant (4%) was asked to cease the protocol on 
each of his experimental visits by the researcher as he had reached 80% of his age-
predicted maximum heart rate.  
 
3.6.1 GAS EXCHANGE THRESHOLD 
 
Oxygen saturations and methaemoglobin quantitation were observed during each 
cycle ergometry test. No participants developed methaemoglobinaemia.  
Pulmonary oxygen uptake and carbon dioxide output were recorded breath-by-
breath throughout a ramp incremental exercise test in order to determine the gas 
exchange threshold (GET).  
Data obtained was normal in distribution. The mean work rate at which GET was 
reached at baseline study visits was 51 Watts (W) (SD 12 W), while this work rate 
was 2 W higher (53 W, SD 11 W) after PL supplementation (p = 0.042, CI -3.933 to -
0.077). Those same participants reached their GET at a lower work rate by 1 W after 
BR supplementation (50 W, SD 12 W) compared to the mean of their baseline visits 
(p value not statistically significant at 0.34) while a comparison of the two 
supplemented experimental conditions reveals that GET after PL was 3 W higher 
than following BR supplementation (p = 0.014, CI 0.71 to 5.73) (Figure 18). There 
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was marked variation between the GET amongst participants within the current 
study, ranging from 27 W to 78 W. 
Further analysis was performed comparing the individual change in GET between 
each participant’s pre- and post-supplementation visits rather than comparing BR 
and PL with the mean of the two baseline visits. This demonstrated no significant 
change in GET at either PL; the cohort mean GET at this post-supplementation visit 
was 1 W higher than the baseline immediately prior to it (SD 6.6, CI 2.6, p = 0.96). 
Similarly, there was no significant change between the post-BR supplementation visit 
and the baseline visit beforehand; the cohort mean GET at BR was 1W higher than 





































Figure 18: Work rate (Watts) at which gas exchange threshold is reached at each 
experimental condition. 25 participants underwent a sub-maximal incremental 
exercise physiology test on an electronically braked cycle ergometer at each 
experimental visit. Baseline 1 + 2 refers to the two non-supplemented visits, while 
participants underwent beetroot juice supplementation prior to the ‘PL’ and ‘BR’ 
experimental conditions. This graph demonstrates each participant’s individual GET 
(black symbols and lines), the mean GET at each experimental condition (red 
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symbols and solid line) and the standard deviation at each condition (red dotted line). 
GET was reached at 51 W work rate in the baseline 1 + 2 experimental condition, but 
rose to 53 W after PL supplementation (t test p = 0.042). There was no statistical 
difference between GET work rate at baseline and BR. One way ANOVA analysis of 
all groups p = 0.0238, while post-hoc LSD test shows statistically significant 
difference between conditions Baseline 1 + 2 and PL (0.042) and between PL and 
BR (0.014) but not between Baseline 1 + 2 and BR. 
 
3.6.2 VO2 PEAK  AND PEAK POWER DURING A SYMPTOMS-LIMITED INCREMENTAL 
EXERCISE TEST 
 
Breath by breath oxygen uptake (VO2) was displayed digitally during cycle ergometry 
on a real-time basis after automated correction of concentration and volume signals 
of each breath. On completion of the study, analysis of this raw data was performed 
to determine the participants’ VO2 peak, the maximum rate of oxygen uptake 
measured during this incremental exercise. As the participants were given 
restrictions preventing maximal exercise to ensure none came to harm, the 
maximum measured VO2 was technically not VO2max. Twenty-five of the 26 patients 
who completed all four experimental visits were included in this aspect of the 
analysis. The only exclusion was the elderly gentleman who was precluded from 
cycle ergometry testing as outlined above.  
The mean observed VO2 peak across the entire cohort of participants at all 
experimental visits was 1209 ml/kg/min (SD 459 ml/min/kg). This standard deviation 
demonstrates the large range in exercise capability amongst this cohort of people, 
and represents the marked variation in individuals’ age, co-morbidities, haemoglobin 
and concurrent treatment. The mean VO2 peak was 1170 ml/kg/min at the baseline 
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experimental visits (SD 375 ml/kg/min) (Figure 19). There was a trend for this to be 
higher at the post-PL experimental visit, with an observed increase to 1230 
ml/kg/min which was not quite statistically significant (p = 0.062, CI -123 ml/kg/min to 
3.16 ml/kg/min). There was no difference in the mean VO2 peak between baselines 
and at the post-BR supplementation visit (1153 ml/kg/min, p = 0.43). When 
comparing the post-supplementation visits, the VO2 peak following PL supplementation 
tended to be higher than that recorded following BR supplementation (mean 78 
ml/kg/min, p = 0.09, CI -13 ml/kg/min to 168 ml/kg/min).  
Further analysis of this data assessing the change in VO2 peak between each of the 
individual baselines with the post-supplementation visits showed no significant 
difference between baseline and PL (Δ8 ml/kg/min, SD 139, CI 55, p 0.54) or 




































Figure 19: Change in VO2 peak (ml/kg/min) observed with each experimental 
condition. This bar graph shows the means and standard deviations of maximal 
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oxygen consumption (VO2 peak) of 25 participants whilst performing a sub-maximal 
incremental electronically braked cycle ergometry test at each of their experimental 
visits. Baseline 1 + 2 refers to the two non-supplemented visits, while participants 
underwent acute supplementation prior to the ‘PL’ and ‘BR’ experimental conditions. 
This bar graph demonstrates no statistically significant difference in observed VO2 
peak at any of the experimental visits. There was a trend for increased VO2 peak 
between baseline (1170 ml/kg/min) and PL experimental visits (1230 ml/kg/min) 
although this was not significant (p = 0.06). Similarly, VO2 peak following BR 
supplementation tended to be slightly lower (1153 ml/kg/min) than PL but this too 
was did not reach statistical significance (p = 0.09). This trend towards differences 
between all of the means is confirmed through a 1 way ANOVA analysis (p = 
0.0616). 
 
The 25 participants who completed cycle ergometry exercise testing at each of their 
4 experimental visits maintained the same pedalling cadence while performing a 
linear work rate increase of 10 W / minute which continued to intolerance. The 
ergometer imposed a fixed work rate increase through electronic flywheel braking, 
enabling the peak power generated to be calculated following completion of the 
exercise test.  
The mean peak power recorded amongst all participants at all experimental visits 
was 112 W (standard deviation 44 W). The variability in physical fitness of 
participants was again demonstrated by this measure of maximal exercise capacity, 
with peak powers of those able to perform the test ranging between 59 W and 236 W 








































Figure 20: Peak power observed at each experimental condition. This bar chart 
shows the mean and standard deviation of maximal power output in Watts achieved 
by 25 participants whilst performing a symptoms-limited incremental electronically 
braked cycle ergometry test at each of their experimental visits. Baseline 1 + 2 refers 
to the two non-supplemented visits, while participants underwent 48 hours of 
beetroot juice supplementation prior to the ‘PL’ and ‘BR’ experimental conditions. 
This graph demonstrates a statistically significant increase in peak power at the 
experimental visits following PL supplementation (116 W) compared to both baseline 
(peak power = 110 W, t test p = 0.014) and ‘BR’ (peak power = 109 W, t test p = 
0.027). A one way ANOVA calculation showed the difference between data sets was 
statistically significant (p = 0.0088) while LSD test concluded that comparison of PL 
with both baseline and BR was significant (*). The error bars signify SD, 
demonstrating a broad range between peak power particularly in the post-PL 
experimental visit. 
 
The mean peak power recorded across the baseline visits was 110 W (SD 36 W). 
This increased to 116 W (SD 41 W) at the post-PL supplementation experimental 
visit (t test p = 0.014, CI -11.2 W to 1.41 W). There was no statistically significant 
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difference when comparing the peak power after BR supplementation (109 W, SD 37 
W) with the mean of the peak power at baseline (p = 0.449). However, comparison of 
peak power between the post-intervention trial visits showed a statistically significant 
improvement in performance at the post-PL visit over the post-BR supplementation 
of 8 W (p = 0.027, CI 0.96 W to 14.29 W). Hence, there was a small but statistically 
significant improvement in peak power following supplementation with nitrate-
depleted beetroot juice (PL) over both baseline and post-BR study visits.  
There was no significant change in the peak power between participants’ pre-PL 
baseline and post-PL supplementation visits (Δ4 W, SD 10.5, CI 4.1, p = 0.27) or 
between their pre-BR baseline and post-BR supplemented visits (Δ1 W, SD 8.2, CI 
3.2, p = 0.27). 
Time elapsed prior to the intolerance of exercise during a cycle ergometry linear 
work rate increase was recorded as the time limit of exercise tolerance (Tlim). As 
demonstrated by all of the other physiological measures in the cycle ergometry 
testing, there was marked variation of the Tlim between participants and also between 
each individual’s study visits. The population mean Tlim was 560 seconds (s) (SD 258 

































Figure 21: Time to limit of exercise tolerance (Tlim) of cycle ergometry testing. 
This bar chart shows the mean and standard deviation of the T lim of 25 participants 
who were performing a symptoms-limited incremental electronically braked cycle 
ergometry test. Baseline 1 + 2 refers to the two non-supplemented visits, while 
participants underwent 48 hours of beetroot juice supplementation prior to the ‘PL’ 
and ‘BR’ experimental conditions. This graph demonstrates that the mean T lim of 
participants at the ‘PL’ visit (580 seconds) was higher than the same participants’ 
mean Tlim at both the baseline (Tlim  = 543 s, p = 0.013) and ‘BR’ experimental 
conditions (Tlim = 530 s, p = 0.023). One way ANOVA calculation shows statistical 
significance (p = 0.007) while LSD test confirms statistically significant differences 
between the baseline 1 + 2 and PL (0.013), and between PL and BR supplemented 
visits (0.023), but not between baseline 1 + 2 and BR. 
Supplementation with PL was associated with a statistically significant improvement 
in Tlim over the mean of the baseline visits of 37 s (p = 0.013*, CI = -65.99 to -8.42). 
There was no difference in Tlim following BR supplementation and baseline visits (p = 
0.252). Comparison of the two post-supplementation visits demonstrates a 50 s 
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difference in Tlim (580 s compared to 530 s) following PL supplementation compared 
to BR (p = 0.023*, CI = 7.666 to 92.494). 
When looking at the data in a different manner by comparing the change in Tlim 
between the pre-PL baseline and the post-PL visits, this apparent change becomes 
statistically not significant (Δ 24 s, SD 62 s, CI 24 s, p = 0.14). Similarly, there is no 
significant change in Tlim between pre-BR baseline and post-BR supplementation (Δ 
1 s, SD 41 s, CI 16 s, p = 0.14).  
Hence there was a physiologically and statistically significant improvement in Tlim 
following PL supplementation compared to both the mean of the non-supplemented 
visits and with the post-BR supplemented visits. This difference was not 
demonstrated when comparing the change in Tlim between individual baselines and 
supplemented visits. However, the observed difference in haemoglobin 
concentration between PL and BR experimental conditions (see section 3.2) was 
positively correlated with the difference in Tlim between the same conditions (r = 0.64, 
p – 0.0006).  
 
3.7 31PHOSPHOROUS (31P) MAGNETIC RESONANCE SPECTROSCOPY 
 
31Phosphorous magnetic resonance spectroscopy (31P-MRS) was performed at each 
experimental visit by 24 of the 26 participants (92%). The two people who did not 
complete this aspect of the testing were excluded by the investigator. One participant 
had previously undergone spinal decompression / reconstruction surgery and a 
significant length of her spine was supported by a titanium framework of rods and 
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screws. She was therefore excluded as the quantity of titanium in her body was felt 
to preclude her from this aspect of the study, despite the fact the risk was probably 
negligible given titanium’s non-ferrous nature. The second participant was unable to 
perform this aspect of testing as he had an age-related marked increase in thoracic 
kyphosis. As a result, he was unable to lie supine in the scanner without significant 
discomfort regarding his head position, and a sensation of breathlessness. Hence, 
he was advised to not perform this part of the testing. All other participants tolerated 
the procedure without adverse effect. 
Participants repeatedly completed 24 seconds of exercise with a single leg knee 
extension ergometer whilst lying in the bore of the 1.5T superconducting magnet, 
followed by 3.5 minutes of recovery. Recorded 31P-MRS results were used to 
determine the rate of phosophocreatine (PCr) recovery, while PCr concentration and 
pH of the quadriceps muscle was calculated at completion of exercise.  
 
3.7.1 RATE OF PHOSPHOCREATINE RECOVERY 
 
There was no difference in the rate of phosphocreatine (PCr) recovery amongst any 
of the trial conditions.  The time constant (τ) rate of PCr recovery amongst all 24 






































Figure 22: The time constant of phosphocreatine (PCr) recovery in each 
experimental condition. 24 participants completed an exercise protocol involving 
single-legged knee extensions while the quadriceps muscle of their right leg was 
analysed during 31Phosphorous  magnetic resonance spectroscopy (31P-MRS) inside 
the bore of a 1.5T superconducting magnetic resonance scanner (see methods 
section 2.8.6). Baseline 1 + 2 refers to the two non-supplemented visits, while 
participants underwent 48 hours of beetroot juice supplementation prior to the ‘PL’ 
and ‘BR’ experimental conditions. This box and whisker plot displays the medians, 
interquartile range and extremes of observed PCr recovery rate amongst all 
participants at each experimental visit. It shows that there was no statistically 
significant difference amongst the medians of any of the experimental conditions 
(one way ANOVA p = 0.59). 
 
At baseline visits, the median PCr time constant was 42 seconds (SD 10, CI 38.05 – 
46.33). At the post-BR experimental visit, the median PCr time constant was 38 
seconds (SD 10, CI 36.5 – 45.24). Following supplementation with PL, median PCr 
recovery was 42 s (SD 7, CI 39.27 – 45.55), which was not different from baseline (p 
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= 0.43, CI -3.04 – 2.60). Comparing the two post-supplementation experimental 
visits, there was no significant difference between PCr recovery τ following BR 
supplementation (38 s) and PL supplementation (42 s). A one way ANOVA analysis 
of all experimental visits confirmed no statistically significant difference between 
experimental conditions (p = 0.59). 
Further interrogation of the data demonstrated no significant change in the PCr time 
constant between participants’ pre-PL baseline and post-PL supplementation visits 
(Δ0 s, SD 6, CI 2.42, p = 0.21) or between their pre-BR baseline and post-BR 
supplemented visits (Δ-3 s, SD 9, CI 3.78, p = 0.21). 
 
3.7.2 END-EXERCISE PH 
 
There was no significant difference in calculated pH of the quadriceps muscle at 
termination of the knee-extension exercise protocol between any of the experimental 
conditions (Figure 23). One participant had an extremely outlying pH of 6.70 at one 
of their baseline visits, with pH between 7.12 and 7.16 at each of their other visits. 
This much more acidotic pH was observed in the absence of any symptoms of 
cramp or marked fatigue during the single leg ergometry suggesting this is a 































7.3 n = 24
p = 0.3035
 
Figure 23: Quadriceps muscle pH at the termination of exercise regime during 
31phosphorous magnetic resonance spectroscopy (31P-MRS). Magnetic 
resonance spectroscopy was performed while 24 participants underwent a low 
intensity exercise protocol involving single leg knee extension against resistance 
inside the bore of a 1.5T superconducting magnetic resonance scanner (see ‘2.7.6 
31Phosphorous - Magnetic Resonance Spectroscopy (31P-MRS)’). Baseline 1 + 2 refers to 
the two non-supplemented visits, while participants underwent 48 hours of beetroot 
juice supplementation prior to the ‘PL’ and ‘BR’ experimental conditions. This box 
and whisker plot demonstrates the medians, interquartile ranges and extremes of 
end-exercise pH amongst the 24 participants at each experimental visit. It 
demonstrates that there was no statistically significant difference in end-exercise pH 
between any of the experimental conditions (one way ANOVA p = 0.3035), and that 
two extreme outliers were recorded amongst baseline visits.  
The median pH of all the other baseline experimental visits was pH 7.08 (SD 0.041, 
95% CI 7.07 – 7.09). Following supplementation with PL, end-exercise pH was 7.09 
(SD 0.03, 95% CI 7.07 – 7.10). Following supplementation with BR, end-exercise pH 
was lower than each of the other experimental conditions at pH 7.08 (SD 0.04, 95% 
CI 7.06 – 7.09). Further analysis of the data demonstrated no significant change in 
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the pH between participants’ pre-PL baseline and post-PL supplementation visits (Δ0 
pH, SD 0.05, CI 0.052, p = 0.01) or between their pre-BR baseline and post-BR 
supplemented visits (Δ0 pH, SD 0.03, CI 0.01, p = 0.01). 
 Hence supplementation with beetroot juice made no difference to pH (one way 
ANOVA p = 0.3035). 
 
3.8 PLATELET AGGREGOMETRY 
 
Fourteen of the 26 participants (54%) were excluded from the platelet aggregometry 
aspect of this study at their screening visit as they were taking aspirin, clopidogrel, 
non-steroidal anti-inflammatory drugs, warfarin or another anticoagulant. Only three 
participants (11.5%) were able to undergo platelet aggregometry testing on each of 
their four experimental visits. The remainder were unable to proceed with this test on 
one or more of their visits for a number of reasons. Some participants were excluded 
from this aspect of the study as they ingested an antiplatelet, anticoagulant or non-
steroidal anti-inflammatory drug within a week before the experimental visit. Most of 
these took over the counter aspirin or ibuprofen for pain such as tension headache, 
having forgotten that such an act would preclude them from this aspect of the study. 
Others were excluded because their platelet rich plasma (PRP) failed quality control 
because of insufficient platelet count (fewer than 50 x 109/l). In all such cases, this 
was always associated with a marked reduction in numbers of other blood cells as a 
result of the effect their underlying disease or chemotherapy was exerting on their  
bone marrow function at that time. Thirdly, a number of participants were excluded 
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on at least one of their experimental visits due to a lack of reagent tubes for use in 
the platelet aggregometer as a result of supply problems from the manufacturer. 
Platelet aggregation testing measures the ability of various agonists to platelets to 
induce in vitro activation and platelet-to-platelet activation. Classically Born 
aggregometry uses platelet rich plasma [PRP] but whole blood aggregometry can be 
also used. In the Born aggregometer, PRP is rapidly stirred in a cuvette at 37°C and 
the cuvette is positioned in a well between a light source and a photocell (Born and 
Cross 1963). When an agonist is added the platelets initially change shape from 
discs to rounded forms with extended filopodia, resulting in a small, transient 
decrease in light transmission that is followed by an increase as they aggregate or 
stick together in a fibrinogen-dependent manner. Platelet aggregation reduces the 
degree of side scatter of light, increasing light transmission through the cuvette. This 
increase is detected by the photocell. A curve comparing light transmission with time 
elapsed is generated as seen in the sample from the second experimental visit of 
participant number 26 below (Figure 24). 
 
Figure 24: Platelet aggregometry trace from participant number 26 in response 
to collagen. Venepuncture and the preparation of platelet rich plasma (PRP) and 











displays monophasic platelet aggregation of PRP from the second experimental visit 
of participant 26 in response to the addition of the platelet aggregation agonist, 
collagen. The x axis of this figure depicts time elapsed (minutes) while the y axis 
displays percentage of light transmission through the cuvette containing PRP and 
agonist within the platelet aggregometer. Collagen (agonist) is added to the PRP at 
blue arrow 1, which binds to the glycoprotein VI and glycoprotein Ia/IIa receptors on 
platelets inducing granule release. This results in a shape change in platelets within 
the sample resulting in a transient slight reduction in light transmission (blue arrow 
2). After a lag phase of just less than a minute which is typical in platelet 
aggregometry agonised by collagen, platelets within the sample soon begin to 
aggregate, the rate of which is measured as the primary aggregation of the sample 
(red line), a measure of the platelets’ ability to aggregate. The point at which 
maximal light transmission is reached is the maximal aggregation of the sample. This 
example demonstrates maximal aggregation at only 51% (green line). It is a 
monophasic curve, indicating that no secondary aggregation occurred, whereby 
platelets often release nucleotides such as adenosine diphosphate (ADP) and 
irreversibly change in shape producing a secondary phase of aggregation. The 
reason no secondary aggregation was observed in this sample could be that either 
there was an insufficient initial stimulus, or that the activated platelets were unable to 
make sufficient thromboxane A2 and thus could not sustain glycoprotein IIb/IIIa 
activation.  
The majority of participants’ samples were analysed simultaneously in 8 separate 
reaction chambers within the platelet aggregometer, assessing the platelet 
aggregation response of both participant and control platelet rich plasma to the 
addition of 4 different agonists, adenosine diphosphate, arachidonic acid, collagen, 
and epinephrine. The platelet aggregometer analysed the curve of optical density 
change over time, calculating the primary aggregation, primary slope, secondary 
aggregation, area under the curve, lag phase, final aggregation and disaggregation 




Figure 25: Platelet aggregometry trace for participant 12 experimental visit 2 
and control in response to agonists. Platelet rich plasma was produced as 
outlined above from both participant and healthy volunteer control (methods section 
2.7.7). Platelet aggregation was analysed in response to the addition of 4 agonists, 
adenosine diphosphate (ADP), arachidonic acid (AA), epinephrine and collagen. The 
resultant platelet shape change, aggregation and secondary aggregation produced 
an increase in light transmission as detected by the photo cell. Channels 1 to 4 are 
samples from participant 12 demonstrating aggregation upon the addition of each of 
the above agonists, while channels 5 – 8 display aggregation of control PRP with the 
same agonists. 
In all but one of the participant and control sample analyses, platelets within the PRP 
aggregated successfully on the addition of agonists. However, samples from 
participant 12’s first experimental visit did not aggregate in response to any agonists 
despite passing the PRP quality control check (Figure 26). The sample contained 68 
x 109/l platelets (accepted if greater than  50 x 109/l, normal range 150 x 109/l – 400 x 
109/l), a white cell count of 0.1 x 109/l (accepted if less than 0.5 x 109/l, normal range 
3.8 – 10.6 x 109/l), and a red cell count of 0.01 x 1012/l (accepted if less than 0.5 x 
1012/l, normal range 4.5 – 5.9 x 1012/l ). On visual inspection, it was evident that the 
magnetic stirring rods had failed to function, explaining the lack of aggregation; 
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platelets will only aggregate if they are activated by an agonist and they are in 
contact with one another (Born and Cross 1963).  A repeat of the analysis was not 
complicated by the same equipment failure and aggregometry occurred as expected. 
 
Figure 26: Failed platelet aggregometry of platelet rich plasma (PRP) samples 
from participant 12's first experimental visit. This participant’s PRP was produced 
as described above (methods section 2.7.7) and passed quality control quantification 
of platelets (68 x 109/l), white cells (0.1 x 109/l ) and red cells (0.01 x 1012/l). 
However, the addition of the platelet aggregation agonists ADP, arachidonic acid, 
collagen and epinephrine induced no platelet aggregation. On visual inspection of 
the well containing PRP and agonist, it was apparent that the magnetic stirring rod 
had failed to function and the sample was therefore unable to aggregate. A repeat 
analysis brought about successful aggregation in all wells. 
 
3.8.1 PLATELET AGGREGATION INDUCED BY ADP 
 
Of those three participants in whom a complete set of platelet aggregometry data 
was available, there was no discernible difference between their aggregometry 
results at any of the experimental conditions (ANOVA p = 0.77). The mean primary 
slope of aggregation following the addition of ADP at the baseline experimental 
stage was 37.7 (SD 20.5, 95% CI 16.2 – 59.2). After supplementation with BR, this 
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mean primary slope of aggregation rose to 45.3 (SD 25.5, 95% CI -18.1 – 108.8) 
although this was not statistically significant (t test p = 0.70). Following PL 
supplementation, the primary slope of aggregation was 41.3 (SD 4.0, 95% CI 31.3 – 
51.4), with no significant difference compared to baseline 1 + 2 (t test p = 0.34). 
Each of these mean values for the primary slope of aggregation following ADP 
addition was within the normal range quoted by the manufacturer of the PAP8 
analyser in the analyser’s handbook. 
The median final platelet aggregation at 5 minutes after the addition of ADP was 
65% at baseline, 73% following PL and 77% following BR. The comparison of each 
of these non-parametric data through Wilcoxon matched-pairs signed rank test 
showed no statistically significant difference between experimental conditions (p = 
0.50 comparing baseline and PL, p = 1.0 comparing baseline and BR, and p = 0.75 
comparing BR and PL), while ANOVA analysis gave p = 0.66 for all of the 















































Figure 27: Final platelet aggregation following the addition of ADP. This scatter 
graph depicts the total percentage of platelet aggregation for platelet rich plasma 
samples from the three participants in this study who successfully completed 
aggregometry testing after each of their four experimental visits. Participant samples 
were analysed through light aggregometry of platelet rich plasma in response to the 
addition of the platelet agonist ADP (see section 2.7.7 for methods). This figure 
demonstrates that one participant’s baseline experimental visit blood test did not 
successfully aggregate, while all other specimens aggregated to an acceptable 
degree (manufacturer’s reference range 63 – 89%). The median final percentage 
aggregation (depicted by the line on the graph) was not statistically different between 
each experimental condition and was thus not affected by supplementation with 
nitrate-rich beetroot juice (BR) or nitrate-depleted placebo (PL) (ANOVA p = 0.66) 
 
The manufacturer’s quoted reference range for this total platelet aggregation was 
63% – 89%, indicating that all median values were within the normal range, although 
three individual samples aggregated less fully than this level. The platelets of one 
participant did not aggregate well with any agonist at experimental visit 3 (non-
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supplemented, baseline) without any obvious reason; they had taken no medications 
as listed above and the platelet rich plasma passed quality control standards.  
Further analysis of all available data including those from participants who did not 
have results from each of their four experimental visits still demonstrated no 
significant difference in the primary aggregation or final aggregation of platelets in 
response to the addition of ADP. The primary aggregation at baseline was 73.4% 
(SD16, CI 8.4), PL was 83.7% (SD17.7, CI 10.9), and BR was 72.5 (SD 16.8, CI 9.9) 
with p values of 0.17 and 0.35 derived from T tests comparing each of the 
conditions, and an ANOVA comparing all supplementation states of p = 0.34. The 
final aggregation at baseline was 76.2% (SD 14.4, CI 7.5), PL was 83.5 % (SD 14.2, 
CI 8.8) and BR was 72.7 (SD 14.8, CI 8.7) with t-test p values of 0.36 and 0.11 and 
an ANOVA of p = 0.27. Hence no difference was observed between experimental 
conditions in platelet aggregation in response to ADP. 
 
3.8.2 PLATELET AGGREGATION INDUCED BY ARACHIDONIC ACID 
 
Following the addition of arachidonic acid to platelet rich plasma, platelets rapidly 
release alpha granules which initiate primary aggregation. While one participant’s 
platelets did not aggregate well at one of their baseline (non-supplemented) 
experimental visits as described following ADP, the remaining participants’ platelet 
function appeared to be in the normal range. The median rate of primary aggregation 
at baseline was 59, while it was 52 following BR supplementation although this did 
not represent a statistically significant difference (p = 0.75). Following PL 
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supplementation, the median rate of primary aggregation measured 71 but again, 
this was not statistically significant (baseline vs. BR t-test p = 0.45, BR vs. PL t-test p 












































Figure 28: Primary slope of platelet aggregation following the addition of 
arachidonic acid to platelet rich plasma (PRP). This scatter graph depicts the 
primary slope of platelet aggregation for platelet rich plasma samples from the three 
participants in this study who successfully completed aggregometry testing after 
each of their four experimental visits. Participant samples were analysed through 
light aggregometry of platelet rich plasma in response to the addition of the platelet 
agonist arachidonic acid (see section 2.7.7). This figure demonstrates that PRP 
taken at one participant’s experimental visit following supplementation with nitrate-
rich beetroot juice (BR) was very rapidly, while the remainder of PRP aggregated 
more slowly in each experimental condition. One participant’s PRP sample did not 
aggregate well at their baseline visit with a slow rate of aggregation, as also 
demonstrated in response to ADP (see Figure 27). The median primary slope of 
aggregation (depicted by the line on the graph) was not statistically different between 
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each experimental condition and was thus not affected by supplementation with 
nitrate-rich beetroot juice (BR) or nitrate-depleted placebo (PL) (ANOVA p = 0.69). 
 
Total aggregation (not displayed in graph form) following the addition of arachidonic 
acid was within the normal range apart from one participant at one of their baseline 
visits. The mean total aggregation at baseline was 53.8% (SD 22.6), was 53.0% (SD 
43.6) following supplementation with BR and 52.3% following PL supplementation 
(SD 24.2). There were no statistically significant differences between the baseline, 
PL or BR experimental conditions (p = 0.88).  
Further analysis of all available data including those from participants who did not 
have results from each of their four experimental visits still demonstrated no 
significant difference in the primary aggregation or final aggregation of platelets in 
response to the addition of arachidonic acid. The primary aggregation at baseline 
was 63.79% (SD 10.93, CI 5.72), PL was 67.7% (SD 17.77, CI 11.01), and BR was 
61.0% (SD 24.07, CI 14.23) with p values of 0.62 and 0.5 derived from T tests 
comparing each of the conditions, and an ANOVA comparing all supplementation 
states giving a p value of p = .075. The final aggregation at baseline was 61.71% 
(SD 11.83, CI 6.2), PL was 65.50 % (SD 16.69, CI 10.34) and BR was 58.67 (SD 
25.72, CI 15.20) with t-test p values of 0.55 and 0.47 and an ANOVA of p = 0.74. 
Hence no difference was observed between experimental conditions in platelet 




3.9 BLOOD ANALYSIS: CYCLIC GUANOSINE MONOPHOSPHATE 
 
Plasma cyclic guanosine monophosphate (cGMP) concentration was quantified in 
blood samples taken from all 26 participants who completed the entire study at each 
of their experimental visits. After centrifugation, plasma samples were stored at -80 
°C pending analysis. During this analysis as outlined in methods section 2.8.7, 
cGMP was quantified in two large batches of all participant samples along with 5 
standard samples of known cGMP concentrations per batch. All of the standard and 
participant samples were analysed in duplicate using a colourimetric competitive 
immunoassay kit.  This resulted in a change in the optical density of the reactants 
within a plastic plate, which in turn was used to quantify the cGMP concentration of 
































Figure 29: cGMP quantitation standard curve. This demonstrates the results from 
enzyme linked immunospecific assay of standard samples of known concentrations 
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of cGMP. Included are 5 standard samples each analysed in duplicate alongside two 
batches of participant plasma samples.  The standards contained cGMP 
concentrations of 50 pmol/l, 10pmol/l, 2 pmol/l, 0.4 pmol/l and 0.08v pmol/l. The 
mean concentrations of all four analyses of the same standard samples were 50.38 
pmol/l (SD 7.23 pmol/l), 9.92 pmol/l (SD 2.03 pmol/l), 2.01 pmol/l (SD 0.12 pmol/l), 
0.41 pmol/l (SD 0.1 pmol/l) and 0.15 pmol/l (SD 0.12 pmol/l) respectively. The 
coefficient of variation for the assay was 29.1 % if all standard concentrations were 
included in the analysis, although if the least accurate higher concentration (50 
pmol/l) sample results were excluded from this analysis, the CV of this assay was 
16.7%. While the accuracy of the assay was thus demonstrated to be poor at the 
highest standard concentration of cGMP, none of the participants’ cGMP 
concentrations reached 10 pmol/l and therefore the loss of accuracy at far higher 
concentrations was not felt to have a detrimental effect on the validity of data 
generated from participant samples.  
 The mean plasma cGMP amongst all samples was 2.15 µmol/l (SD 1.41 µmol /l). 
There was no difference in cGMP between baseline or after supplementation with 
either BR or PL (Figure 30) (ANOVA p = 0.36). The mean cGMP concentration at 
baseline visit was 2.24 µmol/l (SD 1.17 µmol/l, 95% CI 1.77 – 2.71). There was a 
trend towards a greater cGMP concentration after BR (2.51 µmol/l, SD 1.17 µmol/l) 
compared to baseline (p = 0.079). Mean cGMP after supplementation with PL 
measured 2.48 µmol/l (SD 1.65 µmol/l, 95% CI 1.82 – 3.15) but the difference 
between PL and baseline was not statistically insignificant (p = 0.32). There was no 














































Figure 30: Plasma cGMP concentration at each experimental visit. This bar 
chart demonstrates the mean and standard deviations of measured concentrations 
of cGMP amongst 26 participants’ plasma samples. Baseline 1 + 2 refers to the two 
non-supplemented visits, while participants underwent 48 hours of beetroot juice 
supplementation prior to the ‘PL’ and ‘BR’ experimental conditions. This 
demonstrates that there was no statistically significant difference between the mean 
cGMP plasma concentration amongst any of the experimental conditions, although 
there was a trend to suggest an increase from baseline (mean cGMP = 2.15 µmol/l) 
to BR (mean cGMP = 2.51 µmol/l, p = 0.079) and PL (mean cGMP = 2.48 µmol/l, p = 
0.32). ANOVA p = 0.36. 
 
3.10: BLOOD PRESSURE 
 
At each experimental visit, after all 26 participants had undergone blood tests and 
completed quality of life questionnaires, following 10 minutes of seated rest in a 
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quiet, darkened room, baseline blood pressure of the brachial artery (systolic and 
diastolic) was measured three times and the mean of the readings was recorded.  
 
3.10.1: SYSTOLIC BLOOD PRESSURE 
 
The mean systolic blood pressure of all 26 participants at their baseline (non-
supplemented) experimental visits was 122 mmHg (SD 15 mmHg, CI 116 – 128 
mmHg). After acute supplementation with nitrate-depleted beetroot juice (PL), the 
mean systolic blood pressure was 116 mmHg (SD 15 mmHg, CI 110 – 124 mmHg), 
while systolic blood pressure was 117 mmHg following 48 hours of supplementation 
with nitrate-rich beetroot juice (BR) (SD 15, CI 112 – 123 mmHg) (Figure 31). A one 
way repeated measures ANOVA of these data demonstrates statistical significance 
(p = 0.0081), while post hoc Fisher’s LSD test confirms a statistically significant 
difference between baseline and PL (p = 0.005) and between baseline and BR (p = 
0.011) but no difference between PL and BR. 
Further interrogation of this data analysing the change in systolic blood pressure 
between the baseline visit prior to PL and the post-PL supplemented visits 
demonstrates no statistically significant difference (Δ -6 mmHg, SD 11, CI 4) while 
comparison of pre and post BR supplementation visits similarly showed no 
statistically significant difference in systolic blood pressure (Δ -4 mmHg, SD 9, CI 4) 

















































Figure 31: Systolic blood pressure at each experimental condition. This bar 
chart demonstrates the mean and standard deviations of the observed systolic blood 
pressures of 26 participants at each of their experimental conditions. The 
experimental condition ‘Baseline 1 + 2’ indicates all systolic blood pressures of 
participants at their non-supplemented visits, while ‘PL’ and ‘BR’ indicates the study 
visits following a period of supplementation. This graph demonstrates that the mean 
systolic blood pressure was higher at the baseline visits (122 mmHg, SD 15 mmHg, 
CI 116 – 128 mmHg) than at each of the supplemented visits (PL = 116 mmHg, SD 
15 mmHg, CI 110 – 124 mmHg; BR = 117 mmHg, SD 15 mmHg, CI 112 – 123 
mmHg) (p = 0.0081). LSD shows statistical significant difference between Baseline 
and PL (p = 0.005) and between baseline and BR (p = 0.011). 
 
3.10.2 DIASTOLIC BLOOD PRESSURE 
 
The mean diastolic blood pressure of all 26 participants at their baseline (non-
supplemented) experimental visits was 68 mmHg (SD 5 mmHg, CI 66 - 70 mmHg). 
169 
 
After acute supplementation with nitrate-depleted beetroot juice (PL), the mean 
systolic blood pressure was 66 mmHg (SD 6 mmHg, CI 64 – 69 mmHg), while 
systolic blood pressure was 65 mmHg following 48 hours of supplementation with 
nitrate-rich beetroot juice (BR) (SD 5 mmHg, CI 63 - 67 mmHg) (Figure 32). A one 
way repeated measures ANOVA of these data demonstrates a trend towards 
statistical significance (p = 0.0535). Comparison of diastolic blood pressures using a 
students’ repeated measures t test between baseline and PL also showed a trend 
towards significance (p = 0.0897), while there was a statistically significant difference 
between baseline and BR (p = 0.0067). There was no difference between BR and 
PL. 
Further interrogation of this data analysing the change in diastolic blood pressure 
between the baseline visit prior to PL and the post-PL supplemented visits 
demonstrates no statistically significant difference (Δ -1 mmHg, SD 5, CI 2) while 
comparison of pre and post BR supplementation visits similarly showed no 
statistically significant difference in diastolic blood pressure (Δ -1 mmHg, SD 5, CI 2) 














































Figure 32: Diastolic blood pressure at each experimental condition. This bar 
chart demonstrates the mean and standard deviations of the observed diastolic 
blood pressures of 26 participants at each of their experimental conditions. The 
experimental conditions are described in Figure 31 above. This graph demonstrates 
a trend towards statistically significant differences in the mean diastolic blood 
pressure between each experimental visit; this was 68 mmHg at the baseline visits 
(SD 5 mmHg, CI 66 – 70 mmHg), 66 mmHg at PL (SD 6 mmHg, CI 64 - 69 mmHg) 
and 65 mmHg at BR (SD 5 mmHg, CI 63 - 67 mmHg) (ANOVA p = 0.0535). Paired 
students’ t test comparisons showed a statistically significant difference between 
baseline and BR (p = 0.0067) and a trend towards statistically significant difference 
between baseline and PL (p = 0.0897) but no change between BR and PL. 
 
3.11 BLOOD ANALYSIS:  FERRITIN AND IRON STUDIES 
 
Serum ferritin, iron, transferrin and transferrin saturation were quantified in all 26 
participants who completed each of the experimental visits, although 7 of the 104 
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samples (6.7%) were automatically not processed by the Royal Devon and Exeter 
Hospital biochemistry laboratory as they breached the hospital policy that this test 
could not be repeated on the same person before 28 days had elapsed since the 
previous sample.  
The mean ferritin concentration across all participants’ visits was 358 µg/l (normal 
range 30 – 200 µg/l).  The batch to batch CV was up to 2.8%. No participants were 
iron deficient with a ferritin beneath this range, while a number of participants had a 
ferritin far in excess of this range (Figure 33). Serum transferrin and transferrin 
saturation on those patients with elevated ferritin concentration demonstrated no 
evidence of iron overload, indicating that the elevation in ferritin was probably 
caused by an acute phase response or liver disease, both of which were most likely 
to have been caused by their underlying malignancy. Of note, any patients exhibiting 
symptoms of acute illness such as infection, or whose baseline observations such as 
temperature were indicative of such an illness at the beginning of their experimental 
visit would have been excluded from that day of experiments. No such events 












































Figure 33: Serum ferritin of participant blood samples from each experimental 
visit. This scatter graph demonstrates serum ferritin concentrations from all 26 
participants’ plasma samples from venepuncture at each of their four experimental 
visits, along with the median and the interquartile range of results obtained after 
each experimental condition.  The experimental conditions and ferritin analysis are 
described in Figure 30 and in methods section 2.7.7 respectively. This graph 
demonstrates that the median of all participants’ ferritin at each experimental 
condition was above the normal range (i.e. greater than 200 µg/l), and a small 
number of participants had vastly elevated ferritin concentrations. There was no 
significant difference between the experimental conditions (ANOVA p = 0.90) 
 
Supplementation with either BR or PL had no significant effect on serum ferritin 
compared to either baseline or the other supplemented state (p = 0.68, 0.82 and 
0.73 respectively), while ANOVA analysis of the entire data set showed no significant 
difference (p = 0.90).   
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The mean of participants’ serum iron concentration was within the normal range at 
each experimental condition, measuring 16.0 µmol/l (95% CI 12.2 – 19.8 µmol/l, SD 
7.85 µmol/l) at their baseline visits, 19.1 µmol/l (95% CI 14.4 µmol/l  to 23.7 µmol/l , 
SD 9.6 µmol/l ) at the visit following 48 hours of oral supplementation with nitrate-rich 
beetroot juice (BR) and 21.2 µmol/l ( 95% CI 16.6 – 25.8 µmol/l , SD 9.6 µmol/l) at 
the experimental visit which followed 48 hours of ingestion of oral nitrate-depleted 
beetroot juice (PL) (Figure 34). The laboratory quoted a normal reference range of 
10.0 – 30.0 µmol/l according to the 95% confidence intervals of those members of 
the local population of approximately 500000 patients who had undergone this test, 
while the batch to batch CV was up to 2.6%. There was no statistically significant 
difference when comparing the serum iron of participants at baseline and post-BR 
supplementation visits (p = 0.22) or when comparing PL with BR (p = 0.43), making 
an ANOVA analysis not statistically significant (p = 0.11), although the increase 
















































Figure 34: Serum iron concentration (µmol/l) of participant plasma at each 
experimental condition. This bar graph demonstrates the mean and standard 
deviations of serum iron concentration of the plasma samples from 19 participants. 
The experimental conditions and serum iron analysis are described in figure 29 and 
methods section 2.7.7 above. This demonstrates that there was a statistically 
significant increase in serum iron from 16.0 µmol/l (95% CI 12.2 – 19.8 µmol/l, SD 
7.85 µmol/l) at their baseline visits to 21.2 µmol/l (95% CI 16.6 – 25.8 µmol/l, SD 9.6 
µmol/l) following a 48 hour period of supplementation with nitrate-depleted beetroot 
juice (PL) (p = 0.03), although all means were within the normal range for serum iron. 
There was no difference between baseline and BR serum iron (p = 0.22). ANOVA 
analysis of the entire data set gave p = 0.11. 
 
The mean transferrin concentration for all 18 participants from whom results were 
available from plasma collected at each of their four experimental visits was 30.5 
µmol/l (95% CI 28.7 – 32.3 µmol/l, SD 6.5 µmol/l). The laboratory quoted a normal 
reference range of 25.2 – 45.4 µmol/l according to the 95% confidence intervals of 
those members of the local population of approximately 500000 patients who had 
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undergone this test. The batch to batch CV of this assay was up to 1.8%. There was 
no significant difference between any of the experimental conditions indicating that a 
48 hour period of supplementation with either nitrate-rich or nitrate-depleted beetroot 
juice did not affect this variable (p values of 0.84, 0.28 and 0.48 respectively).   
The mean transferrin saturation concentration for all 19 participants from whom 
results were available from plasma collected at each of their four experimental visits 
was 33.8% (95% CI 28.6 – 39.0%, SD 19.7%). There was also no significant 
difference between any of the experimental conditions (p values of 0.54, 0.12 and 
0.36 respectively).   
Those participants with the highest serum ferritin levels were also found to have the 
highest transferrin concentration and transferrin saturation. One participant was 
found to have a plasma ferritin concentration of between 1558 µg/l and 1791 µg/l, 
transferrin concentration of between 40.7 µmol/l and 47.2 µmol/l, transferrin 
saturation consistently measuring 84%, and a serum iron concentration of between 
34 and 38 µmol/l. All of the above indicate that, while this participant had metastatic 
oesophageal carcinoma with liver metastases which probably exaggerated the 
increase in ferritin and transferrin through their role as acute phase proteins which 
rise in cases of liver disease, he was also overloaded with iron presumably as a 




3.12 RESULTS SUMMARY 
 
The results of this pilot study investigating the effect of oral supplementation with 
inorganic nitrate in people with anaemia demonstrated that the majority of patients 
with anaemia who were approached for trial entry were keen to enrol. Of those, only 
a small minority did not satisfy the inclusion and exclusion criteria of this study, 
although one participant was excluded from the cycle ergometry testing and two 
were excluded from the magnetic resonance spectroscopy analysis. Retention of 
participants was very good, with 93% completing all four experimental visits.  
The study was not powered to prove or disprove the null hypotheses stated. As 
expected, it demonstrated that clinical factors within this unstable and clinically 
varied population of patients can occur such as fluctuations in haemoglobin 
concentration. Thus information obtained will be used to inform power calculations 
when planning a larger study in the future. 
The current study also found that the enterosalivary circulation of nitrate was intact 
even in this population of participants with medical conditions such as 
gastrointestinal cancers, on chemotherapy, using mouthwashes and antibiotics, with 




CHAPTER 4: DISCUSSION 
 
This pilot study is the first to successfully investigate the effects of supplementation 
with dietary inorganic nitrate in people with anaemia. While there is a wealth of 
research regarding the effect of supplementation in both health (Bailey, Winyard et 
al. 2009, Bailey, Fulford et al. 2010, Lansley, Winyard et al. 2011, Kelly, Fulford et al. 
2013, Larsen, Schiffer et al. 2014) and disease (Bryan, Calvert et al. 2007, Allen, 
Giordano et al. 2012, Baliga, Milsom et al. 2012, Bond, Curry et al. 2013, Gilchrist, 
Winyard et al. 2014), no previous research has investigated the effect in this an 
anaemic population. This pilot study investigated the following experimental 
hypotheses which were drawn through extrapolation of the existing literature in this 
field of research. Relative to a nitrate-depleted placebo beetroot juice, this study 
hypothesised that dietary supplementation of anaemic patients with nitrate-rich 
beetroot juice would affect: 
 Thrombogenicity 
 Muscle phosphocreatine recovery rate 
 Exercise tolerance 
 Cognitive function 
 Quality of life 
Thus, this pilot study intended to explore whether people with anaemia could derive 




4.1 ACHIEVEMENT OF KEY OBJECTIVES 
 
This study was easy to recruit for, successfully achieving its key objectives and 
hence, reflecting excellent patient motivation. When approached to offer recruitment, 
most of the eligible population were motivated and keen for some empowerment in 
their control of symptoms and treatment of their disease. Part of their enthusiasm to 
enter the study was borne out of the goodwill they felt towards the recruiting 
departments, as many pointed out that they had received excellent care there and, 
therefore, wanted to ‘give something back.’ The exact percentage of those patients 
approached to consider trial entry who consented to screening is not known, as 
people were told of the trial in a number of different departments in the hospital by 
several different healthcare professionals, not all of whom kept a clear record of this 
activity. The small number of patients screened for this study who then withdrew 
their consent prior to any experimental visits did so with very good reasons. Two 
participants were diagnosed with progressive malignancy with poor prognosis 
between their consent for trial entry and their first experimental visit, and they quickly 
became too unwell to attend. One patient knew his life expectancy was sadly only a 
few months at the time of enrolment but having consented for trial entry, changed his 
mind as he did not want to commit his time to this study. A further participant 
withdrew his consent after developing pneumonia with rib fractures, and felt too 
unwell to proceed. One participant was excluded by the principal investigator of a 
national trial which she was already enrolled in, who declined to give consent for her 
enrolment. Hence 28 of the 33 patients screened for study entry were enrolled to 
participate (84.8%).  
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Two participants decided to withdraw from the trial after two of their four 
experimental visits; one did so because he was on intensive chemotherapy and felt 
too physically and psychologically exhausted to continue with this study, and another 
did so because his wife had become unwell and he was her main carer.  
Thus, the study recruited very well amongst those people who were eligible for 
enrolment. Retention of participants who began the trial was excellent, with a low 
drop-out rate (7% of those enrolled) which was beyond the participants’ control as a 
result of ill health or external factors unrelated to this study. 
 
4.2 THE BIOCHEMICAL EFFECT OF NITRATE SUPPLEMENTATION 
 
This was a pilot study intended to assess feasibility of a future, larger investigation 
into the efficacy of inorganic nitrate supplementation on the physiology and 
symptomatology of people with anaemia. Hence, a relatively small population was 
recruited containing individuals who were variably anaemic, suffering from a wide 
range of medical conditions contributing to their anaemia, had a broad range of co-
morbid medical conditions, and who were undergoing vastly differing treatments for 
their medical complaints.  
One of the key objectives of this study was to ascertain whether the nitrate-nitrite-
˙NO enterosalivary pathway is intact in people with anaemia related to 
haematological and oncological conditions and their treatments. Through this 
pathway, oral nitrate supplementation in healthy individuals can increase the 
bioavailability of ˙NO, hence influencing mitochondrial respiration, vasodilation, 
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muscle contractile efficiency and force, exercise efficiency, platelet aggregation, 




This study demonstrated that the mean plasma nitrate of all individuals rose from 8.4 
µM at the non-supplemented baseline visit and 8.5 µM at the experimental visit 
following supplementation with PL, to 78.2 µM following BR supplementation. Hence, 
this study demonstrated that inorganic dietary nitrate supplementation was 
sufficiently bioavailable to overcome some significant potential hurdles such as 
previous major upper gastrointestinal surgery to treat oesophageal and gastric 
malignancies, concurrent use of a variety of chemotherapies and the use of other 
medications such as isosorbide mononitrate.  
The mean of the observed plasma nitrate at baseline visits and following 
supplementation with PL was 8.5 µM, significantly lower than that reported in healthy 
individuals by previous studies (19.7 µM, (Moshage, Kok et al. 1995), 35.9 µM 
(Suzuki, Yagi et al. 2001), 32.7 µM (Dykhuizen, Masson et al. 1996)). One further 
study (Vanhatalo, Blackwell et al. 2018) found that the mean plasma nitrate 
concentration in young (18 – 22 year old) and older (70 – 80) healthy adults was 28 
µM in each group. This research was conducted in the same laboratory at the 
University of Exeter, using the same methodology for nitrate quantification as the 
present study. Hence, this confirms that the low nitrate concentration found in this 
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cohort of participants was not due to the difference of methodology between 
laboratories.  
A number of possible factors may have contributed to this difference. Firstly, while 
Moshage et al did not stipulate the demographics of the study population who 
provided their blood samples for analysis, one would assume that participants were 
working or studying in the Department of Medicine at the University of Groningen, 
the Netherlands, and therefore, that they were younger than the participants in the 
present study who ranged from 40 – 93 years old. Similarly, the control group in the 
study by Suzuki et al. were aged 33.1 years old on average, while Dykhuizen did not 
report the age of their control volunteers. Increasing age is associated with greater 
likelihood of gastrointestinal (Newton 2004) and vascular disease (Savji, Rockman et 
al. 2013), increased use of concurrent medications (Kaufman, Kelly et al. 2002), and 
therefore absorption of dietary nitrate and the function of the nitrate-nitrite-˙NO 
enterosalivary pathway could be affected. For example, gastrointestinal disease 
such as gastro-oesophageal reflux or peptic ulcer disease is very commonly treated 
with proton pump inhibitors which increase the pH of the stomach. This may in turn 
affect the generation of reactive nitrogen species from swallowed nitrite, which is 
normally potentiated in the acidic environment of the stomach.  Vascular disease 
may include atherosclerosis, the accumulation of plasma-derived lipoproteins within 
the arterial intima (Stary, Chandler et al. 1994). ˙NO metabolism is affected by this 
disease, as the atherosclerotic plaques are associated with reduced endothelial nitric 
oxide synthase activity (Khambata, Ghosh et al. 2017), thus reducing the 
bioavailability of ˙NO and potentially affecting plasma nitrate concentrations. 
Ischaemic heart disease may be treated with organic nitrates which are used to 
vasodilate the coronary arteries, thus reducing myocardial ischaemia and angina 
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symptoms. However, the haemodynamic and anti-anginal effects of organic nitrates 
are rapidly lost upon long-term low-dose administration of this medication due to the 
rapid development of tolerance and of endothelial dysfunction, which in most cases 
is linked with oxidative stress (Daiber and Münzel 2015). Hence, use of this drug 
may have ameliorated the response of that participant to inorganic nitrate 
supplementation.  
Secondly, all but one of the anaemic participants in the present study were of white 
British ethnic origin, many of whom had origins in the South West of England, while 
those enrolled in previous studies were presumably Dutch (Moshage, Kok et al. 
1995), Japanese (Suzuki, Yagi et al. 2001), and Glaswegian (Dykhuizen, Masson et 
al. 1996). There is no published evidence comparing the normal plasma nitrate 
concentration between ethnic groups but differing population habits regarding 
tobacco consumption, alcohol and diet should be considered as possible contributory 
factors.  
Thirdly, concurrent use of medications in this study could have affected the 
absorption and metabolism of participants’ habitually ingested dietary inorganic 
nitrate. For example, one patient was taking isosorbide mononitrate in order to 
control angina; this may have had a bearing on his response to dietary inorganic 
supplementation as outlined at the top of this page (Daiber and Münzel 2015). 
Fourthly, three participants in this study (11.5%) had active malignancy in their 
gastrointestinal tract. The risk of developing gastric or colorectal carcinoma is 
increased by some lifestyle factors such as tobacco consumption and a diet lacking 
in vegetables (Danaei, Vander Hoorn et al. 2005), meaning that those participants’ 
lifelong dietary habits may have contained few vegetables and could have 
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contributed to the development of their malignancies. Vegetables are the source of 
60 – 80% of dietary nitrate in a typical Western diet (Lundberg, Weitzberg et al. 
2004) and therefore, the presence of gastrointestinal malignancy may explain their 
reduced baseline plasma nitrate concentration compared to that of healthy 
individuals, and could reflect a diet poor in vegetables. However, it is important to 
note that the above points are speculative causes for the low concentration of 
plasma nitrate observed at baseline and post-supplementation with nitrate-depleted 
beetroot juice in the current study, and that this thesis presents no definite evidence 
to prove or disprove them. 
Despite the above factors and the relatively low plasma nitrate concentration at 
baseline and post-PL supplementation in comparison to healthy cohorts, 96% of the 
participants in this study derived a marked increase in their plasma nitrate following 
supplementation with nitrate-rich BR; the mean plasma nitrate for participants in this 
study at the post-BR supplementation visit was 78.0 µM. Hence, despite some 
variability in the degree of this response between individuals, this cohort of anaemic 
people absorbed a significant quantity of the ingested nitrate within their BR 
supplementation, with an increase in the mean plasma concentration by 664%. 
While their baseline nitrate concentration was lower than that of healthy individuals 
(Moshage, Kok et al. 1995, Dykhuizen, Masson et al. 1996, Suzuki, Yagi et al. 2001, 
Vanhatalo, Blackwell et al. 2018), the change from pre- to post-supplementation was 
comparable to that of healthy people. This would suggest that the absorption of 
ingested nitrate amongst participants in this trial was efficient, meaning that their low 
baseline plasma nitrate concentration was not due to impaired absorption but to 
some other factor as outlined above, including dietary habits, malignancy, co-
morbidities, chemotherapy and concurrent medications. 
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The only participant who did not develop an increase in nitrate concentration took 
over 10 different herbal remedies and lived on an extremely strict diet which only 
consisted of juiced fruit and vegetables. While the precise content of the herbal 
remedies is unclear, her diet was extremely rich in nitrate prior to and during her 
involvement with this trial. The mean of this participant’s two unsupplemented 
baseline visits and her post-PL visit was 18.1 µM, higher than all other participants, 
although this was only 0.1 µM greater than the second highest patient. This nitrate-
rich diet may have influenced absorption of nitrate in the beetroot juice she received 
in the trial intervention, although this seems unlikely given its ability to rapidly 
penetrate the gastric wall. Distribution of the nitrate was have been altered; if 
potential molecules such as DNICs or thiols were already saturated with NO, the 
impact of ingestion of more nitrate may have been affected in this patient.  In this 
case, her constant exposure to high levels of nitrate may have caused 
downregulation of the nitrate-nitrite-˙NO enterosalivary pathway and of absorption of 
ingested nitrate in the small bowel, attenuating her response in terms of resultant 
increase in plasma nitrate concentration after further doses of nitrate. Interestingly, 
tachyphylaxis, an acute decrease in response to a drug after its administration, has 
been demonstrated in human responses to organic nitrates such as nitroglycerine 
and other nitrovasodilators (Cohen and Kirk 1973), which require a drug-free interval 
to maintain their efficacy when applied transdermally. The same loss of effect has 
also been observed in chronic ingestion of organic nitrate via decreased 
bioactivation, increased ROS production and endothelial dysfunction (Omar, Artime 
et al. 2012). However, there is no evidence to suggest that inorganic nitrate induces 
tolerance build-up in the same way as organic nitrate, with studies examining 
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efficacy of such supplementation over a period of up to six months (Kapil, Khambata 
et al. 2015, Velmurugan, Gan et al. 2016, Faconti, Mills et al. 2019).  
Another possible reason for this participant’s lack of response in plasma nitrate 
concentration is her medical history; she had oesophageal carcinoma and had 
undergone a total oesophagectomy. While in healthy individuals, nitrate is rapidly 
and completely absorbed in the proximal jejunum, this lady’s previous surgery may 
have affected this process through a number of possible mechanisms. Firstly, the 
total oesophagectomy may have reduced the transit time of orally ingested 
substances, meaning the dietary nitrate supplementation may have reached and 
passed through the jejunum sooner and faster than other participants, limiting her 
ability to absorb it. An alternative explanation is that her known oesophageal 
carcinoma could have metastasised to involve her jejunum or ileum unbeknown to 
her and the research team. If so, this may have also brought about a partial bowel 
obstruction and an alteration in her ability to absorb ingested nitrate.  
Another variable which may have influenced this participant’s plasma nitrate 
concentration is that she was also undergoing chemotherapy treatment with 
Epirubicin, Carboplatin and Capecitabine chemotherapy. While other participants 
were being treated with these drugs as single agents or in combination with different 
chemotherapeutic agents, no one else was taking this combination. This 
chemotherapy regime has been associated with mucositis, or chemotherapy-induced 
damage of the mucosal membranes (Rothermundt, Hubner et al. 2006), this 
participant did not complain of diarrhoea and therefore one must assume her small 
bowel function was not significantly hindered by this chemotherapy regimen and was 
able, therefore, to absorb nitrate.   
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Another possible explanation for this participant’s attenuated response to BR 
supplementation is poor compliance. However, it was felt that this is a very unlikely 
explanation; this lady had been informed by her medical team that she had a 
terminal malignancy and was willing to try anything which might help, including the 
‘juicing’ diet consisting only of fruit and vegetables and her numerous herbal 
remedies. She was extremely motivated, actively sought me out to request trial 
recruitment, and gave no indication that she was finding the supplement unpalatable 




This study has shown that oral dietary supplementation with beetroot juice containing 
inorganic nitrate brings about a marked rise in plasma nitrite, proving that the nitrate-
nitrite-˙NO enterosalivary circulation was functioning in the majority of individuals 
included in this trial. It also, therefore, suggests that the oral microbiome involved in 
nitrate metabolism was similar to that of a normal healthy person, and included 
facultative anaerobic bacterial genera such as Actinomyces and Veillonella that used 
NO3
- from the BR supplementation as a terminal electron acceptor and produced 
NO2
- as a by-product. This was somewhat unexpected as many of the participants in 
this study were using bactericidal mouthwash such as chlorhexidine digluconate 
(Corsodyl®), while others were treated with antibiotics either prophylactically or in 
response to infection. Mouthwash and antibiotics may have attenuated the quantity 
of oral bacteria capable of involvement in this crucial reaction in the enterosalivary 
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circulation as previously reported (McDonagh, Wylie et al. 2015, Pinheiro, Amaral et 
al. 2015).  
Similarly, 3 participants had active infections between their experimental visits. While 
they were treated with antibiotics which may have reduced the number of 
commensal oral bacteria and impaired the function of the nitrate-nitrite-˙NO 
enterosalivary circulation, such infections may have increased the bioavailability of 
˙NO within the vasculature through an increase in inducible nitric oxide synthase 
(iNOS) (Neilly, Copland et al. 1995). This response is demonstrated in patients with 
sepsis and neutrophilia, as iNOS within neutrophils produces ˙NO through the 
arginine-NO system. Hence, those participants in this trial with infections may have 
had increased ˙NO and NO2
-, potentially affecting their response to dietary 
supplementation with inorganic nitrate or placebo. 
Significant variation was noted in the degree of rise in plasma nitrite concentration 
within this cohort, with a standard deviation of the BR experimental condition of 1006 
nM. For example, two participants’ plasma NO2
- concentration increased to over 
3750 nM, in excess of 2000%, while at the other end of the spectrum, one 
participant’s plasma NO2
- concentration only increased by 155% to 142 nM. 
Interestingly, the latter person with a very modest response in plasma NO2
- was the 
same participant in whom there was observed only a minor increase in plasma NO3
- 
concentration following BR supplementation. Hence it would seem likely that, as 
there was only a minor rise in plasma NO3
-, there was a minor increase in available 
substrate (NO3
-) for the facultative anaerobic bacteria located on the base of her 
tongue, and therefore less NO2
- was produced and absorbed into the blood.  
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Of the two participants in whom a very large response to BR supplementation was 
observed, one participant had a history of gastric carcinoma and, having previously 
undergone a total gastrectomy, was being treated with Epirubicin, Oxaliplatin and 
Capecitabine chemotherapy. Unlike the patient with a poor response to BR 
supplementation however, his diet consisted of relatively few vegetables and other 
foods rich in nitrate. One could speculate that the contrast between these two 
participants’ responses despite similar chemotherapy regimens and cancers (both 
upper gastro-intestinal) could suggest that the biggest contributory factor in 
determining the depth of their response to BR supplementation was their usual 
dietary intake of NO3
-. This may reflect variability in the individuals’ pharmacokinetics 
around ingested inorganic nitrate.  The lack of response observed in the patient who 
likely consumed huge quantities of dietary inorganic nitrate under normal 
circumstances may have been due reduced ability to absorb ingested nitrate, 
although this seems unlikely given its ability to rapidly penetrate the gastric wall. 
Distribution of the nitrate and nitrite may have been altered; if potential molecules 
such as DNICs or thiols were already saturated with NO, the impact of ingestion of 
more nitrate may have been affected in this patient. Similarly, an as-yet unknown 
homeostatic mechanism may exist providing negative feedback to limit the efficacy 
of the nitrate-nitrite-˙NO reduction pathway. Another possible explanation is the oral 
microbiome as outlined above; each of these participants was on active 
chemotherapy and was therefore advised to maintain good oral hygiene. They were 
prescribed mouthwash, some of which was antibacterial, by their oncology and 
haematology teams and, while this is known to attenuate the rise in NO2
- following 
ingestion of NO3
- (Govoni, Jansson et al. 2008), it was felt that, from an ethical 
perspective, it was not justified to not ask participants to omit such treatment given 
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the resultant increased risk of potentially life-threatening infections at this time when 
they were at significant risk of developing neutropaenic sepsis. In the author’s 
personal experience, significant numbers of patients on chemotherapy do not heed 
advice to use mouthwashes; hence a potential difference in their mouthwash 
compliance might explain the variation in the response of these two participants’ 
NO2
- and NO3
- plasma concentrations following dietary NO3
- supplementation. 
However, this is made unlikely by the fact that both NO2
- and NO3
- were attenuated 
while only NO2
- production through the nitrate-nitrite-˙NO enterosalivary circulation 
relies on the presence of the oral microbiome.  
Another participant was demonstrated to have a high baseline plasma NO2
- 
concentration of 375 nM at his post-PL supplementation visit. This gentleman had a 
history of ischaemic heart disease and had been prescribed oral isosorbide 
mononitrate to dilate his coronary arteries and reduce symptoms of angina pectoris. 
Despite this chronic supplementation, he still derived a good response to oral NO3
- 
supplementation, with an increase of plasma NO2
- concentration to 1733 nM at his 
post-BR experimental visit. 
The mean plasma NO2
- concentration of this cohort of 26 participants was 136 nmol/l 
when at their experimental visits which were either non-supplemented or had 
followed a 48 hour period of nitrate-depleted beetroot juice supplementation. Normal 
values of plasma NO2
- reported amongst healthy individuals are comparable to this; 
a recent publication producing data from the same laboratory as the current study 
reported a median NO2
- concentration of 232nmol/l. Other laboratories elsewhere in 
the world give similar results, with Bondonno et al. (Bondonno, Liu et al. 2014) 
describing unsupplemented plasma nitrite of 262 nmol/l in their study based in Perth, 
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Australia.  This possible slight reduction in baseline and un-supplemented NO2
- 
concentration amongst participants may well reflect the use of medications such as 
antibiotics and antimicrobial mouthwashes as outlined above. 50% of the participants 
in the present study were on chemotherapy during their period of trial activity. A 
common side effect of chemotherapy, particularly regimens which include 
corticosteroids, is gastritis and peptic ulceration. Hence, many of the participants in 
the current study were taking omeprazole or alternative proton pump inhibitor 
medications which reduce the risk of such side effects. However, omeprazole has 
been found to cause a large increase in the NO2
- concentration of gastric secretions 
(Mowat, Carswell et al. 1998). Therefore one could speculate that this NO2
—rich fluid 
may not be entirely re-absorbed during their gastrointestinal transit and could lead to 
a reduction in their plasma NO2
- concentration. Similarly, esomeprazole, a similar 
proton pump inhibitor to omeprazole, has been demonstrated to blunt the blood 
pressure lowering effect of intravenous or oral sodium nitrite in healthy individuals 
despite an expected rise in those individuals’ plasma nitrite concentration 
(Montenegro, Sundqvist et al. 2017). The mechanism for this change is not clear, but 
may demonstrate that the physiological effect of blood pressure lowering is 
dependent on bioactivation in the acidic stomach environment. S-nitroso groups 
(RSNOs) may be the link between the effect proton pump inhibitors exert on the 
bioactivity of ingested nitrates and nitrites. The formation and degradation of RSNOs 
is a dynamic process largely determined by the prevailing redox environment which 
would be significantly altered by the effect of proton pump inhibitors on gastric pH. 
RSNOs have bioactivities similar to those of ˙NO but with half-lives in the order of 
hours (Stamler, Jaraki et al. 1992). 
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An alternative explanation for this observed reduction in plasma NO2
- compared to 
healthy individuals is that it may have been caused by some of the participants’ 
underlying medical conditions; 2 participants had gastric cancer which had 
previously been treated with gastrectomy operations in which their stomachs had 
been removed in their entirety. This would potentially affect the absorption of 
swallowed NO3
- and NO2
- and could reduce baseline plasma concentrations as a 
result. A further participant had a history of colorectal carcinoma which had been 
treated with surgical removal of the entire length of their ascending and transverse 
colon, hence requiring an iliostomy. This external bag bypasses the patient’s colon 
and / or small bowel and can potentially reduce reabsorption of substances such as 
NO2
- from the intestinal lumen. However, as 98% of nitrate and nitrite reabsorption 
occurs in the small intestine, this is less likely to have exerted a significant effect on 
plasma nitrite. 
 
In summary, almost all participants involved in this pilot study derived a good 
response to BR supplementation both in terms of an increase in their plasma NO3
- 
and NO2
- concentration, although there was marked variation in the degree of this 
response. This indicates that they were compliant with supplementation and 
absorbed NO3
- effectively despite their active medical complaints, co-morbidities and 
treatments which in some cases included previous major gastrointestinal surgery. 
These factors which were expected to limit NO3
- uptake and interfere with the nitrate-





4.2.3 CYCLIC GUANOSINE MONOPHOSPHATE 
 
The plasma cGMP concentration of participants in this trial was unaffected by 
supplementation with dietary inorganic nitrate. cGMP is formed by the action of 
guanylate cyclase on glycerine triphosphate. Presence of ˙NO stimulates the action 
of guanylate cyclase, hence increasing cGMP levels. While the nitrate and nitrite 
concentrations increased following BR supplementation, plasma cGMP did not alter 
to a statistically significant level. However, a student’s paired t test of the observed 
increase in plasma cGMP concentration suggested a trend for an increase in cGMP 
following BR supplementation (p = 0.079). The small numbers of participants and 
between subject variability in responses to supplementation in this study are likely 
reasons that this level did not reach significance. An expanded investigation enrolling 
more participants is recommended to explore the cGMP response to nitrate 
supplementation in anaemic patients. 
 
 
4.3 THE PHYSIOLOGICAL EFFECT OF NITRATE SUPPLEMENTATION  
 
The mean systolic blood pressure of this cohort of participants was relatively low 
measuring 122 mmHg. While formal body mass index was not recorded during the 
current study, no participants appeared to be significantly overweight and a number 
had lost weight as a result of their malignancy itself, treatments they were 
undergoing such as surgery or chemotherapy, and lifestyle changes in order to 
improve their general health such as the ‘juicing’ diet as outlined above. The 
193 
 
observed physiological responses to nitrate supplementation during the current study 
gave unexpected results according to existing evidence. Firstly, blood pressure was 
anticipated to be lowest in participants at their experimental visit which had been 
preceded by acute supplementation with nitrate-rich beetroot juice, consistent with 
previous research in healthy individuals which reports this to be due to the nitrate 
component of the supplementation (Kelly, Fulford et al. 2013, Berry, Justus et al. 
2015). The participants in this study did indeed have a statistically significant 
reduction in their systolic blood pressure following a 48 hour period of 
supplementation with nitrate-rich beetroot juice (BR) compared to baseline. 
However, this same systolic blood pressure reduction was also observed following 
ingestion of nitrate-depleted beetroot juice (PL) compared to the baseline visit.  
There are a number of potential explanations for this observed effect. Firstly, each of 
the supplemented visits occurred 7 – 10 days after each of the baseline visits, 
whereas the baseline visits were either 4 – 6 weeks following their initial 
supplementation visit, or they were the first ever experimental visit. One could 
speculate that participants may have felt more anxious or excited prior to their 
baseline study visits, and may have been more relaxed a few days later in the 
supplemented experimental state. In susceptible people, emotional stress results in 
immediate stimulation of the sympathetic nervous system, with a vasomotor 
response that results in a high-output state and elevated blood pressure (Mustacchi 
1990). Hence, the potentially heightened sympathetic activity at the baseline visits 
may have brought about an increase in systolic blood pressure in some individuals. 
A further speculative explanation for the observed reduction in systolic blood 
pressure following supplementation with both PL and BR is that, rather than nitrate, 
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another component of the beetroot juice may have caused a reduction in blood 
pressure. Epidemiological evidence suggests that antioxidants and vitamin C found 
in beetroot juice may be therapeutic in lowering blood pressure, although 
interventional trials have had mixed results with these substances (Schiffrin 2010). 
These antioxidants include carotenoids, phenolic acids and flavonoids. Beetroot is 
also one of few vegetables which contain a group of highly bioactive pigments known 
as betalains, which appear to have anti-oxidant and anti-inflammatory capabilities in 
vitro and in animal models (Clifford, Howatson et al. 2015). Hence this component of 
beetroot may have influenced participants’ blood pressure following acute juice 
supplementation. Folate deficient hypertensive rats have been found to have a 
raised blood pressure and increased oxidative stress compared to folate replete 
controls (Pravenec, Kožich et al. 2012). A number of the individuals in the current 
study had risk factors for folate deficiency such as previous gastrointestinal surgery, 
chemotherapy, and high cell-turnover malignancies. Hence those participants may 
have had a higher systolic blood pressure at baseline compared to placebo if they 
underwent supplementation with folate-rich beetroot juice. Similar epidemiological 
studies have demonstrated an inverse relationship between dietary iron uptake and 
blood pressure (Tzoulaki, Brown et al. 2008) so, as beetroot juice is rich in iron, this 
component may have led to a reduction in systolic blood pressure. However, given 
the short duration of supplementation in this current study (48 hours), this 
explanation is made unlikely. 
Similar to the unexpected results findings regarding blood pressure response to 
supplementation, the hypothesised beneficial effect of inorganic nitrate 
supplementation (BR) on rate of muscle phosphocreatine (PCr) recovery and 
exercise tolerance was also not supported by results obtained. Contrary to 
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expectation, participants’ cycle ergometry and magnetic resonance spectroscopy 
results were superior following supplementation with nitrate-deplete placebo (PL) 
rather than BR. A major confounding factor which may explain this unexpected 
finding is the significant variation in haemoglobin (Hb) levels between experimental 
conditions. The mean Hb concentration in participants attending for their post-PL 
experimental visit was 114.7 g/l while the same participant population at their post-
BR appointment had a mean Hb of 109.1 g/l. Two participants had a change in their 
Hb between these visits by more than 30 g/l while another 3 had a change in excess 
of 12 g/l. Whatever the order of actual supplementation, all of these larger 
fluctuations in Hb were between a lower value at the post-BR visit and a higher value 
post-PL. Therefore, while the crossover study design was selected in an attempt to 
overcome such variables, chance appears to have skewed the level of anaemia 
between each of the post-supplementation visits. Given the plethora of symptoms 
and physiological disadvantages conveyed by anaemia, such an alteration in the 
level of Hb could have a significant effect on quality of life, exercise capacity, and 
muscular physiological function (Wright, Pearce et al. 2014). Hence, the change in 
haemoglobin is very likely to underlie practically all of the physiological differences 
between PL and BR. 
 
4.3.1 CYCLE ERGOMETRY 
 
The gas exchange threshold (GET) is a surrogate of the lactate threshold, which is 
defined as the first loss of linearity in the relationship between oxygen uptake (VO2) 
and carbon dioxide output (VCO2) during incremental exercise (Beaver, Wasserman 
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et al. 1986). The GET provides a key landmark of aerobic fitness, which is correlated 
with exercise tolerance in healthy and patient populations (Nishijima, Kondo et al. 
2017). Participants who performed the cycle ergometry aspect of this study 
demonstrated a greater GET following supplementation with PL compared to BR. 
Similarly, VO2peak, the peak rate of oxygen consumption, was expected to improve 
following nitrate supplementation whereas there was a statistically insignificant trend 
towards a deterioration in this measure following BR supplementation compared to 
PL. The third cycle ergometry parameter which was measured was peak power, 
which was also hypothesised to improve following BR supplementation compared to 
both PL and baseline visits. However, there was a statistically significant 
improvement in peak power following PL supplementation compared to BR, and a 
trend towards an improvement compared to the baseline (unsupplemented) 
experimental condition. The fourth and final measure of exercise physiology which 
was recorded during the cycle ergometry was time to exercise limit (Tlim). There was 
a significant improvement in Tlim following PL supplementation compared to both the 
non-supplemented and post-BR supplemented visits. Hence, across all exercise 
physiology variables, participants performed consistently better in the PL condition 
than in BR. As highlighted above, this is likely due to greater Hb concentration in PL 
than in BR, which would have enabled a greater O2 delivery to active muscle during 
incremental exercise that would in turn result in elevated GET, VO2peak and exercise 
tolerance. The critical effect of haemoglobin fluctuation in dictating all cycle 
ergometry variables is supported by the finding that the difference in Hb between PL 
and BR conditions was positively correlated with the difference in Tlim (r = 0.64, P = 
0.0006). Previous literature would support this conclusion drawn from the current 
study; it is widely accepted that the delivery of oxygen to mitochondria is the principal 
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limiting factor to the VO2peak measured during large muscle group exercise in humans 
(Wagner 1995). For example, voluntary donation of 450 ml of whole blood causing a 
~5% reduction in the haemoglobin of healthy individuals leads to a significant 
reduction in the time to exhaustion and VO2peak during severe intensity exercise 
(Burnley, Roberts et al. 2006). Achieving a similar degree of enhancement in 
haemoglobin concentration either through reinfusion of packed red blood cells or 
through exogenous administration of recombinant human erythropoietin leads to an 
improvement in VO2peak and time to exhaustion during maximal intensity exercise 
(Spriet, Gledhill et al. 1986, Wilkerson, Rittweger et al. 2005). Reduction in 
haemoglobin leads to reduced oxygen carrying capacity of the circulating blood and 
thus the potential for muscle oxygen delivery.  
˙NO plays an essential role in maintenance of endothelial function and vascular tone, 
hence controlling vasodilation, blood pressure and oxygen delivery to hypoxic tissue 
beds, whilst affording some protection against hypoxic ischaemia/reperfusion injury 
(Bryan, Calvert et al. 2007, Dezfulian, Raat et al. 2007, Granger and Kvietys 2015). It 
affects mitochondrial respiration, myocyte calcium handling and ATP turnover, hence 
contributing to muscle metabolic efficiency in the setting of resting metabolic rate, 
and in conditions of normoxia and hypoxia (Vanhatalo, Fulford et al. 2011, Larsen, 
Schiffer et al. 2014). It was therefore hypothesised and expected that dietary 
inorganic nitrate supplementation would improve GET amongst trial participants 
through the nitrate-nitrite-˙NO enterosalivary circulation and increased ˙NO 
bioavailability. Nitrate supplementation was also expected to reflect previously 
reported beneficial effect on peak power (Lansley, Winyard et al. 2011), Tlim and VO2 
max (Bailey, Winyard et al. 2009) through improvement in the delivery of oxygen to 
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muscle beds during exercise and in the efficiency of ATP generation within myocytes 
(Bailey, Fulford et al. 2010, Larsen, Schiffer et al. 2011).  
There are a number of possible explanations for the discrepancy between data 
observed during this trial and previously published evidence suggesting that this 
intervention would convey a physiological advantage in these participants (Bailey, 
Winyard et al. 2009, Bailey, Fulford et al. 2010, Lansley, Winyard et al. 2011). Nitrate 
supplementation in healthy individuals can modify mitochondrial respiration, 
vasodilation, muscle contractile efficiency and rate of force generation, platelet 
aggregation, cerebral blood flow and neurotransmission. However, any potential 
beneficial effect participants in this study might have derived from nitrate-rich 
beetroot juice supplementation over placebo could have been obscured by such a 
change in Hb between the two supplementation conditions. An alteration in Hb 
between experimental conditions may well have had a greater effect on cycle 
ergometry performance than any effect nitrate supplementation could have exerted. 
This likely explanation is supported by the fact that nitrate supplementation has no 
effect on VO2max during incremental exercise in healthy individuals (Bailey, Winyard 
et al. 2009), yet there was a trend towards improvement in this measure following PL 
supplementation compared to the BR and baseline experimental conditions. An 
increase in plasma Hb concentration would contribute to an improvement in VO2max 
or VO2peak as a direct consequence of improved oxygen delivery to skeletal muscle, 
while it would also lead to an increase in peak power output through improved 
muscular efficiency and / or enhanced blood flow distribution in active muscle.  
When considering the cause of this alteration in haemoglobin between experimental 
conditions, another potential explanation regarding this discrepancy between 
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subjects’ exercise performance reported in previous literature and this study 
becomes clear. Many of the participants in this trial had cancer-related anaemia 
either because of bone marrow infiltration with malignancy, or because of 
chemotherapy side effects. When at their most anaemic, participants had a greater 
burden of disease, were recovering from more recent chemotherapy or had received 
a greater cumulative dose of chemotherapy. Active cancer causes fatigue through a 
variety of mechanisms including direct effect of the tumour, treatment side effects, 
co-morbid conditions such as malnutrition, thyroid dysfunction and infection. It can 
also cause fatigue by exacerbating comorbid symptoms like chronic pain, sleep 
disturbance, and through psychosocial factors (Wagner and Cella 2004). During 
more intensive chemotherapy, participants may have been more sedentary and 
experienced deconditioning and skeletal muscle-mass atrophy, resulting in 
deterioration in their performance during cycle ergometry following BR 
supplementation.  
Some chemotherapy agents themselves can exert a direct cardiotoxic effect. These 
include anthracyclines such as Epirubicin which 4% of the participants were 
receiving, and cyclophosphamide which 8% of the study population were treated 
with. Following these drugs, cardiac output can be diminished and respiratory 
function can be compromised as a result (Keefe 2002). 
Skeletal muscle function can be affected by the use of chemotherapy agents and by 
tumours themselves. A common side effect of malignancy is weight loss as a result 
of the release by tumours of inflammatory chemokines and cytokines such as 
prostaglandin E2. This factor induces inflammation in muscle tissue and results in 
muscle wasting (Ardies 2002), and consequentially would have a detrimental effect 
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on exercise physiology performance when the tumour is more active. Furthermore, 
metabolically active molecules such as tumour necrosis factor (TNFα) released from 
tumour or mast cells can necrotise muscle membranes and thus impair excitation – 
contraction (E-C) coupling (Lucía, Earnest et al. 2003). E-C coupling is the 
mechanism by which the electrical discharge on the muscle fibre membrane brought 
about by nerve impulses initiates chemical events inside the fibre—release of 
intracellular calcium from the sarcoplasmic reticulum. This in turn signals for 
immediate contractile activity which is followed by calcium reuptake to initiate the 
relaxation process. Coupling (contraction) and uncoupling (relaxation) continuously 
operate during any type of exercise or physical activity. Despite common belief, 
lactate accumulation and lactic acidosis do not alter E-C coupling and thus are not 
major determinants of muscle fatigue. Other factors independent of lactic-acid build-
up are more likely to alter E-C coupling and thus to cause fatigue in healthy people, 
such as accumulation inside working muscle fibres of inorganic phosphate due to an 
insufficient rate of ATP resynthesis or accumulation of reactive oxygen species 
derived from aerobic metabolism (Lucía, Earnest et al. 2003). This effect could 
explain, at least partly, the increase in muscle fatigue induced by TNFα, and could 
explain the reduction in Tlim, GET and peak power observed in cycle ergometry 
testing at the post-PL supplementation experimental visit if those patients’ cancers 
were more active at that time. 
Nineteen percent of the participants in this study were being treated with high doses 
of corticosteroids while a further 8% of people were receiving cyclophosphamide. 
Each of these agents can have adverse effects on the ultrastructure and function of 
skeletal muscles. These effects include a decline of myofibrillar mass, altered 
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aerobic metabolism (due to decreased mitochondrial volume or mitochondrial 
myopathy), or reduced capillarisation (Lucía, Earnest et al. 2003).  
Hence those participants receiving chemotherapy at the time of increased anaemia, 
which coincided with BR supplementation, had a number of physiological changes 
which could account for this unexpected improvement in exercise physiology 
performance in the post-PL study visit rather than following inorganic nitrate 
supplementation.  
One further potential source of anaemia-related confounding which was observed in 
participants in this trial was blood transfusions. Three participants received a blood 
transfusion within 2 months of any of their experimental visits. One received this 
blood 40 days prior to their first visit and hence 51 days before their second visit 
which was post-BR supplementation visit. One participant was transfused within two 
weeks of their post-PL supplementation visit while a further participant received a 
blood transfusion 5 days before their post-BR supplementation visit.  
While the mean lifespan of human RBCs in vivo is 110-118 days (Mock, Matthews et 
al. 2011), transfused red blood cells survival is similar, with a maximum reported 
lifespan of 135 days after transfusion. A proportion of these cells are removed from 
the circulation within 24 hours of transfusion; this varies according to the duration of 
storage of the cells, and can be between 9% and 23% (Luten, Roerdinkholder-
Stoelwinder et al. 2008). Hence, some of these transfused cells were still present in 
the first participant’s circulation at the time of testing despite the amount of time 
which had elapsed between transfusion and that visit. The other two participants’ 
transfusions were potentially more significant given the proximity to their 
experimental visits, but were balanced in terms of experimental arms; one potentially 
202 
 
affected the participant’s performance on their post-PL supplementation visit and the 
other potentially affected that participant’s post-BR supplementation visit. Therefore, 
transfusions may have influenced cycle ergometry performance in two participants’ 
post-BR supplementation, and one participant’s post-PL visit. Stored red cells have a 
greater affinity for oxygen and therefore reduced oxygen dissociation in hypoxic 
tissue beds such as contracting muscles. They also contain less bioavailable ˙NO 
through deregulation of S-nitrosation of haemoglobin. The latter consequence of 
storage may limit the red blood cell’s ability to induce hypoxic vasodilation and 
hence, reduces its ability to match oxygen delivery with metabolic demand 
(Reynolds, Bennett et al. 2013). This uncoupling of delivery and demand of oxygen 
is also an effect of the increased concentration of haemoglobin-containing 
microparticles and free haemoglobin in stored blood. This consequence of 
morphological change in red blood cells as a result of ATP-depletion and lipid loss in 
stored blood, in turn causes a reduction in bioavailability of ˙NO. Free haemoglobin 
and microparticles scavenge ˙NO 1000 times faster than haemoglobin within red 
blood cells (Liu, Zhao et al. 2013). They are also free to enter the cell-free zone at 
the periphery of blood vessels, where scavenging of ˙NO will limit the ability of ˙NO 
released by red blood cells in conditions of hypoxia to cause vasodilation (Butler, 
Megson et al. 1998, Liao, Hein et al. 1999). Hence coupling of oxygen delivery and 
demand is impaired in the presence of stored blood, and could potentially limit 
exercise tolerance.  
While only 11.5% of participants received blood transfusions within 40 days of their 
study visits, those people may have demonstrated a detrimental effect of this blood 
on their physiological responses during cycle ergometry. As 2 participants were 
transfused prior to BR supplementation, and only one received blood prior to their PL 
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supplementation, this could have contributed to the observed and unexpected 
difference in their performance during cycle ergometry which demonstrated improved 
results following PL supplementation.  
The improved exercise performance observed in PL compared to BR may have also 
been influenced by the placebo effect. . A placebo is defined as; 
 ‘Any therapeutic procedure (or part of a therapeutic procedure) which is given 
either deliberately to have an effect, or unknowingly and has an effect on a 
symptom, syndrome, disease or patient without specific activity for the 
condition being treated. The placebo is also used as an adequate control in 
research. The placebo effect is defined as the changes produced by placebo’ 
(Shapiro 1964). 
The subjective nature of the symptoms-limited cycle ergometry test may have 
enabled a placebo effect to be exerted. Time to exhaustion (T lim) and VO2peak results 
could have been affected by the participants’ knowledge they had previously 
undergone a period of supplementation before both PL and BR experimental visits, 
as these variables are both subjective measures of symptoms. As a result, these 
variables of exercise performance may have improved following beetroot juice, 
although this potential effect would not have preferentially improved performance for 
PL rather than BR. The placebo effect is less likely to have altered the GET as this is 
an objective, submaximal index. 
 
One further potential explanation for the improved performance in cycle ergometry 
which was observed following supplementation with PL rather than BR, was the 
contents of the beetroot juice supplements themselves. The nitrate-depleted beetroot 
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juice (PL) was produced by passing beetroot juice through a column containing the 
anion exchange resin Purolite a520e which exchanges nitrate for chloride (Lansley, 
Winyard et al. 2011, Gilchrist, Winyard et al. 2014). The resultant products are very 
similar bar their nitrate component, with no substantial change in the concentrations 
of sodium, potassium or magnesium ions, a modest reduction in calcium ion 
concentration within the PL product and an increase in chloride concentration 
(Gilchrist, Winyard et al. 2014). However, these minor differences in calcium and 
chloride content would not be expected to influence exercise performance, and 
indeed, in healthy individuals who do not experience such fluctuations in Hb 
concentration, nitrate-rich beetroot juice has been shown to enhance exercise 
tolerance (Bailey, Winyard et al. 2009, Bailey, Fulford et al. 2010, Jones 2014). 
While the relatively small numbers in this pilot study were sufficient to inform the 
researchers regarding recruitment, tolerability and numbers required to power future 
trials, they were insufficient to overcome the potentially dramatic effect the marked 
change in Hb of a small number of individual participants had on this cohort’s overall 
physiological responses during exercise. Similarly, the small numbers were 
insufficient to overcome the progression of malignancy or initiation of chemotherapy 
during the course of some individuals’ experimental involvement. The present study 
recruited an extremely diverse group of participants, with very different ongoing and 
past health problems and medications, surgical histories, smoking histories, baseline 
athletic performances and nutritional states. Any observed differences in 
performance during cycle ergometry testing could have been caused by the 
heterogeneity of this group of volunteers; their individual and varying clinical factors 
were expected to dwarf any observed difference nitrate supplementation may have 
made in this small, deliberately inclusive pilot study. The potential effect this 
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heterogeneity of participants may have was countered through the use of a before 
and after crossover study, so that participants acted as their own controls. However, 
while this design accounted for the inter-participant variability, it did not overcome 
the intra-participant variability which was quite marked in a number of volunteers. 
 
4.3.2 31PHOSPHOROUS MAGNETIC RESONANCE SPECTROSCOPY (31P-MRS) 
 
The muscle pH during a gentle exercise protocol using a single-leg knee extension 
ergometer was unaffected by experimental condition. It had been hypothesised that 
dietary inorganic nitrate supplementation with BR would have brought about a 
decrease in muscle phosphocreatine (PCr) recovery time constant (τ). However no 
statistically significant difference was observed. Muscle O2 delivery is a key 
determinant of the rate at which muscle PCr concentration recovers following 
exercise (Vanhatalo, Fulford et al. 2011, Vanhatalo, Jones et al. 2014), such that the 
severity of anaemia would have been a major factor determining the PCr recover τ in 
this study.. Being less anaemic at the post-PL experimental visit may have caused 
an improvement in PCr recovery compared to their post-BR and baseline visits, 
overcoming and reversing any potential benefit nitrate supplementation could have 
had on the measure of oxidative capacity.  
Another possible cause for the observed lack of efficacy of BR supplementation in 
PCr recovery rate is that malignant muscle cells contain 90% less PCr than healthy 
controls (Patra, Bera et al. 2008). While none of the participants in this trial were 
known to have muscular metastases, 3 of the people enrolled in this trial were known 
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to have disseminated malignancy affecting more than one organ system and it is 
therefore not inconceivable that their quadriceps could have contained malignant 
cells.  
A potential difference in the degree of muscular metabolic perturbation following 
supplementation with inorganic nitrate and placebo may have become apparent with 
further testing involving larger numbers of participants, under conditions where large 
fluctuations in Hb during the study period could be avoided. However this pilot study 
was not sufficiently powered to demonstrate such an effect. 
 
4.4 THE EFFECT OF NITRATE SUPPLEMENTATION ON QUALITY OF LIFE 
 
All participants in this study underwent sequential monitoring of their subjective 
responses to the FACT-An questionnaire at each of their four trial visits, giving 
validated insight into their quality of life, exploring their emotional wellbeing, 
functional wellbeing, physical wellbeing and social / family wellbeing. 
Supplementation with both PL and BR brought about a small but statistically 
significant improvement in this measure of quality of life compared to the non-
supplemented state, with no difference between the two supplemented experimental 
conditions. Significant work has been performed recently in order to assist 
interpretation of these scores; the Functional Assessment of Chronic Illness Therapy 
(FACIT) group has issued guidance regarding the minimal important differences 
(MIDs) for scores and scales of several similar qualitative assessments of health-
related quality of life, including FACT-An. They define MID as the "smallest 
difference in score in the domain of interest that patients perceive as important, 
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either beneficial or harmful, and that would lead the clinician to consider a change in 
the patient's management" (Cella, Eton et al. 2002). According to their ‘tentative’ 
guidance, the MID for FACT-An is 7 points, meaning the observed difference in the 
participants involved in the current study is statistically significant but may not be 
clinically significant across this population.  
This small subjective improvement in the quality of life of the trial participants was 
therefore independent of the nitrate content of their supplements, and has two 
possible explanations. Firstly, there might have been a placebo effect, as defined 
above (section 4.3.1). Hence, as participants may have expected that drinking 
supplements would make them feel physically and emotionally better and answered 
the quality of life questionnaire accordingly to reflect that. Twenty-three of the 26 
participants in this trial had active malignancy during their study involvement, while 
50% of all participants were undergoing treatment with chemotherapy at that time. 
They were a highly motivated group of people, many of whom were striving to try 
and improve their prognosis by any means possible, including this study 
supplementation. Hence, there is a strong possibility that this beetroot juice would 
have made them feel subjectively better in a number of different areas of their daily 
lives through a purely placebo effect mediated by their psychosocial circumstances. 
Alternatively, if participants were desperate to derive benefit from this 
supplementation, reporter bias could be expected as a reflection of their hope that 
this supplementation would make them feel better, or in order to try and please the 
investigators. 
A further possible explanation for the observed improvement in quality of life 
following supplementation is the other constituent elements of beetroot juice itself. 
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Irrespective of its nitrate component, some of the other components of beetroot juice 
supplements may have brought about this improvement in participants’ FACT-An 
quality of life scores through some unanticipated physiological effect. Beetroot juice 
is rich in antioxidants, folate, vitamin C, manganese, iron and potassium; possible 
explanations for the observed beneficial effect include the following. Antioxidant 
therapy improves quality of life measures in patients with chronic pancreatitis (Kirk, 
White et al. 2006), while folate deficiency is associated with worse quality of life in 
patients with heart failure (van der Wal, Comin-Colet et al. 2015). High-dose 
intravenous and oral vitamin C supplementation has been associated with an 
improvement in the quality of life of patients with terminal cancer (Yeom, Jung et al. 
2007). Beetroot juice is also rich in manganese, a heavy metal which is usually 
excreted via the biliary tree. Accumulation of manganese is associated with greater 
fatigue scores in patients with primary biliary sclerosis (Forton, Patel et al. 2004), 
possibly in part because of accumulation in the central nervous system of the cohort 
of patient under investigation. Intravenous iron supplementation is of benefit in 
quality of life and fatigue scores for patients with mild anaemia and iron deficiency 
(Strauss and Auerbach 2018). There is no evidence potassium supplementation 
improves quality of life measures. While all of the above components within beetroot 
juice are potential confounding variables masking or augmenting nitrate-induced 
effects, this was still chosen as the intervention of choice in the present study over 
potassium nitrate or sodium nitrate for three reasons. Firstly, in the author’s 
experience, patients often ask in clinic about supplements which they can take to try 
and improve their symptoms when anaemic, so it was felt likely that such a trial 
would be more attractive than a tablet-based intervention. Secondly, such a 
supplement would have been classified as an investigational medicinal product 
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unlike beetroot juice, and therefore approval would have been required from the 
medicines and healthcare regulatory authority before the trial could have been 
opened, a potential source of significant delay. Thirdly, nitrate-rich beetroot juice has 
been proven to demonstrate significantly different physiological effects when 
compared to nitrate-depleted placebo in a number of previous studies (Kelly, 
Vanhatalo et al. 2013, Gilchrist, Winyard et al. 2014, Vanhatalo, Blackwell et al. 
2018) and therefore, while the other components of the juice may have altered the 
physiological effect of this supplementation, this did not appear to mask results in the 
above studies and others. Hence beetroot juice was selected as the best method of 
providing reproducible dietary supplementation of inorganic nitrate in the present 
study. 
While there is a lack of published evidence to support this, one final possible 
explanation for the observed improvement in the FACT-An scores at the participants’ 
second and fourth experimental visits which occurred shortly after their first and third 
visits, was that there may have been an element of learning and they may have 
scored more highly on their quality of life and cognitive function questionnaires at the 
post-supplementation appointments. 
The marked range in quality of life scoring is very likely to be merely a reflection of 
the huge diversity of this group of participants. All subjects in this trial had very 
different diseases, treatments and prognoses along with marked differences in their 
physical and psychological co-morbidities. Some participants were faced with a 
terminal diagnosis and as a result, had a visible heavy psychological burden which 
must have had an impact on all of the areas assessed within this quality of life 
questionnaire. At the other end of the spectrum, some participants had longstanding 
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mild anaemia with no need for treatment, no associated cancer diagnosis and hence, 
their FACT-An score was less likely to be affected by their minor blood abnormality. 
 
4.5 THE EFFECT OF NITRATE SUPPLEMENTATION ON COGNITION 
 
This study intended to investigate the hypothesis that, relative to a nitrate-depleted 
placebo beetroot juice, dietary supplementation of anaemic patients with nitrate-rich 
beetroot juice would beneficially alter cognitive function. Cognitive function was 
assessed subjectively rather than objectively, by participants self-completing a 37 
part questionnaire enquiring about their performance over six cognitive domains; 
memory, concentration, mental acuity, verbal fluency, functional interference, and 
multitasking ability. There was a marked difference in the results obtained, with some 
participants scoring very poorly indeed. However, there was an observed small but 
statistically significant improvement in cognitive function between the baseline visit 
and each of the supplemented visits, irrespective of the nitrate component of the 
supplementation. This observed improvement represented only ~3% of the mean 
FACT-Cog score at each experimental visit respectively, which makes the clinical 
significance of this improvement uncertain. Indeed, Cheung et al (Cheung, Foo et al. 
2014) reported that the minimum clinically important difference in FACT-Cog scored 
amongst a population of Chinese patients with breast cancer ranged from 6.9 – 10.6 
depending on the statistical method used for interpretation. The participants in the 
present study were predominately Caucasian and had a number of different 
conditions leading to their anaemia, so the previously reported guide to interpretation 
of FACT-Cog scoring may not be applicable to results observed in the current study. 
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However, the above publication provides further suggestion that the observed 
differences in the current study in FACT-Cog scores after both BR and PL 
supplementation were statistically but not clinically significant. 
The increased FACT-Cog scores observed after both PL and BR supplementation 
compared to baseline are likely to have a similar aetiology to the subjective 
improvement in the FACT-An quality of life scores as discussed above. The 
improvement in subjective assessment of participants’ cognitive function may be a 
placebo effect; participants enrolled in this study and drank beetroot juice 
supplements in the hope that they would make them feel better, both in terms of their 
physical symptoms and their cognitive function. The results of this subjective area of 
this investigation could therefore have been influenced by the participants’ 
expectations regarding the efficacy of this juice, contributing to a cognitive 
improvement stemming from their feeling of psychosocial wellbeing, or from reporter 
bias amongst participants. However, such an improvement might reflect the natural 
course of the participants’ disease, fluctuations in symptoms, regression to the 
mean, or other concurrent treatments.  
Similar to the postulated explanations for improved FACT-An scores above, an 
alternative explanation for improved FACT-cog scores following acute ingestion of 
beetroot juice is that another component of the supplement may improve cognition. 
High dietary intake of antioxidants has been postulated to protect individuals from 
dementia, although there is conflicting evidence in this area (Crichton, Bryan et al. 
2013). Folate supplementation in healthy older adults in the Netherlands significantly 
improved domains of cognitive function that tend to decline with age (Durga, van 
Boxtel et al. 2007), while supplementation with potassium of a murine model of 
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Alzheimer’s disease can improve cognition (Cisternas, Lindsay et al. 2015). There is 
a large body of evidence that maintaining healthy vitamin C levels in humans can 
have a protective effect against age-related cognitive decline and Alzheimer’s 
disease, although supplementation above a normal healthy diet is of less benefit 
(Harrison 2012). Those participants in the current study who did not ingest healthy 
levels of vitamin c may have therefore derived cognitive benefit from this component 
of the beetroot juice. Manganese is critical for neurodevelopment but has also been 
implicated in the pathophysiology of several diseases. However, correction of 
deficiency is associated with an improvement in cognition (Pfalzer and Bowman 
2017) and could possibly explain an improvement in the FACT-cog score of 
participants in the current study.  Beetroot juice is rich in iron, supplementation of 
which has previously been demonstrated to improve verbal learning and memory in 
adolescent girls who were iron deficient and not anaemic (Bruner, Joffe et al. 1996).  
Hence, one can speculate that the minor improvement in reported cognitive function 
in the current study following supplementation with both nitrate-rich and nitrate-
depleted beetroot juice could be to any of a number of other components of the juice. 
 
 
4.6 THE EFFECT OF NITRATE SUPPLEMENTATION ON THROMBOGENICITY 
 
This pilot study intended to investigate the hypothesis that, relative to a nitrate-
depleted placebo beetroot juice, dietary supplementation of anaemic patients with 
nitrate-rich beetroot juice would beneficially alter thrombogenicity. Unfortunately a 
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large proportion of the study population were excluded from this part of the trial as a 
result of concurrent use of antiplatelet, anticoagulant or non-steroidal anti-
inflammatory drugs. A number of the remaining participants were also unable to 
complete this aspect of the study at individual experimental visits, most of whom as a 
result of a reduction in their platelet count. Like anaemia, this reduction in platelets 
below normal levels is a very common side effect of all of the chemotherapy 
regimens the participants were taking, and also of some of the diseases the 
participants had been diagnosed with. Of those participants who were able to 
complete this testing, a number of logistical problems were encountered. Firstly, 
there were periodic supply issues in the delivery of the required reaction tubes which 
had to be a specific size to fit into the PAP8 platelet aggregometer and without 
which, the machine was useless. Secondly, the PAP8 aggregometer was sited in the 
Royal Devon and Exeter Hospital, 0.6 miles away from the exercise physiology and 
magnetic resonance spectrometry laboratories at the University of Exeter. Analysing 
the samples before 4 hours had elapsed since venepuncture was difficult; patients 
underwent their blood tests at the beginning of each experimental visit following 
observations, underwent cycle ergometry and then magnetic resonance 
spectrometry testing, before the investigator was able to process the samples which 
had been centrifuged during cycle ergometry. However, getting samples to the 
hospital laboratory and completing platelet aggregometry within the recommended 4 
hour time window was difficult, and usually the investigator travelled between the two 
institutions on foot at quite high speed whilst carrying the samples. Platelet rich 
plasma (PRP) and platelet poor plasma (PPP) were prepared prior to this journey 
but, as PRP should not be agitated prior to platelet aggregometry, this geographic 
location may have affected the results obtained amongst the few samples that could 
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be processed. Unfortunately the location of the analyser could not be changed as it 
was required on the hospital site for its intended clinical utilisation in the investigation 
of patients with bleeding disorders.  
Platelet aggregometry results were only available for 3 participants out of 26 enrolled 
in the trial (11.5%). Hence, no statistically significant difference was observed 
between baseline, post-PL supplementation and post-BR supplementation visits and 
this hypothesis was not addressed effectively by this study. 
 
 
4.7 FUTURE WORK 
 
4.7.1 CONSIDERATIONS FOR STUDY DESIGN 
 
While designing this pilot study, advice was sought from a medical statistician 
regarding the sample size required to provide adequate sufficient power to test the 
proposed hypotheses. Their recommendation was that no power calculation was 
possible without any initial results upon which to base it, and hence they suggested 
that a pilot study was the most appropriate design at this stage. Therefore, in future, 
a larger investigation should be performed recruiting more participants, the precise 
number of which should be dictated by power calculations as guided by the results 
obtained in this study. This future research should be adequately powered to 
overcome the effect confounding variables might have on the observed results, and 
could potentially negate the likely effect  factors such as variable levels of anaemia in 
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each experimental condition have on the overall study results. Such research would 
therefore be better able to conclusively prove or disprove the hypotheses and could 
guide recommendations regarding nitrate supplementation in people experiencing 
anaemia. Given the relative ease with which participants in this trial were recruited, 
the high rates of eligibility and of retention in those approached to enter, it is very 
likely such a larger investigation in future would also be successful in recruiting 
enough participants and obtaining sufficient data to satisfy the requirements of the 
power calculations.  
The design of future studies should be considered; they may not use the same 
cross-over design as the current trial. The cross-over was chosen with the intention 
that all participants acted as their own internal controls for each experimental 
condition; it was expected that randomisation of the order of supplementation might 
overcome any minor fluctuations in the physiological status of the participants. The 
cross-over design was also utilised because statistically, it is more sensitive than 
parallel groups, and was therefore hoped that it would detect potentially small effects 
of dietary supplementation. However, the degree of fluctuation in the haemoglobin of 
individual participants during their trial involvement was unanticipated and would 
almost certainly have hidden any potential effect nitrate supplementation has on the 
variables under investigation. Future work may therefore consider using the parallel 
groups study design, where one cohort of participants is randomised to receive 
placebo while another is given nitrate-rich beetroot juice.  
Data handling and analysis should be carefully planned prior to any future studies in 





4.7.2 MAPPING THE ORAL MICROBIOME 
 
The oral microbiome plays a crucial role in the nitrate-nitrite-˙NO pathway by 
enabling people to reduce nitrate, the first step in this vital pathway which ultimately 
increases bioavailability of ˙NO, a biologically highly reactive substance which has a 
large number of roles in maintenance of homeostasis. This study led to further 
questions while answering another; the nitrate-nitrite-˙NO enterosalivary circulation 
functions well to allow a similar increase of plasma nitrate and nitrite following oral 
supplementation with inorganic nitrate as healthy individuals. However, the 
participants in this trial had a low plasma nitrate concentration at their non-
supplemented or placebo experimental visits compared to those same healthy 
individuals. Many of the participants in this trial were taking antibiotics or using 
bactericidal mouthwash; did this influence the species or the quantity of bacteria 
within their oral microbiome and in turn, affect the baseline activity of the participants’ 
nitrate-nitrite-˙NO enterosalivary circulation and ultimately, their plasma nitric oxide 
bioavailability? Are some bacterial species which colonise the dorsum of the tongue 
more effective at nitrate reduction than others, or did the anaemia, chemotherapy 
drugs or concomitant medications have a greater impact on this activity than the oral 
microbiome? A future study could provide further insight into this area of interest by 
collecting oral swabs and saliva samples from two cohorts; people with anaemia and 
medical complaints, and healthy age matched controls. These samples could be 
utilised to map the oral microbiome and investigate the dynamics of oral nitrate 






Following completion of this study, frozen plasma samples obtained have undergone 
further analysis by a PhD student, Mohammed Abu Alghayth, within the University of 
Exeter, ensuring that the original patient consent and ethics approvals were not 
conflicted. Because of the low levels of total RSNOs in human plasma samples, the 
student modified the size of the standard purge vessel to allow analysis of larger 
volumes of participant plasma using a tri-iodide chemiluminescent assay. This 
modification increased the signal peak to noise ratios on the chemiluminescent 
traces and reduced problems with foaming in the purge vessel. This analysis has 
proven that, contrary to results reported within previous publications in which pure 
nitrate salt was orally administered, an approximately ten-fold increase in plasma S-
nitrosothiols was observed following inorganic nitrate ingestion in the form of 
beetroot juice (104 nM) compared to the baseline (12 nM) and nitrate-depleted 
supplementation (11 nM) experimental conditions. Previous research has indicated 
that oral supplementation with sodium nitrite or sodium nitrate brought about a far 
more modest rise in plasma S-nitrosothiol concentration from 5 to 13 nM in 
hypertensive rats (Pinheiro, Amaral et al. 2015), while sodium nitrate 
supplementation brought about no increase in S-nitrosothiol concentration in humans 
(Lundberg and Govoni 2004). This much more marked rise in the current study may 
be a result of other components within beetroot juice influencing the uptake of 
nitrate, as these would not be present in pure organic nitrate such as sodium nitrate. 
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In summary, further analysis of samples obtained from this investigation’s 
participants has demonstrated that oral nitrate ingestion did not just alter plasma 
nitrite levels, but also other potential reservoirs of ˙NO, including S-nitrosothiols. The 
physiological importance of such an increase in S-nitrosothiols is yet to be 
determined, however, and further work is required to fully characterise the 




This pilot study successfully fulfilled its aims, demonstrating that patients for a larger 
scale study could be recruited from this population of motivated individuals keen to 
‘give something back’ to their healthcare providers. This investigation was not 
powered to provide any conclusive outcomes regarding the efficacy of dietary 
supplementation with inorganic nitrate on any of the areas discussed. However, it 
revealed that almost all patients with anaemia, many of whom in this cohort had 
active cancers and a host of other medical co-morbidities, were undergoing 
chemotherapy, and were of vastly differing ages, displayed increases in their plasma 
nitrate and nitrite concentrations following this supplementation. This indicated that 
the nitrate-nitrite-˙NO pathway was intact despite the frequent use of antibiotics and 
bactericidal mouthwashes which may have affected the oral microbiome. This study 
also demonstrated that supplementation with both nitrate-depleted and nitrate-rich 
beetroot juice brought about an improvement in the quality of life and cognitive 
function of participants with anaemia. Finally and contrary to expectations, athletic 
performance during strenuous cycle ergometry testing was improved following 
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supplementation with nitrate-depleted placebo juice (PL) compared to both nitrate-
rich beetroot juice (BR) and the non-supplemented experimental condition. While 
other components of the placebo juice such as sucrose or polyphenols may explain 
this observed improvement of performance at PL over baseline, they would not 
explain the difference between PL and BR. It seems likely that this area of the study 
was affected by the confounding effect exerted by an improved haemoglobin 
concentration observed in participants at the time of the post-PL supplementation 
experimental visit compared to the post-BR visit. However, given the relatively small 
numbers of participants recruited into this pilot study, such potential confounding 
related to chance was unavoidable despite best intentions with the design of this 
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Raw Data Figure 1. Individual haemoglobin concentrations of 26 participants 
throughout their experimental visits. These scatter graphs demonstrate the 
change in haemoglobin concentrations of those 13 participants in the current study 
who received five 70 ml bottles of nitrate-deplete beetroot juice (placebo [PL]) at 2.5, 
12, 24, 36 and 48 hours before their second experimental visit, and five 70 ml bottles 
of nitrate-rich beetroot juice (BR) at the same time points in the 48 hours prior to their 
fourth experimental visit (panel A).  The experimental timepoints ‘Baseline 1’ (no 
beetroot supplementation) and ‘PL’ were within 7 to 10 days of each other, while 3 to 
6 weeks elapsed between ‘PL’ and ‘Baseline 2’ (no beetroot supplementation), 
before only 7 to 10 days passed before they returned for the ‘BR’ visit. Panel B 
displays the remaining 13 participants in this study whose order of supplementation 
was reversed, receiving a 48 hour period of supplementation of BR before visit 2 and 
of PL before visit 4. This figure demonstrates that, while some individuals displayed 
little change in haemoglobin with time, a number of participants’ Hb was significantly 
better at their PL experimental condition than their BR timepoint. One way ANOVA of 
all data sets demonstrated statistical significance (p = 0.0449) between the means of 
the experimental conditions, although this was not significant according to Fisher’s 































5000 n = 26
p = < 0.0001*
 
Raw Data Figure 2. Plasma nitrite concentrations of participants at each 
experimental visit. This scatter plot displays the plasma nitrite concentrations of 
each of the 26 participants (black data points and lines) and the means values (red 
data points and lines) at each of the four experimental. The experimental condition 
‘Baseline 1 + 2’ indicates all nitrate concentrations of  participants at their non-
supplemented visits, while ‘PL’ and ‘BR’ indicates the study visit following a period of 
supplementation. Participants ingested a 70 ml bottle of nitrate-depleted beetroot 
juice (PL) at 2.5, 12, 24, 36 and 48 hours before study visit ‘PL’, while they ingested 
a 70 ml bottle of nitrate-rich beetroot juice (BR) at the same time points prior to visit 
‘BR’. The nitrite concentration of each stored plasma sample was quantified by gas-
phase chemiluminescence analysis of each participant plasma sample from every 
experimental visit (see Methods section 2.8.7).  This graph demonstrates that the 
mean plasma nitrite concentration was significantly higher at experimental condition 
BR (923 nM, SD 1006 nM) than at either baseline (142 nM, SD 79 nM) or PL (134 
nM, SD 69 nM) (1 way ANOVA p = < 0.0001, statistically significant according to 
Fisher’s LSD post hoc analysis [LSD = 0.000]). The data was skewed and therefore 
made non-parametric by two participants’ nitrite concentration at condition BR which 
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